

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 November 2001 (08.11.2001)

(10) International Publication Number  
WO 01/83729 A2

PCT

(51) International Patent Classification<sup>7</sup>: C12N 15/00 (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(21) International Application Number: PCT/EP01/04863 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 30 April 2001 (30.04.2001) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English (26) Publication Language: English

(30) Priority Data: 09/562,934 1 May 2000 (01.05.2000) US

(71) Applicants: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(71) Applicants and

(72) Inventors: NEMEROW, Glen, R. [US/US]; 462 Cerro Street, Encinitas, CA 92024 (US). VON SEGGERN, Daniel, J. [US/US]; Apartment 30, 5175 Luigi Terrace, San Diego, CA 92122 (US). FRIEDLANDER, Marty [US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/83729 A2

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.

## VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

Work described herein was supported by NIH grants EY11431 and HL54352. The government has certain rights in such subject matter.

### 5 RELATED APPLICATIONS

This application claims the benefit of priority to U.S. application Serial No. 09/562,934, filed May 1, 2000, to Glen R. Nemerow, Daniel Von Seggern, Martin Friedlander, entitled "VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY".

10 This application is related to copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000), to Daniel Von Seggern, Glen R. Nemerow, Paul Hallenbeck, Susan Stevenson, Yelena Skripchenko, filed January 14, 2000, entitled "Adenovirus Vectors, Packaging Cell Lines, Compositions, and

15 Methods for Preparation and Use," which is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S. Provisional Application 60/115,920 filed January 14, 1999. Where permitted, the contents and subject matter of each application and of the provisional application are incorporated in their entirety herein by reference.

### 20 FIELD OF INVENTION

The present invention relates to gene therapy, especially to adenovirus vector-based gene therapy. In particular, adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene

25 therapy are provided.

### BACKGROUND OF THE INVENTION

#### Retinal dystrophies

The eye is susceptible to a number of hereditary and/or age related degenerative disorders. In the United States, common causes of irreversible blindness or severe loss of vision are retinal dystrophies (see, e.g., Cotlier *et al.* (1995) *Surv. Ophthalmology* 40:51-61; Bird (1995) *Am. J. Ophthalmol.* 119: 543-562; and Adler (1996) *Arch Ophthal* 114:79-83). The retina is the sensory

-2-

tunic of the eye, containing light sensitive receptors, a complex of neurons, and pigmented epithelium, arranged in discrete layers. In humans, the macula is the portion of the retina that lies directly behind the lens. Cones, the photoreceptor cells responsible for central vision, are heavily concentrated in the macula.

5 Central dystrophies, which affect the macula, include Best's disease, age-related macular degeneration, and Stargardt's macular dystrophy. The peripheral retina is composed mainly of rods, which are responsible for side and night vision. Peripheral degenerative retinal diseases include retinitis pigmentosa, choroideremia and Bietti's crystalline dystrophy.

10 Macular degenerations are a heterogenous group of diseases, characterized by progressive central vision loss and degeneration of the macula and underlying retinal pigmented epithelium. Age-related macular degeneration (ARMD) is the most common form of the disease, affecting an estimated 20% of persons over 75 years of age. ARMD is poorly understood in terms of etiology 15 and pathogenesis. The very late onset of the disease has made genetic mapping particularly difficult. Certain macular degenerative conditions with a clear genetic basis, such as Stargardt's and Best's diseases, share many features with ARMD, but have been more amenable to molecular and genetic analysis.

Hereditary peripheral retinopathies are also relatively common. Retinitis pigmentosa (RP), for example, affects approximately 1.5 million people worldwide. Substantial genetic heterogeneity has been observed in this condition, with over 20 chromosomal loci identified. A predisposition to retinitis pigmentosa can be inherited by autosomal dominant, autosomal recessive, X-linked or digenic mode. Mutations have been identified in seven genes, four of 25 which encode proteins in the rod phototransduction cascade: rhodopsin, alpha and beta subunits of rod cGMP phosphodiesterase, and rod cGMP cation-gated channel protein .alpha. subunit. Mutations in the peripherin/RDS gene have been linked to retinitis pigmentosa and macular degeneration. A single peripherin/RDS mutation apparently caused retinitis pigmentosa, pattern dystrophy and fundus 30 flavimaculatus, in different family members.

-3-

In spite of causal heterogeneity, there is significant clinical similarity among RP subtypes. Common signs and symptoms include early electroretinographic abnormalities, ophthalmoscopic findings, and protracted, contiguous expansion of the ring-like scotoma toward the macula, 5 leading to progressively worsening tunnel vision. A recent hypothesis is that active photoreceptor cell death, which is characteristic of these genetically distinct disorders, is mediated by a common induction of apoptosis. It may be possible to treat these conditions by the administration of agents that block induction of apoptosis in photoreceptors, such as neurotrophic factors.

**10 Adenovirus delivery vectors**

Adenovirus, which is a DNA virus with a 36 kilobase (kb) genome, is very well-characterized and its genetics and genetic organization are understood. The genetic organization of adenoviruses permits substitution of large fragments of viral DNA with foreign DNA. In addition, recombinant adenoviruses are 15 structurally stable and no rearranged viruses are observed after extensive amplification.

Adenoviruses have been employed as delivery vehicles for introducing desired genes into eukaryotic cells. The adenovirus delivers such genes to eukaryotic cells by binding to cellular receptors followed by internalization. The 20 adenovirus fiber protein is responsible for binding to cells. The fiber protein has two domains, a rod-like shaft portion and a globular head portion that contains the receptor binding region. The fiber spike is a homotrimer, and there are 12 spikes per virion. Human adenoviruses bind to and infect a broad range of cultured cell lines and primary tissues from different species.

25 The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described (see, e.g., Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Virol.* 161: 549-554, 30 1987).

The 35,935 bp sequence of Ad5 DNA is also known and portions of many other adenovirus genomes have been sequenced. The upper packaging limit for adenovirus virions is about 105% of the wild-type genome length (see, e.g., Bett, *et al.*, *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this 5 would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats permit single strands of viral DNA to circularize by base-pairing of their terminal sequences to form base-paired "panhandle" structures that are 10 required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and 15 contiguous packaging sequence) have been constructed.

Ad vectors have several distinct advantages as gene delivery vehicles. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to 20 accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins. Adenovirus (Ad)-based gene delivery vectors efficiently infect many different cells and tissues. This broad tropism, however, means that gene delivery cannot be directed to a specific target cell. A large fraction of intravenously administered adenovirus is 25 retained by the liver, which could lead to undesirable side-effects. Adenovirus may potentiate immune responses. For example, Adenovirus type 5 (Ad5) also transduces dendritic cells, which present antigens very efficiently, thereby possibly exacerbating the immune response against the vector. It has been proposed that vectors with different targeting efficiencies might eliminate these 30 problems, permitting a lower total particle dose and more specific targeting (see, e.g., U.S. application Serial No. 09/482,682).

The wealth of information on adenovirus structure and mechanism of infection, its efficient infection of nondividing cells, and its large genetic capacity make adenovirus a popular gene therapy vector. The wide expression of receptors to which adenovirus binds makes targeting adenovirus vectors 5 difficult.

Hence there is a need to improve delivery and targeting of adenoviral vectors and also to provide treatments for ocular disorders. Therefore, it is an object herein to provide adenoviral vectors that specifically or selectively target cells in the eye. It is also an object herein to provide these vectors for treatment 10 of ocular disorders.

#### **SUMMARY OF THE INVENTION**

Degenerative ocular diseases, such as, but not limited to, retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, and others (see, e.g., Table below), have a genetic basis. Genes expressed in 15 the photoreceptor cells at the back of the retina are implicated in these diseases. Provided herein are recombinant viral vectors for targeting therapeutic products to these cells.

Recombinant adenoviral vectors that include nucleic acid that permits specific binding to these photoreceptors are provided. In particular, the vector 20 particles contain a fiber protein of Ad37 or a modified form thereof. As shown herein, fiber protein from Ad37 permits efficient infection of photoreceptor cells. Fiber proteins from other adenovirus D serotypes may also be used. In addition, the portions of the fiber protein, particularly those that interact with other viral structural proteins, such as penton, may be modified to resemble the viral source 25 of the other structural proteins. As exemplified herein, the recombinant virus provided herein include Ad5 structural components. The N-terminus of the Ad37 fiber protein, which interacts with the penton protein, is modified to resemble the Ad5 fiber protein N-terminus to ensure production of viral particles.

The recombinant adenoviral vectors are intended for gene therapy of 30 diseases in which genes expressed in the photoreceptors are implicated. Such diseases include, but are not limited to, degenerative ocular diseases, such as retinitis pigmentosa and Stargardt's disease. These vectors are also useful for

targeting to other ocular cells, such as conjunctival cells, which also bear receptors to which fiber from Ad37 and related serotypes bind.

The vectors will deliver therapeutic agents to the targeted cells for treatment of a variety of disorders (see e.g., Tables 3 and 4, below)). The 5 therapeutic agents are intended for expression in the photoreceptors and for secretion from the photoreceptor cells, which are surrounded on one side by choroidal vasculature, and on the other side by retinal vasculature, thereby providing a means for delivery of products. In addition, expression of growth factors, such as VEGF and others, can be used to enhance blood flow to the 10 retina and prevent or slow the degeneration.

Therapeutic agents encoded by the recombinant adenoviral vectors include, but are not limited to, nucleic acid nucleic acid molecules encoding genes that are defective in certain hereditary disorders, nucleic acid molecules that encode antiangiogenics and antitumor agents for treatment of retinal 15 disorders, such as retinoblastomas; nucleic acid molecules encoding trophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF), growth factors and growth factor inhibitors, antiapoptotic factors, such as Bcl-2 (CNTF), antitumor agents, anti-angiogenics, and genes or portions thereof for gene replacement or repair of defective genes. 20 Hence, methods for treatment of inherited and acquired retinal diseases, including diseases involving neovascular and vascular degeneration are provided.

Methods for treating diseases involving genes expressed in photoreceptor cells are provided herein. The methods provided herein are practiced by 25 administration of the recombinant viral vectors by any means suitable for delivery to the photoreceptors. A preferred mode of administration is intraocular injection including intravitreal and subretinal injection. Other modes of administration include, but are not limited to, intrascleral, periorbital and intravenous administration. The vectors also can include photoreceptor-specific 30 promoters thereby providing a means, not only for specific targeting of expression in these cells, but also for photoreceptor-restricted transgene expression.

## DETAILED DESCRIPTION OF THE INVENTION

## A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, applications, published applications and other publications and sequences from GenBank and other data bases referred to anywhere in the disclosure herein are incorporated by reference in their entirety.

As used herein, the amino acids, which occur in the various amino acid sequences appearing herein, are identified according to their three-letter or one-letter abbreviations. The nucleotides, which occur in the various DNA fragments, are designated with the standard single-letter designations used routinely in the art (see, Table 1).

As used herein, amino acid residue refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. §§ 1.821 - 1.822, abbreviations for amino acid residues are shown in the following

Table:

25

Table 1  
Table of Correspondence

30

SYMBOL		
1-Letter	3-Letter	AMINO ACID
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine

SYMBOL		
A	Ala	alanine
S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
5	T	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
10	Q	glutamine
E	Glu	glutamic acid
Z	Glx	Glu and/or Gln
W	Trp	tryptophan
R	Arg	arginine
15	D	aspartic acid
N	Asn	asparagine
B	Asx	Asn and/or Asp
C	Cys	cysteine
20	X	Unknown or other

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. §§ 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or

-9-

more amino acid residues or to an amino-terminal group such as NH<sub>2</sub> or to a carboxyl-terminal group such as COOH.

In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering 5 the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson *et al.* *Molecular Biology of the Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224).

10 Such substitutions are preferably made in accordance with those set forth in TABLE 2 as follows:

TABLE 2

	Original residue	Conservative substitution
15	Ala (A)	Gly; Ser
	Arg (R)	Lys
	Asn (N)	Gln; His
	Cys (C)	Ser
	Gln (Q)	Asn
	Glu (E)	Asp
20	Gly (G)	Ala; Pro
	His (H)	Asn; Gln
	Ile (I)	Leu; Val
	Leu (L)	Ile; Val
	Lys (K)	Arg; Gln; Glu
	Met (M)	Leu; Tyr; Ile
25	Phe (F)	Met; Leu; Tyr
	Ser (S)	Thr
	Thr (T)	Ser
	Trp (W)	Tyr
	Tyr (Y)	Trp; Phe
	Val (V)	Ile; Leu
30		

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

35 As used herein, a complementing plasmid describes plasmid vectors that deliver nucleic acids into a packaging cell line for stable integration into a chromosome in the cellular genome.

As used herein, a delivery plasmid is a plasmid vector that carries or delivers nucleic acids encoding a therapeutic gene or gene that encodes a

-10-

therapeutic product or a precursor thereof or a regulatory gene or other factor that results in a therapeutic effect when delivered *in vivo* in or into a cell line, such as, but not limited to a packaging cell line, to propagate therapeutic viral vectors.

5 As used herein, a variety of vectors with different requirements are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors are generally identified herein as complementing plasmids. A further type of vector described herein carries or delivers nucleic 10 acid molecules in or into a cell line (e.g., a packaging cell line) for the purpose of propagating therapeutic viral vectors; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is used to carry nucleic acid molecules encoding therapeutic proteins or polypeptides or regulatory proteins or are regulatory sequences to specific cells or cell types in a 15 subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or recombinant adenoviral vectors or viral Ad-derived vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette for expressing the therapeutic gene.

As used herein, a DNA or nucleic acid homolog refers to a nucleic acid 20 that includes a preselected conserved nucleotide sequence, such as a sequence encoding a therapeutic polypeptide. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith or a lesser percentage of homology or identity and conserved biological activity or function.

25 The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482 30 (1981). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default

-11-

parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE*

5 *AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

10 Whether any two nucleic acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the National Center for Biotechnology Information database may be used to

15 determine identity.

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

25 While there exist a number of methods to measure identity between two polynucleotides or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in *Guide to Huge*

30 *Computers*, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred

computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., et al., *J Molec Biol* 215:403 (1990)).

5 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the 10 reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the 15 reference polypeptides. Similar comparisons may be made between a test and reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or 20 deletions.

As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is 25 expressed and a therapeutic product encoded thereby is produced. Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy may also be used to deliver nucleic 30 acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth

-13-

factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified 5 prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, heterologous DNA is DNA that encodes RNA and proteins that are not normally produced *in vivo* by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous DNA by 10 affecting transcription, translation, or other regulatable biochemical processes. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which it is expressed is herein encompassed by heterologous DNA. Examples of heterologous DNA include, but are not limited to, DNA that encodes 15 traceable marker proteins, such as a protein that confers drug resistance, DNA that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and DNA that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous DNA may be secreted or expressed on the surface of the cell in which the heterologous DNA has been 20 introduced.

Hence, herein heterologous DNA or foreign DNA, refers to a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in the corresponding wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or 25 from another Ad serotype.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.

30 Typically, DNA encoding the desired heterologous DNA is cloned into a plasmid vector and introduced by routine methods, such as calcium-phosphate mediated DNA uptake (see, (1981) Somat. Cell. Mol. Genet. 7:603-616) or

-14-

microinjection, into producer cells, such as packaging cells. After amplification in producer cells, the vectors that contain the heterologous DNA are introduced into selected target cells.

As used herein, an expression or delivery vector refers to any plasmid or 5 virus into which a foreign or heterologous DNA may be inserted for expression in a suitable host cell — *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors that allow cloning 10 of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

As used herein, a gene is a nucleic acid molecule whose nucleotide sequence encodes RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and 15 trailer) as well as intervening sequences (introns) between individual coding segments (exons).

As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by the fiber protein, such as by the C-terminus portion that comprises the knob.

20 As used herein, isolated with reference to a nucleic acid molecule or polypeptide or other biomolecule means that the nucleic acid or polypeptide has separated from the genetic environment from which the polypeptide or nucleic acid were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is 25 not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides 30 that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compound can be substantially purified by the one-step method described in

-15-

Smith and Johnson, *Gene* 67:31-40 (1988). The terms isolated and purified are sometimes used interchangeably.

Thus, by "isolated" is meant that the nucleic acid is free of the coding sequences of those genes that, in the naturally-occurring genome of the 5 organism (if any) immediately flank the gene encoding the nucleic acid of interest. Isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

10 Isolated or purified as it refers to preparations made from biological cells or hosts means any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of 15 interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

18 A preparation of DNA or protein that is "substantially pure" or "isolated" 20 should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

25 A cell extract that contains the DNA or protein of interest should be understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.

30 As used herein, a packaging cell line is a cell line that provides a missing gene product or its equivalent.

As used herein, an adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of

-16-

particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

As used herein, "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may 5 also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

As used herein, a plasmid refers to an autonomous self-replicating extrachromosomal circular nucleic acid molecule, typically DNA.

10 As used herein, a post-transcription regulatory element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA sequence.

15 As used herein, pseudotyping describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 fiber protein. This may be 20 accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

25 As used herein, promoters of interest herein may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters do not require the presence of any additional molecule to regulate gene expression. a regulatable or inducible promoter may also be described as a promoter where the rate or extent of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include, but are not limited to various compounds or compositions, light, heat, stress and chemical energy sources. Inducible, suppressible and repressible 30 promoters are considered regulatable promoters. Preferred promoters herein, are promoters that are selectively expressed in ocular cells, particularly photoreceptor cells.

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.

5 As used herein, recombinant refers to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

10 As used herein, a transgene or therapeutic nucleic acid molecule includes DNA and RNA molecules encoding an RNA or polypeptide. Such molecules may be "native" or naturally-derived sequences; they may also be "non-native" or "foreign" that are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleic acid molecule," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

15 Therefore, therapeutic nucleotide nucleic acid molecules include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) all include nucleic acid molecules that function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic 20 nucleic acid molecule can include a sequence of nucleotides that encodes a functional protein intended for delivery into a cell which is unable to produce that functional protein.

As used herein, the vitreous of the eye refers to material that fills the chamber behind the lens of the eye (i.e., vitreous humor or vitreous body).

25 As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region 30 includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be *cis* acting or

may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

Thus, promoters are nucleic acid fragments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the 5 promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences that direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a 10 particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance efficiency of expression.

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by 15 external stimuli. (see, e.g., U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters. 20 Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then 25 it is expressed appropriately in the correct cell types (see, e.g., Palmiter et al. (1986) *Ann. Rev. Genet.* 20: 465-499).

As used herein, the phrase "operatively linked" generally means the 30 sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form, whereby control sequences on one segment control expression or replication or other such control of other segments. The two segments are not necessarily contiguous.

-19-

As used herein, exogenous encompasses any therapeutic composition that is administered by the therapeutic methods provided herein. Thus, exogenous may also be referred to herein as foreign, or non-native or other equivalent expression.

5     **B. Ad37 fiber tropism**

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol.* 70:2116-2123; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson *et al.* 10 (1968) *J. Virol.* 2:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek *et al.* (1995) *Curr.Top.Microbiol.Immunol.* 199:163-200; Riurok *et al.* (1990) *J.Mol.Biol.* 215:589-596; Stevenson *et al.* 15 (1995) *J. Virol.* 69:2850-2857). Fiber proteins of most adenovirus subgroups have been shown to bind specifically or selectively to the 46 kDa coxsackievirus-adenovirus receptor (CAR), (Bergelson *et al.* (1997) *Science* 275:1320-1323; Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). CAR appears to be expressed in a variety of human tissues, including the lung, at various levels (Bergelson *et al.* 20 (1997) *Science* 275:1320-1323), but Ad37 binds poorly to lung epithelial cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). This suggests that the tropism of this serotype may be influenced by factors independent of CAR expression.

Structural and biochemical data also suggest that distinct receptor binding sites are located on different regions of the Ad5 and Ad37 fiber knobs.

25     Adopting the nomenclature of Xia *et al.* (Xia *et al.* (1994) *Structure* 2:1259-1270), the receptor binding site for Ad5 is located at the AB-loop on the side of the fiber knob (Bewley *et al.* (1999) *Science* 286:1579-1583; Roelvink *et al.* (1999) *Science* 286:1568-1571). It is known that a lysine residue at position 240 of the Ad37 fiber, located in the CD-loop, is important for receptor binding 30 (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). The co-crystal structure of the Ad12 knob and the N-terminal domain of CAR (Bewley *et al.* (1999) *Science* 286:1579-1583) show that the CD-loop does not contact CAR. It thus appears

-20-

that different regions of the Ad5 and Ad37 fiber knobs recognize distinct cell receptors.

A 46 kDa receptor for coxsackieviruses and adenoviruses (CAR) mediates attachment for many adenovirus serotypes. The wide distribution of CAR fails 5 to explain why certain adenovirus serotypes (i.e. Ad37) are highly associated with severe ocular infections such as epidemic keratoconjunctivitis (EKC). Ad37 does not use CAR, but instead uses a glycoprotein that contains sialic acid as its primary receptor (Arnberg *et al.* (2000) *J. Virol.* 74:42-48). The modest number of Ad37 binding sites per cell (Huang *et al.* (1999) *J. Virol.* 73:2798-10 2802) also suggests that Ad37 recognizes a specific glycoprotein as its primary receptor for binding to conjunctival cells.

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract. The tropism of Ad37 derives from the binding 15 preference of its fiber protein, which binds to a receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang *et al.* (1999) *J. Virology* 73:2798-2802).

A protein receptor that is preferentially expressed on conjunctival cells to which Ad37 fiber binds is shown herein. The preferential expression of the 20 Ad37 receptor protein on conjunctival cells suggests that this receptor likely influences Ad37 tropism and should play a key role in ocular pathogenesis. It is shown herein that Ad37 uses a distinct protein receptor that is selectively expressed on conjunctival cells. It is shown that Ad37 binds well to conjunctival cells (Chang C), but poorly to lung carcinoma cells (A549). To determine if 25 infection correlated with cell binding, an Ad5 vector containing the Ad37 fiber protein was constructed. The 'pseudotyped' vector delivered transgenes to Chang C cells better than to A549 cells. Ad37 binding was abolished by protease treatment of Chang C cells, indicating the receptor is a membrane protein. Ad37 binding to conjunctival cells is shown herein to be calcium-dependent. It is also shown that Ad37 infection was not inhibited by a function- 30 blocking anti-CAR monoclonal antibody, which is a feature distinct from Ad5 fiber interaction with CAR. Using a virus overlay protein blot assay (VOPBA), calcium-dependent Ad37 binding to a 50 KDa membrane protein on Chang C

-21-

cells, but not A549 cells was detected. Ad19p a closely related serotype that fails to bind to conjunctival cells, does not recognize the 50 kDa protein. Together, these data indicate that the 50 kDa protein is a candidate receptor for Ad37 on conjunctival cells.

5 Significantly, it is also shown herein that, upon administration of the vector to the vitreous humor, the recombinant adenovirus with the Ad37 fiber preferentially and selectively binds to photoreceptor cells. Hence, a recombinant adenoviral delivery vehicle that has an Ad37 fiber protein can serve as a vector for delivery of therapeutic agents to the eye for treatment of ocular disorders, 10 including genetic and acquired disorders. The identification of the receptor for Ad37 and the resulting recognition of Ad37 tropism allows targeting of adenovirus vectors to specific human ocular cells.

As noted, fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on a cell surface. Hexon, penton and fiber 15 capsomeres are the major components on the surface of the virion. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber includes three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that 20 forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus (see, e.g., Hong and Engler, 25 *Virology 185: 758-761, 1991*). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery.

As shown herein, alteration of fiber in recombinant Ad vectors such that the fiber is derived from Ad37 or another adenovirus serotype D, provides a means for selective delivery of a recombinant virus to particular cells in the eye, 30 including conjunctival cells, and most significantly photoreceptors, thereby providing a means for targeted delivery to photoreceptor cells.

-22-

Photoreceptor cells are implicated in a number of hereditary and acquired retinal degenerative disorders. In addition, photoreceptor cells are located such that products produced therein can be delivered to other areas of the eye by virtue of the blood flow in the vicinity of the photoreceptor cells and also by virtue of the proximity of the photoreceptors to the retinal pigmented epithelium (RPE) and other retinal cells.

Hence it is contemplated herein that the recombinant viral vector will include a packaged recombinant adenovirus genome containing at least the minimal elements for replication and packaging; heterologous DNA encoding a desired gene product, typically a therapeutic product or plurality of products, such as several trophic factors, whose combined activity is effective for treating a disorder, such as a retinal degenerative disorder; and the resulting virion particles will include a fiber that has a sufficient portion to confer specific targeting to photoreceptor cells when the recombinant viral particles are introduced into the aqueous humor of a mammalian, preferably a human, eye, or otherwise contacted with the photoreceptor cells. The fiber may be a chimeric protein that has been modified for effective interaction with other coat structural proteins, such as penton. In addition, the fiber may be modified to include other elements that alter its tropism to permit binding to other cells as well (see, e.g., U.S. Patent Nos. 5,756,086 and 5,543,328, International PCT application No. WO 95/26412 and WO 98/44121 and Krasnykh, et al. (*J. Virol.* 70: 6839-46, 1996)).

#### C. Construction of the viral particles

##### 1. Selection of viral genome and fiber protein

Methods for preparing recombinant adenoviral vectors for gene product delivery are well known. Preferred among those are the methods exemplified herein (see EXAMPLES) and also described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000, which claims priority to U.S. 30 provisional application Serial No. 60/115,920, as does U.S. application Serial No. 09/482,682)).

As noted, any desired recombinant adenovirus is contemplated for use in the methods herein as long as the viral genome is packaged in a capsid that includes at least the portion of a fiber protein that provides selective binding to photoreceptor cells. This fiber protein is preferably from an adenovirus type D serotype and is preferably an Ad37 fiber. The fiber protein should retain the 5 knob region at the C-terminus ("head domain") from the Ad virus of subgroup D that contains the type-specific antigen and is responsible for binding to the cell surface receptor. Hence the fiber protein can be a chimeric fiber protein as long as it retains a sufficient portion of the type D serotype to specifically or 10 selectively bind to photoreceptor cells. Generally the portion retained will be all or a portion of the knob region. The precise amount of knob region required can be determined empirically by including portions thereof and identifying the minimum residues from an Ad type D serotype, preferably Ad37, to effect 15 selective targeting of a virion packaged with such fiber to photoreceptors in the eye upon introduction of the packaged virion into the aqueous humor.

Recombinant adenovirus containing heterologous nucleic acids that encode a desired product, such a gene to correct a genetic defect, may be made by any methods known to those of skill in the art. The viruses must be packaged in a cell line that results in expression of fiber on the particles that 20 specifically, electively or preferentially targets (binds and results in internalization) the viral particle to cells in the eye. The fiber protein from Ad37 and other Adenoviruses of serotype D that infect the eye effects such targeting. The resulting adenovirus particles that express such fiber is administered by 25 intraocular injection, subretinal injection, particularly intravitreal injection, or any means that results in preferential accumulation in photoreceptor cells.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as 30 members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses and members of the Aviadenovirus genus, including bird viruses, such as CELO.

Thus it is contemplated that the methods herein can be applied to any recombinant viral vectors derived from any adenovirus species. One of skill in the art would have knowledge of the different adenoviruses (see, e.g., Shenk, *Virology*, Chapter 67, in *Fields et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) and can construct recombinant viruses containing portions of the genome of any such virus.

In the exemplified embodiment, viral particles with Ad37 fiber were prepared. Site-directed mutations were made to the Ad37 fiber gene to make the tail sequence more closely match that of Ad5 to facilitate Ad37 fiber binding to the Ad5 penton base. The plasmid for the expression of the Ad37 fiber protein, pDV80, contains the CMV promoter, the adenovirus type 5 tripartite leader (TPL), and the modified Ad37 fiber gene sequence. Genes of interest, such as nucleic acid encoding the  $\beta$  subunit of cGMP phosphodiesterase ( $\beta$ PDE),  $\beta$ -glucuronidase, rhodopsin, growth factors, anti-cancer agents, growth factor receptors and other anti-angiogenic agents, and anti-apoptotic agents, can be incorporated into these vectors using the methods known to those of skill in the art and exemplified herein.

Known adenovirus vectors, previously constructed for intraocular therapy (see, e.g., Bennett et al. (1996) *Nature Medicine* 2:649-654, which provides an Ad virus encoding  $\beta$ PDE for treatment of retinitis pigmentosa; Cayouette et al. (1998) *Human Gene Therapy* 8:423-430, which provides an Ad vector that expresses CNTF for treatment of retinitis pigmentosa and other retinal degenerative diseases; and Li et al. (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:7700-7704, which provides an Ad virus vector that encodes a human  $\beta$ -glucuronidase for treatment of lysosomal storage disease caused by  $\beta$ -glucuronidase deficiency) can be modified by repackaging the recombinant genome using a packaging line that expresses an Ad37 fiber or other D serotype fiber.

For exemplification, nucleic acid encoding GFP was incorporated into these vectors as a means to visualize their localization. Other genes, such as genes that encode therapeutic products, may be included in place of or in addition to GFP.

Plasmid pDV80 was electroporated into E1-2a S8 cells and stable lines were selected. The fiber-deleted vectors Ad5. $\beta$ gal. $\Delta$ F and Ad5.GFP. $\Delta$ F were grown in cells in a resulting cell line, designated 705, to produce virions, which express the Ad37 fiber (Ad5. $\beta$ gal. $\Delta$ F/37F and Ad5.GFP. $\Delta$ F/37F) and CsCl-  
5 purified. These virions selectively transduce photoreceptor cells when injected intraocularly into the vitreous humor.

## 2. Packaging

Recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b regions. Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1  
10 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, e.g., Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines  
15 that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378).

Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

Copending U.S. application Serial No. 09/482,682 (also filed as  
25 International PCT application No. PCT/US00/00265, filed January 14, 2000) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the  
30 chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or mutated in the adenovirus vector genome to

be replicated and packaged. The packaging cell line express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The 5 expression can be constitutive or under the control of a regulatable promoter. These cell lines are designed for expression of recombinant adenoviruses intended for delivery of therapeutic products.

Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, 10 regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be 15 introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D, such as Ad 37, polypeptide or fragment thereof.

For therapeutic applications, the delivery plasmid further includes a 20 nucleotide sequence encoding a foreign polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, pΔE1Bβ-gal and pΔE1sp1B. In a similar or analogous manner, therapeutic genes may be introduced.

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a 25 chromosome(s) of the cellular genome of the cell.

In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second 30 delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

In a variation, the packaging cell line expresses fiber protein or chimeric variant thereof from an Ad virus of subgroup D, preferably Ad37, serotype or it can be any fiber protein but one that has been modified to include the portion of the Ad virus of subgroup D, such as Ad37, responsible for selective targeting to photoreceptors upon introduction into the vitreous humor of the eye of a mammal, preferably a human. The fiber protein can be further modified to include a non-native amino acid residue sequence that targets additional specific receptors. In all instances, the modification should not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. The structural protein is fiber can include amino acid residue sequences from more than one adenovirus serotype. The nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein, may be modified "internally" as well as at the termini.

15 Additional nucleic acid fragments can encode polypeptides that are added to the fiber protein. In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker.

20 Suitable ligands include, but are not limited to, ligands that specifically or selectively bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, the packaging cell lines will contain nucleic acid encoding the fiber protein or modified protein stably integrated into a chromosome or chromosomes in the cellular genome.

25 The packaging cell line can be derived from a prokaryotic cell line or from a eukaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from among the 293, A549, W162, HeLa, 30 Vero, 211, and 211A cell lines, and any other cell lines suitable for such use are likewise contemplated herein.

3. Components of the nucleic acid molecule included in the particle

A recombinant viral vector or therapeutic viral vector for use in the methods herein, typically includes a nucleic acid fragment that encodes a protein or polypeptide molecule, or a biologically active fragment thereof, or other regulatory sequence, that is intended for use in therapeutic applications.

5        The nucleic acid molecule to be packaged in the viral particle also may include an enhancer element and/or a promoter located 3' or 5' to and controlling the expression of the therapeutic product-encoding nucleic acid molecule if the product is a protein. Further, for purposes herein, the promoter and/or other transcriptional and translational regulatory sequences controlling 10 expression of the product is preferably one that is expressed specifically in the targeted cells, such as the a photoreceptor-specific promoter, such as a rhodopsin gene promoter.

The nucleic acid molecule to be packaged in viral capsid includes at least 2 different operatively linked DNA segments. The DNA can be manipulated and 15 amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce such molecule, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous 20 replication in a cell either *in vivo* or *in vitro*. By operatively linking the enhancer element or promoter and nucleic acid molecule to the vector, the attached segments are replicated along with the vector sequences.

Thus, the recombinant DNA molecule (rDNA) is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in 25 nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. The nucleic acid molecule intended to be packaged is from about 20 base pairs to about 40,000 base pairs in length, preferably about 50 bp to about 38,000 bp in length. In various embodiments, the nucleic acid molecule is of sufficient length 30 to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, encoding nucleic acid molecules

-29-

from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic product-encoding nucleic acid molecules.

Preferably the molecule includes an adenovirus tripartite leader (TPL) nucleic acid sequence operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron. The intron includes any sequence of nucleotides that function in the packaging cell line to provide RNA processing signals, including splicing signals. Introns have been well characterized from a large number of structural genes, and include but are not limited to a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs (see, e.g., Petitclerc *et al.* (1995) *J. Biotechnol.*, 40:169; and Choi *et al.* (1991) *Mol. Cell. Biol.*, 11:3070).

The nucleic acid molecule encoding the TPL includes either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from among the complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples.

25 The use of a TPL with a partial exon 1 has been reported (International PCT application No. WO 98/13499).

The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence. An intron may not be a part of the construct. For example, the intron can be positioned between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment,

-30-

complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral 5 systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL 10 nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an 15 adenovirus TPL nucleotide sequence as described herein.

#### 4. Complementing Plasmids

Also contemplated are the use of nucleic acid molecules, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are 20 used to complement the defective genes of a recombinant adenovirus vector genome, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product encoded by the nucleic acid 25 molecule. Expression cassettes typically contain a promoter and a structural gene operatively linked to the promoter. The complementing plasmid can further include a sequence of nucleotides encoding TPL nucleotide to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

A complementing plasmid can include a promoter operatively linked to a sequence of nucleotides encoding an adenovirus structural polypeptide, such as, 30 but are not limited to, penton base; hexon; fiber; polypeptide IIIa; polypeptide V;

polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid may also include a sequence of nucleotides encoding a first adenovirus regulatory polypeptide, a second regulatory polypeptide, and/or a third regulatory polypeptide, and any combination of the foregoing.

5 Plasmid pDV80 is a preferred plasmid herein. Other plasmids constructed in an analogous manner to encode modified fiber proteins and chimeric fiber proteins are also contemplated herein.

##### 5. Nucleic Acid Molecule Synthesis

10 A nucleic acid molecule comprising synthetic oligonucleotides can be prepared using any suitable method, such as the phosphotriester or phosphodiester methods (see, e.g., Narang (1979) *et al.*, *Meth. Enzymol.*, 68:90; U.S. Patent No. 4,356,270; and Brown *et al.*, (1979) *Meth. Enzymol.*, 68:109). For oligonucleotides, the synthesis of the family members can be 15 conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected 20 nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected 25 nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants (see, e.g., Ausubel *et al.* (*Current Protocols in Molecular Biology*, Suppl. 8. p.2.11.7, John Wiley & Sons, Inc., New York 30 ,1991).

-32-

Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be

5 found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures 10 are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the 15 preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and 20 ligation, as is well known.

**D. Adenovirus Expression Vector Systems**

The adenovirus vector genome that is encapsulated in the virus particle and that expresses exogenous genes in a gene therapy setting is a key component of the system. Thus, the components of a recombinant adenovirus 25 vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat containing an adenovirus origin of replication, as is well known 30 and described herein.

Although adenovirus include many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector). Thus, deletion of the appropriate genes from a recombinant Ad vector permits accommodation of even larger "foreign" DNA segments.

5 A preferred recombinant adenovirus vector genome is "helper independent" so that genome can replicate and be packaged without the help of a second, complementing helper virus. Complementation is provided by a packaging cell.

In a preferred embodiment, the adenovirus vector genome does not 10 encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is 15 referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

Thus, contemplated for use are helper-independent fiberless recombinant adenovirus vector genomes that include genes that (a) express all adenovirus 20 structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contain an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

25 The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

30 A vector herein includes a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, e.g., a gene or polynucleotide, can be operatively linked to bring about replication of the

-34-

attached segment. For purposes herein, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule. As noted above, therapeutic nucleic acid molecules include those encoding proteins and also those that encode regulatory factors 5 that can lead to expression or inhibition or alteration of expression of a gene product in a targeted cell.

#### 1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also 10 feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least a portion of a therapeutic nucleotide sequence 15 operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

The choice of viral vector into which a therapeutic nucleic acid molecule is operatively linked depends directly, as is well known in the art, on the functional properties desired, e.g., vector replication and protein expression, and 20 the host cell to be transformed – these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the use of any adenovirus serotype, including hybrids and derivatives thereof are contemplated.

25 A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the 30 nucleic acid material and any polypeptides that are to be inserted into the cell.

## 2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector may also include a promoter, particularly a tissue or cell specific promoter, preferably one expressed in ocular cells, particularly photoreceptors.

5 Promoters contemplated for use herein include regulatable (inducible) as well as constitutive promoters, which may be used, either on separate vectors or on the same vector. Some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, e.g., International PCT application No. WO 10 96/14061). Preferably the promoter selected is from a photoreceptor-specific gene, such as a rhodopsin gene or gene that encodes a protein that regulates rhodopsin expression.

## E. Formulation and administration

Compositions containing therapeutically effective concentrations of 15 recombinant adenovirus delivery vectors are provided. These are for delivery of therapeutic gene products to cells, particularly cells express a particular 50 kDa receptor or other receptor with which the vectors interact. These cells include cells of the eye and genital tract. Of particular interest are photoreceptor cells of the eye. Administration is effected by any means through which contacting with 20 the photoreceptors is effected. Preferable modes of administration include, but are not limited to, subretinal injection, particularly intravitreal injection, to provide access to photoreceptor cells.

The recombinant viral compositions may also be formulated for 25 implantation into the anterior or posterior chamber of the eye, preferably the vitreous cavity, in sustained released formulations, such as those adsorbed to biodegradable supports, including collagen sponges, or in liposomes. Sustained release formulations may be formulated for multiple dosage administration, so that during a selected period of time, such as a month or up to about a year, several dosages are administered. Thus, for example, liposomes may be 30 prepared such that a total of about two to up to about five or more times the single dosage is administered in one injection.

The vectors are formulated in an ophthalmologically acceptable carrier for intraocular, preferably intravitreal, administration in a volume of between about 0.05 ml and 0.150 ml, preferably about 0.05 and 0.100 ml.

The composition can be provided in a sealed sterile vial containing an 5 amount of a compound of formula I, that upon intraocular administration will deliver a sufficient amount of viral particles to the photoreceptors in a volume of about 50 to 150  $\mu$ l, containing at least about  $10^7$ , more preferably at least about  $10^8$  plaque forming units in such volume. Typically, the vials will, thus, contain about 0.150 ml of the composition.

10 To prepare compositions the viral particles are dialyzed into a suitable ophthalmologically acceptable carrier or viral particles, for example, may be concentrated and/or mixed therewith. The resulting mixture may be a solution, suspension or emulsion. In addition, the viral particles may be formulated as the sole pharmaceutically active ingredient in the composition or may be 15 combined with other active agents for the particular disorder treated.

For administration by intraocular injection or via eyedrops, suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline (PBS), balanced salt solution (BSS), lactate Ringers solution, and solutions containing thickening and solubilizing agents, such as glucose, polyethylene 20 glycol, and polypropylene glycol and mixtures thereof. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. Suitable ophthalmologically acceptable carriers are known. Solutions or mixtures intended for ophthalmic use may be formulated as 0.01% - 10% isotonic 25 solutions, pH about 5-7, with appropriate salts [see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of ophthalmic irrigation solutions and solutions for local application]. Such solutions, which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM 30 sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium acetate, 10-20 mM D.L.-sodium  $\beta$ -hydroxybutyrate and 5-5.5 mM glucose.

The compositions may be prepared with carriers that protect them from rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers,

5 such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and other types of implants that may be placed directly into the anterior or posterior chamber or vitreous cavity of the eye. The compositions may also be administered in pellets, such as Elvax pellets (ethylene-vinyl acetate copolymer resin).

10 Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. For example, liposome formulations may be prepared by methods known to those of skill in the art [see, e.g., Kimm *et al.* (1983) *Bioch. Bioph. Acta* 728:339-398; Assil *et al.* (1987) *Arch Ophthalmol.* 105:400; and U.S. Patent No. 4,522,811]. The viral particles

15 may be encapsulated into the aqueous phase of liposome systems.

The active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action or have other action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON, which is a solution of a high

20 molecular weight (MW) of about 3 millions fraction of sodium hyaluronate [manufactured by Pharmacia, Inc; see, e.g., U.S. Patent Nos. 5,292,362, 5,282,851, 5,273,056, 5,229,127, 4,517,295 and 4,328,803], VISCOAT [fluorine-containing (meth)acrylates, such as, 1H,1H,2H,2H-hepta-decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751

25 and 5,214,080; commercially available from Alcon Surgical, Inc.], ORCOLON [see, e.g., U.S. Patent No. 5,273,056; commercially available from Optical Radiation Corporation], methylcellulose, methyl hyaluronate, polyacrylamide and polymethacrylamide [see, e.g., U.S. Patent No. 5,273,751]. The viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%,

30 preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues. The compositions may also include a dye, such as

methylene blue or other inert dye, so that the composition can be seen when injected into the eye. Additional active agents may be included.

The compositions can be enclosed in ampules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material.

5 Such enclosed compositions can be provided in kits. In particular, kits containing vials, ampules or other containers, preferably disposable vials with sufficient amount of the composition to deliver about 0.100 ml thereof, and disposable needles, preferably self sealing 25-30 gauge needles, are provided herein.

10 Finally, the compounds may be packaged as articles of manufacture containing packaging material, typically a vial, an ophthalmologically acceptable composition containing the viral particles and a label that indicates the therapeutic use of the composition.

Also provided are kits for practice of the methods herein. The kits 15 contain one or more containers, such as sealed vials, with sufficient composition for single dosage administration, and one or more needles, such as self sealing 25-33 gauge needles, preferably 33 gauge or smaller needles, precisely calibrated syringes or other precisely calibrated delivery device, suitable for intravitreal injection.

20 Administration of the composition is preferably by intraocular injection, although other modes of administration may be effective, if the sufficient amount of the compound achieves contact with the vitreous cavity. Intraocular injection may be effected by intravitreal injection, aqueous humor injection or injection into the external layers of the eye, such as subconjunctival injection or 25 subtenon injection, or by topical application to the cornea, if a penetrating formulation is used.

#### Administration

The compositions containing the compounds are administered 30 intraocularly or by other means, such as topically in the form of penetrating eyedrops, whereby contact of the recombinant vectors with the aqueous humor is effected. Intraocular administration may be effected by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as

-39-

subconjunctival injection or subtenon injection, preferably in free form, but, alternatively, in liposomes or other sustained drug delivery device.

Administration is preferably by intravitreal injection, preferably through self sealing 25-30 gauge needles or other suitably calibrated delivery device.

5 Injection into the eye may be through the pars plana via the self-sealing needle.

It is further understood that, for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the recombinant viruses, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or

10 practice of the claimed methods

F. Diseases, Disorders and therapeutic products

1. Disease and disorders

Retinitis pigmentosa

15 Methods for specifically or selectively targeting recombinant adenovirus vectors for delivery of gene products, particularly therapeutic products are provided herein. These methods are particularly suitable for targeting cells that express receptors that are selectively recognized by Ad virus of subgroup D viruses, particularly Ad37. It is shown herein that these viruses selectively

20 recognize receptors on cells, such as conjunctival cells and photoreceptors, that are not recognized by other adenoviruses. Hence, methods for targeting to these cell types by providing vectors that are packaged in viral particles that contain a sufficient portion of a fiber protein from one of these Ad serotypes to bind to these receptors. These methods are useful for targeting to

25 photoreceptors and for treating ocular disorders, including, but are not limited to, inherited and acquired retinal, neovascular degenerative diseases (see table below).

It is estimated that 1 in 3,500 individuals in the United States suffer from one of the pigmented retinopathies. This group of retinal diseases, commonly 30 called retinitis pigmentosa, is characterized by progressive loss of peripheral and night vision. Patients may be affected at almost any age and it is not uncommon to experience symptoms in early childhood in certain inherited forms.

-40-

It has been shown that there are a variety of mutations in genes expressed in the photoreceptors, including genes in the rhodopsin gene and pathway that appear to be responsible for these diseases. In addition to mutations in rhodopsin, changes in the retinal pigmented epithelial (RPE) cells, also undergo 5 degenerative changes and can form clumps of pigment that give rise to the characteristic pigmentary changes seen in patients with RP.

#### Angiogenesis and ocular diseases and disorders

The vast majority of diseases that cause catastrophic loss of vision do so as a result of ocular neovascularization; age related macular degeneration 10 (ARMD) affects 12-15 million American over the age of 65 and causes visual loss in 10-15% of them as a direct effect of choroidal (sub-retinal) neovascularization. The leading cause of visual loss for Americans under the age of 65 is diabetes; 16 million individuals in the United States are diabetic and 40,000 per year suffer from ocular complications of the disease, which often are 15 a result of retinal neovascularization. Laser photocoagulation has been effective in preventing severe visual loss in subgroups of high risk diabetic patients, but the overall 10 year incidence of retinopathy remains essentially unchanged. For patients with choroidal neovascularization due to ARMD or inflammatory eye disease, such as ocular histoplasmosis, photocoagulation, with few exceptions, 20 is ineffective in preventing visual loss. While recently developed, non-destructive photodynamic therapies hold promise for temporarily reducing individual loss in patients with previously untreatable choroidal neovascularization, only 61.4% of patients treated every 3-4 months had improved or stabilized vision compared to 45.9% of the placebo-treated group.

25 In the normal adult, angiogenesis is tightly regulated and limited to wound healing, pregnancy and uterine cycling. Angiogenesis is turned on by specific angiogenic molecules such as basic and acidic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiogenin, transforming growth factor (TGF), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and platelet derived growth factor 30 (PDGF). Angiogenesis can be suppressed by inhibitory molecules such as interferon- $\alpha$ , thrombospondin-1, angiostatin and endostatin. It is the balance of these naturally occurring stimulators and inhibitors that controls the normally

quiescent capillary vasculature. When this balance is upset, as in certain disease states, capillary endothelial cells are induced to proliferate, migrate and ultimately differentiate.

Angiogenesis plays a central role in a variety of diseases, including, but 5 are not limited to, cancer and ocular neovascularization. Sustained growth and metastasis of a variety of tumors has also been shown to be dependent on the growth of new host blood vessels into the tumor in response to tumor derived angiogenic factors. Proliferation of new blood vessels in response to a variety of stimuli occurs as the dominant finding in the majority of eye diseases that blind, 10 such as, but are not limited to, proliferative diabetic retinopathy (PDR), ARMD, rubeotic glaucoma, interstitial keratitis and retinopathy of prematurity. In these diseases, tissue damage can stimulate release of angiogenic factors resulting in capillary proliferation. VEGF plays a dominant role in iris neovascularization and neovascular retinopathies. While reports clearly show a correlation between 15 intraocular VEGF levels and ischemic retinopathic ocular neovascularization, FGF likely plays a role. Basic and acidic FGF are known to be present in the normal adult retina, even though detectable levels are not consistently correlated with neovascularization. This may be largely due to the fact that FGF binds very tightly to charged components of the extracellular matrix and may not be readily 20 available in a freely diffusible form that would be detected by standard assays of intraocular fluids.

A final common pathway in the angiogenic response involves integrin-mediated information exchange between a proliferating vascular endothelial cell and the extracellular matrix. This class of adhesion receptors, called integrins, 25 are expressed as heterodimers having an  $\alpha$  and  $\beta$  subunit on all cells. One such integrin,  $\alpha_v\beta_3$ , is the most promiscuous member of this family and allows endothelial cells to interact with a wide variety of extracellular matrix components. Peptide and antibody antagonists of this integrin inhibit angiogenesis by selectively inducing apoptosis of the proliferating vascular 30 endothelial cells. Two cytokine-dependent pathways of angiogenesis exist and may be defined by their dependency on distinct vascular cell integrins,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$ . Specifically, basic FGF- and VEGF-induced angiogenesis depend on integrin

-42-

$\alpha_v\beta_3$  and  $\alpha_v\beta_5$ , respectively, since antibody antagonists of each integrin selectively block one of these angiogenic pathways in the rabbit corneal and chick chorioallantoic membrane (CAM) models. Peptide antagonists that block all  $\alpha_v$  integrins inhibit FGF- and VEGF-stimulated angiogenesis. While normal 5 human ocular blood vessels do not display either integrin,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins are selectively displayed on blood vessels in tissues from patients with active neovascular eye disease. While only  $\alpha_v\beta_3$  was consistently observed in tissue from patients with ARMD,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  were present in tissues from patients with PDR. Systemically administered peptide antagonists of integrins blocked 10 new blood vessel formation in a mouse model of retinal vasculogenesis.

In addition to adhesion events described above, cell migration through the extracellular matrix also depends on proteolysis. Matrix metalloproteinases are a family of zinc-requiring matrix-degrading enzymes that include the collagenases, gelatinases and stromelysins, all of which have been implicated in invasive cell 15 behavior. Invasive cell processes such as tumor metastasis and angiogenesis have been found to be associated with the expression of integrins and MMP-2, MMP-2 are all found throughout the eye where they may interact to maintain a quiescent vasculature until the balance is upset, resulting in pathological angiogenesis. A non-catalytic C-terminal hemopexin-like domain of MMP-2 20 (PEX) can block cell surface collagenolytic activity and inhibit angiogenesis in the CAM model by preventing localization of MMP-2 to the surface of invasive cells through interaction with the integrin  $\alpha_v\beta_3$ .

Hence, anti-angiogenic agents have a role in treating retinal degeneration to prevent the damaging effects of these trophic and growth factors.

25 Angiogenic agents, also have a role in promoting desirable vascularization to retard retinal degeneration by enhancing blood flow to cells.

Members of adenovirus subgroup D, Ad8, 19A, and 37, are infectious agents that cause particularly severe cases of epidemic keratoconjunctivitis (EKC) (Arnberg *et al.* (1998) *Virology* 227:239-244; Curtis *et al.* (1998) *J.Med.Microbiol.* 47:91-94; Ritterband *et al.* (1998) *Rev.Med.Viro.* 8:187-201; 30 and Takeuchi *et al.* (1999) *J.Clin.Microbiol.* 37:3392-3394). There is no effective treatment for this debilitating and contagious disease and EKC

-43-

continues to be a problem in ophthalmology clinics worldwide (Curtis *et al.* (1998) *J.Med.Microbiol.* 47:91-94, Lukashok *et al.* (1998) *Curr.Clin.Top.Infec.Dis.* 18:286-304). Hence the vectors herein may be used for treating the disease.

5

Table 3  
Candidate targets for ocular disease therapy

CANDIDATE TARGETS FOR OCULAR DISEASE THERAPY	
Disease	Candidate target(s)
Retinitis pigmentosa	Rhodopsin gene, and genes that regulate expression thereof <i>rds</i> /peripherin
10 Stargardt's disease	rim protein (ARC protein)
Choroideremia	rab geranylgeranyl transferase CHM, TCD, CHML*
Gyrate Atrophy	ornithine aminotransferase
Macular dystrophy	<i>rds</i> /peripherin

15

\* see, "MSR6-yeast homologue of the choroideraemia gene," *Nature Genetics* 3: 193-4 (1993)

TABLE 4

Other Diseases	
Exudative Choroidal Diseases	
20	ICSC, fluorescein angiogram
	ICSC with large serious detachment of RPE (retinal pigmented epithelium)
	ICSC with bullous retinal detachment
	Macular drusen, exudative, confluent
25	Drusen, sub-RPE choroidal neovascularization
	Drusen, notched serous detachment of RPE

-44-

Other Diseases	
	Drusen, notched serous and hemorrhagic detachment of RPE
	Drusen, serous and hemorrhagic detachment of RPE and retina
	Drusen, organized RPE detachment causing bullous retinal detachment
5	Drusen, geographic atrophy of RPE
	Drusen, exudative and cuticular, vitelliform macular detachment
	Drusen, cuticular, large vitelliform macular detachment
	North Carolina dystrophy with macular staphyloma
	North Carolina dystrophy with macular staphyloma
	Angioid streaks, pseudoxanthoma elasticum (PXE), CNVM
10	Angioid streaks, PXE, large notched retinal detachment
	Myopic degeneration, Foerster-Fuchs spot
	Presumed ocular histoplasmosis syndrome (POHS)
	Submacular bacterial abscess
	<i>Toxocara canis</i> , subretinal granuloma
15	Serpiginous (geographic) choroiditis
	Posterior scleritis
	Harada's disease
	Posterior sympathetic uveitis
	Benign reactive lymphoid hyperplasia of uveal tract
20	Choroidal ruptures and CNVM
	Cavernous hemangioma of choroid
	Choroidal osteoma
	Choroidal nevus, serous macular detachment
	Choroidal nevus with CNVM
25	Diffuse sclerochoroidal melanocytic nevus
	Choroidal melanoma with serous detachment of RPE
	Metastatic lung carcinoma to choroid
	Sub-RPE reticulum cell sarcoma

Other Diseases	
RPE tear, idiopathic choroidal neovascularization	
Heredodystrophic Disorders Affecting RPE & Retina	
5	Best's vitelliform macular dystrophy
	Best's vitelliform macular dystrophy with CNVM
	Best's vitelliform macular dystrophy, multiple lesions
	Adult-onset vitelliform foveomacular dystrophy
	Pattern dystrophy simulating fundus flavimaculatus
	Stargardt's disease (fundus flavimaculatus)
	Asteroid macular dystrophy
10	Sjögren-Larsen syndrome
	Oguchi's disease, light-adapted state
	Oguchi's disease, dark-adapted state
	Fundus albipunctatus
15	Retinitis pigmentosa, cystoid macular edema
	Crystalline tapetoretinal dystrophy
	Choroideremia
	Goldmann-Favre syndrome
	Sex-linked juvenile retinoschisis
	Perivenous retinitis pigmentosa
	Retinal Vascular Disorders
20	Retinal arteriovenous aneurysm
	Central retinal artery occlusion
	Cilioretinal artery obstruction
	Ischemic retinopathy in systemic lupus erythematosus
	Ischemic retinopathy in scleroderma
	Hemorrhagic detachment of internal limiting membrane, hypertensive retinopathy
	Acquired retinal arterial macroaneurysm

Other Diseases	
	Cystoid macular edema, aphakic
	Cystoid macular edema, nicotinic acid maculopathy
	Congenital retinal telangiectasis
	Acquired bilateral juxtapapillary telangiectasis
5	Acquired bilateral juxtapapillary obliterative telangiectasis
	Diabetic optic neuropathy
	X-ray radiation exudative retinopathy
	Sickle cell SC disease, macular hemorrhage
	Retinal arterial aneurysms, arteritis, neuroretinitis
10	Branch retinal vein obstruction (BRVO)
	BRVO, exudative maculopathy
	BRVO, optic disc new vessels, photocoagulation
	Waldenström's macroglobulinemia
Inflammatory Diseases of the Retina and Choroid	
15	Luetic retinal vasculitis
	Focal <i>Candida</i> retinal abscess
	Toxoplasmosis, atrophic chorioretinal scar
	Toxoplasmosis retinitis and macular detachment
	Toxoplasmosis scar, CNVM, macular detachment
20	Diffuse unilateral subacute neuroretinitis, small worm
	Diffuse unilateral subacute neuroretinitis, large worm
	Cytomegalic inclusion disease, papillitis
	Acute posterior multifocal placoid pigment epitheliopathy
	Acute macular neuroretinitis
25	Sarcoid retinitis
	Sarcoid papillitis
	Behcet's disease
	Vitiliginous (bird-shot) chorioretinitis

Other Diseases		
Multifocal choroiditis and panuveitis (pseudo-POHS)		
Retinal and Pigment Epithelial Hamartomas		
Congenital grouped albinotic RPE spots		
Congenital hyperplasia of RPE		
5	Combined RPE and retinal hamartoma, juxtapapillary	
	Combined RPE and retinal hamartoma, peripheral	
	Cystic astrocytoma, juxtapapillary	
	Astrocytoma, macula	
	Astrocytoma, juxtapapillary	
10	Cavernous hemangioma of retina	
	Juxtapapillary sessile retinal capillary hemangioma	
	Juxtapapillary endophytic retinal capillary hemangioma	
Other Tumors of the Choroid		
Choroidal metastasis		
15	Choroidal osteoma	
	Choroidal hemangioma	
	Miscellaneous uveal tumors	
Intraocular Lymphoid Tumors		
The leukemias and lymphomas		
20	Tumors of the Vitreous	
	Non-Hodgkins ("reticulum cell") lymphoma	
	Tumor involvement of the vitreous cavity	
Macular Disease		
Age-related macular degeneration -- atrophic form		
25	Exudative age-related macular degeneration	
	Choroidal neovascular membrane in degenerative myopia	
	Central serous retinopathy	
	Macular hole	

Other Diseases	
	Macular dystrophies
	Retinal Vascular Disease
	Etiologic mechanisms in diabetic retinopathy
	Background diabetic retinopathy
5	Proliferative diabetic retinopathy
	Retinal arterial obstructive disease
	Central retinal vein occlusion
	Retinal branch vein occlusion
	Pregnancy and retinal disease
10	Pregnancy-induced hypertension
	Hypertension
	The rheumatic disease
	Parafoveal telangiectasis
	Coats disease
15	Disseminated intravascular systemic coagulopathy and related vasculopathies
	Hemoglobinopathies
	Retinopathy of prematurity
	Acquired retinal macroaneurysms
	Eales disease
20	Radiation retinopathy
	The ocular ischemic syndrome
	Inflammatory Disease
	Ocular toxoplasmosis
	Ocular toxocariasis
25	Ocular cysticercosis
	Cytomegalovirus infections of the retina
	Retinal and ophthalmologic manifestations of AIDS
	Acute retinal necrosis syndrome

-49-

Other Diseases	
	Endogenous fungal infections of the retina and choroid
	Pars planitis
	Syphilis and tuberculosis
	Diffuse unilateral subacute neuroretinitis
5	Scleritis
	Birdshot retinochoroidopathy
	Punctate inner choroidopathy
	Sarcoidosis
	Acute multifocal placoid pigment epitheliopathy
10	Geographic helicoid peripapillary choroidopathy (GHPC): serpiginous choroiditis
	Sympathetic ophthalmia
	Vogt-Koyanagi-Harada syndrome (uveomeningitic syndrome)
	Ciliochoroidal (uveal) effusion

15 Reproduced from: Stereoscopic Atlas of Ocular Diseases Diagnosis and Treatment, 2nd Edition, J. Donald O. Gass, Vol. 1 & 2, C.V. Mosley Co. (1987); and Retina Vol. II, Editor, Stephen J. Ryan, Medical Retina, C.V. Mosley Co. (1989).

20 2. Therapeutic products

Therapeutic products include but are not limited to, wild-type genes that are defective in ocular disorders, such as rhodopsin, or fragments thereof sufficient to correct the genetic defect, trophic factors, including growth factors, inhibitors and agonists of trophic factors, anti-apoptosis factors and other 25 products described herein or known to those of skill in the art to be useful for treatment of disorders of the eye or that can be treated by a product expressed by a photoreceptor.

OCULAR GENE THERAPY STRATEGIES		
GENERAL DISEASE	EXAMPLES	STRATEGY

-50-

OCULAR GENE THERAPY STRATEGIES		
Hereditary retinal and macular degeneration	<ul style="list-style-type: none"> <li>• Retinitis pigmentosa</li> <li>• Stargardt's disease</li> <li>• Other macular dystrophies</li> </ul>	Growth factors (e.g., GDNF) anti-apoptotic factors (e.g., bcl2 gene) Stargardt Disease Gene (ABCR) <sup>†</sup>
Neovascular	<ul style="list-style-type: none"> <li>• Diabetes</li> <li>• Choroidal neovascularization</li> </ul>	Anti-angiogenesis factors
Anti-tumor	Retinoblastoma	Antiproliferant
5 Glaucoma	Nerve fiber layer atrophy	Neuroprotective agent

See Allikmets *et al.* (1997) *Science* 277:1805-1807.

For example, for treatment of retinitis pigmentosa the adenovirus vector can deliver a wild-type rhodopsin gene or a growth factor or trophic factor, such as ciliary neurotrophic factor CNTF; for treatment of Stargardt's disease, the vector can deliver a wild type ABCR (also called STGD1) or a growth factor or anti-angiogenic agent; for diabetic retinopathies, retinal vascularization the vector can deliver growth factors, such as a TGF (TGF $\beta$ ), to prevent degeneration.

15 The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

#### EXAMPLE 1

##### Preparation of Adenovirus Packaging Cell Lines

Cell lines that are commonly used for growing adenovirus are useful as 20 host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and other 25 epithelial-derived cell lines. As a result of the adenovirus transformation, the

293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

These cell lines allow the production and propagation of adenovirus-based gene delivery vectors that have deletions in preselected gene regions and that 5 are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a viral vector, plasmid vectors that contain preselected functional units have been designed. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such 10 complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit that is 15 alternately spliced to produce several different mRNA products. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcription unit. A DNA fragment extending from 175 nucleotides upstream of the E4 transcription start site including the natural E4 promoter to 153 nucleotides downstream of the E4 20 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Virol.*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of 25 the primers used were 5'CGGTACACAGAATTCAGGAGACACACTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAC3' (SEQ ID NO: 2) (backward or 3' primer referred to as E4R). To facilitate cloning of the PCR fragment, these oligonucleotides were designed to create new sites for the 30 restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute,

-52-

50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid PBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment.

The isolated BamHI-modified fragment was then cloned into the BamHI site of PBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp. The pE4/Hygro plasmid has been deposited with the ATCC under accession number 97739. The complete nucleotide sequence of pE4/Hygro is set forth in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

**B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses**

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also

-53-

contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites 5 of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

10 The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter 15 provided by the pcDNA vector, a BgIII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral 20 mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-25 7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is included in SEQ ID NO: 8 bordered by BamHI/BgIII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial 30 TPL is also listed separately as SEQ ID No. 22 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt BgIII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1);

-54-

28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BgIII site.

The pCLF plasmid has been deposited with the ATCC as described in  
5 Example 4. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA.

10 C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins

The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*, 15 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10<sup>6</sup> cells were electroporated with 20  $\mu$ g each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25  $\mu$ F. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).

20 Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200  $\mu$ g/ml Hygromycin B (Sigma, St. Louis, MO).

From expanded colonies, genomic DNA was isolated using the 25 "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near adenovirus 5 open reading frame 6.

30 One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the product, indicating the presence of inserted DNA corresponding to most, if

-55-

not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 4. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected.

5 Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell

10 line, the labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event.

Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected.

15 Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional electroporation with the fiber-encoding pCLF plasmid as described above.

20 Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 µg/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate sublines of 211 were then screened for fiber protein expression by indirect immunofluorescence as described above. The three sublines screened, 211A, 211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSVβgal (1 pfu/cell) and stained 24 hours post-infection.

25 Lines positive for nuclear staining in this assay were then subjected to Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the predicted molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including

-56-

211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 4.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a seminative electrophoresis system demonstrated that the 5 fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein. The predicted molecular weight of a trimerized fiber is 186 kd. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in 10 complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

**D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses**

In order to prepare adenoviral packaging cell lines other than those based 15 on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers 20 used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and Xhol as indicated by the underlines. The sites are used 25 to clone the amplified E1 gene fragment into the NheI/Xhol sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides 30 from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the

pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the *E. coli* *gpt* gene that allows stable transfecants to be isolated using hypoxanthine/amino-pterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide 5 positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

**E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins**

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C, 10 alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following 15 transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R, as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber 20 antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

**F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses**

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in 30 various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for

use in generating recombinant adenovirus viral vectors thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

5        1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer 5'GACGGATCAGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the 10 nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector 15 is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides dexamethasone-inducible E1 function as described for 20 DEX/E1 and expression of Ad5 fiber protein as described above.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998 25 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more 30 delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions preformed as

previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

**2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes**

5 Plasmid pCLF prepared as described in Example 1B is partially digested with BgIII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber 10 gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4 15 gene are located at respective nucleotide positions 21 and 3149 followed by fused BgIII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BgIII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BgIII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide 20 positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

**EXAMPLE 2**

**25 Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines**

Adenoviral delivery vectors are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector is replication competent but only via a 30 non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, these adenovirus delivery vectors have a higher capacity for insertion of foreign DNA.

-60-

**A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use**

To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid pΔ 5 E1B $\beta$ gal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli*  $\beta$ -galactosidase gene was isolated from pSV $\beta$ gal (Promega) by digesting with Vspl, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with Bam H1. The resulting fragment was cloned into the EcoRV and BamHI 10 sites in the polylinker of pΔ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form pΔ E1B  $\beta$ gal that therefore contained the left end of the adenovirus genome with the Ela region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSV $\beta$  gal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the 15 Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)

20 The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994) (see, also International PCT application No. WO 95/00655) using methods well known to one of skill in the art. This vector 25 is also commercially available from Microbix and contains an Ad5 genome with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme Pael. An 11.9 kb BamHI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the BamHI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. The p11.3 30 plasmid was then digested with Pael and Sall to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

-61-

This fragment was replaced with a 3.4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences:

5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17; and

5 5'CACAACGAGCTC AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18.

These primers incorporated sites for Pael and BamHI. Cloning this fragment into the Pael and blunt ended Sall sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resulting p11.3 plasmid containing the ITR and E4 regions, designated plasmid pDV43a, was then digested with BamHI. 10 This BamHI fragment was then used to replace a BamHI fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the 15 following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb BamHI fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3. 20 The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a Sall restriction site. pDV42 was then digested with Pael, 25 which cuts at a unique site (bold type) in one of the PCR primers, and with Sall, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding Pael/Xhol fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique Xhol site), creating pDV43. 30 A plasmid designated pDV44 was constructed by replacing the 11.9 kb BamHI fragment of pBHG10 by the analogous BamHI fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the

-62-

deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was

5 constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10. pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Plasmids pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection and subsequent homologous recombination with DNA carrying functional 10 packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with pΔE1Bβgal, which contains the left end of the Ad5 genome with an SV40-driven β-galactosidase reporter gene inserted in place of the E1 region.

15 In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences 20 corresponding to viral gene delivery vectors.

A selected cell line is plated in dishes and cotransfected with pDV44 and pΔE1Bβ gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a 25 full-length viral chromosome where pDV44 and pΔE1Bβ gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of 30 the recombinant virus are produced by standard methods.

Because of the fiber deletion, a pDV44-derived virus is replication-defective, cells in which it is grown must complement this defect.

-63-

The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 4) was used for rescue and propagation of the virus described here. pDV44 and pΔE1βgal were cotransfected into 211B cells, and the monolayers 5 were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

One of a total of 58 transfected dishes showed evidence of spreading cell 10 death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5.βgal.ΔF) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B cells were plated in DMEM plus 10% fetal calf serum at approximately  $1 \times 10^7$  15 cells/150 cm<sup>2</sup> flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5.βgal.ΔF, at approximately 100 particles/cell. At day two, an equal volume of medium was added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis 20 via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C. Purified Ad5.βgal.ΔF virus particles containing human adenovirus Ad5.βgal.ΔF genome (described 25 further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 4.

For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at  $1.5 \times 10^6$  cells/well. Duplicate dilutions of 30 virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C, virus was removed and the wells overlaid with 2

ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. $\beta$  gal.wt, which is identical to Ad5. $\beta$ gal. $\Delta$ F except for the fiber deletion, was constructed by cotransfection of 5 pBHG10 and p $\Delta$ E1B $\beta$ gal. In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p $\Delta$ E1B $\beta$ gal and pBHG10 produced virus.

In another embodiment, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector 10 having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to 15 prepare a viral vector lacking fiber. For genetic therapy, the fiber gene can be replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Methods for producing a fiberless vector with a complete TPL are described in Example 3.

Vectors for the delivery of any desired gene and preferably a therapeutic 20 gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p $\Delta$ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing pE1B $\beta$  gal as described above. The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later 25 Examples.

#### 1. Characterization of the Ad5. $\beta$ gal. $\Delta$ F Genome

To confirm that the vector genomes had the proper structures and that the fiber gene was absent from the Ad5. $\beta$ gal. $\Delta$ F chromosome, the DNA isolated 30 from viral particles was analyzed. Briefly, purified viral DNA was obtained by adding 10  $\mu$ l of 10 mg/ml proteinase K, 40  $\mu$ l of 0.5 M EDTA and 50  $\mu$ l of 10% SDS to 800  $\mu$ l of adenovirus-containing culture supernatant. The suspension

-65-

was then incubated at 55°C for 60 minutes. The solution was then extracted once with

400 µl of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was

5 washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 µl of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from Ad5.βgal.wt and Ad5.βgal.ΔF produced the expected restriction patterns following digestion with either EcoRI or with NdeI. Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the 10 presence of fiber sequence in Ad5.βgal.wt but not in Ad5.βgal.ΔF DNA. As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. E4 signal was readily detectable in both genomes at equal intensities. The complete nucleotide sequence of Ad5.βgal.ΔF is presented 15 in SEQ ID NO: 23 and is contained in the virus particle on deposit with ATCC.

## 2. Characterization of the Fiberless Adenovirus Ad5.βgal.ΔF

To verify that Ad5.βgal.ΔF was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5.βgal.ΔF or with Ad5.βgal.wt. Twenty-four hours post

20 infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5.βgal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

## 25 3. Growth of the Fiber-Deleted Ad5.βgal.ΔF Vector in Complementing Cells

Ad5.βgal.ΔF was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5.βgal.ΔF or Ad5.βgal.wt contained similar numbers of viral particles. The particles appeared 30 to band normally on CsCl gradients. Infectivity of the Ad5.βgal.ΔF particles was lower than the Ad5.βgal.wt control, as indicated by an increased particle/PFU ratio. Ad5.βgal.ΔF was also found to plaque more slowly than the control

-66-

virus. When plated on 211B cells, Ad5.βgal.wt plaques appeared within 5-7 days, while plaques of Ad5.βgal.ΔF continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5.βgal.ΔF plaques was essentially normal.

5

#### 4. Production of Fiberless Ad5.βgal.ΔF Particles

As Ad5.βgal.ΔF represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the 10 determination of whether such particles would be stable and/or infectious. Either Ad5.βgal.wt or Ad5.βgal.ΔF was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5.βgal.ΔF particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating 15 that there was not a gross defect in morphogenesis of fiberless capsids.

20

Particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. The Ad5.βgal.ΔF particles produced in 293 cells did not contain fiber protein. 211B-grown Ad5.βgal.ΔF also contained less fiber than the Ad5.βgal.wt control virus. The infectivities of the different viral preparations on epithelial cells correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5.βgal.ΔF was only 25 50-100 fold less than that of Ad5.βgal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

25

#### 5. Composition and Structure of the Fiberless Ad5.βgal.ΔF Particles

The proteins contained in particles of 293-grown Ad5.βgal.ΔF were 30 compared to those in Ad5.βgal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant. The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a

first-generation vector, with the exception of reduced intensity of the composite band resulting from proteins IIIa and IV (fiber). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the 5 low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5.βgal.ΔF and of Ad5βgal.wt. The fiber, having an extended stalk with a knob at the end, was faintly visible in favorable 10 orientations of wild-type Ad5 particles, but not in images of the fiberless particles. Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

Three-dimensional image reconstructions of fiberless and wild-type 15 particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components 20 into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base 25 around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

#### 6. Integrin-Dependent Infectivity of Fiberless Ad5.βgal.ΔF Particles

30 While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates

binding to the cells (via  $\beta 2$  integrins) and internalization (through interaction with  $\alpha v$  integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial 5 cells.

To investigate this, THP-1 monocytic cells were infected with Ad5. $\beta$ gal.wt or with Ad5. $\beta$ gal. $\Delta$ F grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting  $2 \times 10^5$  cells at the indicated m.o.i. in 0.5 ml of complete RPMI. Forty-eight hours post-infection, the cells were fixed with 10 glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy. The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells. Large differences were seen in plaquing efficiency on epithelial (211B) cells. Infection of THP-1 cells by either Ad5. $\beta$ gal. $\Delta$ F or 15 Ad5. $\beta$ gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5. $\beta$ gal $\Delta$ F from internalizing into the cells and delivering its genome to the 20 nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the 25 effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells 30 which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the

-70-

M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for 5 cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

The resulting products are then used to construct chimeric fiber constructs by PCR gene overlap extension (Horton *et al.* (1990) *BioTechniques*, 8:525-535). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region. 10 encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region. 15 encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1. 20 The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as 25 previously described. Other fiber chimeric constructs are obtained with the various adenovirus serotypes using a similar approach.

In an alternative embodiment, the use of modified proteins including with modified epitopes (see, e.g., Michael *et al.* (1995) *Gene Therapy*, 2:660-668 and International PCT application Publication No. WO 95/26412, which describe 30 the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity). In particular, the authors described the

production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following 5 synthesis.

Similar constructs are contemplated for use in the complementing adenoviral packaging cell systems for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic.

Heterologous ligands contemplated for use herein to redirect fiber specificity 10 range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or 15 those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end using routine procedures known to those of skill in the art. The skilled artisan will be with the preparation of linkers to accomplish sufficient protein 20 presentation and to alter the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this disclosure, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

25

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example

30 1.

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20)

-72-

followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The 5 resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral 10 vector packaging systems.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously 15 described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the 20 one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

#### EXAMPLE 3

25 Tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector are provided. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5 30 genomic DNA using the synthetic oligonucleotide primers 5'CTCAACAATTGTGGATCCGTACTCC3' (SEQ ID No. 24) and 5'GTGCTCAGCAGATCTTGCAGACTGTG3' (SEQ ID No. 25). The resulting

-73-

product was cloned to the BamHI and BgIII sites of pΔE1Sp1a (Microbix Biosystems) using sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then 5 amplified using primers 5'GGCGCGTTGGATCCACTCTCTTCC3' (SEQ ID No. 26) and 5'CTACATGCTAGGCAGATCTCGTCGGAG3' (SEQ ID No. 27), and cloned into the BamHI site of pDV52 (again using sites in the primers) to create pDV55.

This plasmid contains a 1.2 kb BamHI/BgIII fragment containing the first 10 TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID No 28 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2); 15 1141-1146 nt fused BamHI and BgIII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BgIII site.

#### EXAMPLE 4

##### Deposit of Materials

The following cell lines and plasmids were deposited on September 25, 20 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty):Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737), 25 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5.βgal.ΔF, was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were 30 deposited at the ATCC on January 5, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

-74-

#### EXAMPLE 5

##### Preparation and Use of Adenoviral Packaging Cell Lines Containing Plasmids Containing Alternative TPLs

Plasmids containing tripartite leaders (TPLs) have been constructed. The 5 resulting plasmids that contain different selectable markers, such as neomycin and zeocin, were then used to prepare fiber-complementing stable cell lines for use as for preparing adenoviral vectors.

###### A. pDV60

Plasmid pDV60 was constructed by inserting this TPL cassette of SEQ ID 10 No. 28 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a neomycin selectable plasmid (see, e.g., U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000); see also Von Seggern *et al.* (1998) *J. Gen Virol.*, 79: 1461-1468). The nucleotide sequence of pDV60 is 15 listed in SEQ ID NO: 29. Plasmid pDV60 has been deposited in the ATCC under accession number PTA-1144.

###### B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone 20 terminator was transferred from pCLF (ATCC accession number 97737; and described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000);), to a zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially available from Invitrogen and for which the sequence is known).

###### C. pDV67

In an analogous process, pDV67 containing complete TPL was constructed by transferring an Asp 718/XbaI fragment from pDV60 into pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is set forth in

-75-

SEQ ID No. 30. Plasmid pDV67 is available from the ATCC under accession number PTA-1145.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric 5 Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.* (1995) *J. Virol.*, 69: 2850-2857) using the primers 5'ATGGGAT CAAGATGAAGCGCGCAAGACCG3' (SEQ ID No. 31) and 5'CACTATAGCGGCCGCATTCTCAGTCATCTT3' (SEQ ID No. 32), and cloned to the BamHI and NotI sites of pcDNA3.1/Zeo(+) via new BamHI and NotI sites 10 engineered into the primers to create pDV68. Finally, the complete TPL fragment described above was then added to the unique BamH1 site of pDV68 to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID No. 33 and has been deposited in the ATCC under accession number PTA-1146.

E. Preparation of Stable Adenovirus Packaging Cell Lines

15 E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC # CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 34) and pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in SEQ ID No. 35), which provide complementation of the adenoviral E1 and E2a 20 functions, respectively. This line and its derivatives were grown in Richter's modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were electroporated as previously described (Von Seggern *et al.* (1998) *J. Gen Virol.*, 79: 1461-1468) with pDV61, pDV67, or with pDV69, and stable lines were selected with zeocin (600 µg/ml).

25 The cell line generated with pDV61 is designated 601. The cell line generated with pDV67 is designated 633 while that generated with pDV69 is designated 644. Candidate clones were evaluated by immunofluorescent staining with a polyclonal antibody raised against the Ad2 fiber. Lines expressing the highest level of fiber protein were further characterized.

30 For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM of dexamethasone was added to cell cultures 16-24 hours prior to challenge with virus for optimal growth kinetics. For preparing viral plaques, 5 X 10<sup>5</sup>

-76-

cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone the day prior to infection with 0.5  $\mu$ M included at a final concentration in the agar overlay after infection.

**F. Development of Cell Lines for Complementation of E1<sup>-</sup>/E2a<sup>-</sup> Vectors**

5 The Adenovirus 5 genome was digested with Scal enzyme, separated on an agarose gel, and the 6,095 bp fragment containing the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A., 10 under accession number VR-5. The Scal 6,095 bp fragment was digested further with Clal at bp 917 and BgIII at bp 3,328. The resulting 2,411 bp Clal to BgIII fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with Clal and BgIII, to form pSE280-E.

15 Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an Xhol and Sall restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:

5' end, Ad5 bp 552-585:

5'-GTCACTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCACGGA

20 CC-3' (SEQ ID No 36)

3' end, Ad5 bp 922-891:

5'-CGAGATCGATCACCTCCGGTACAAGGTTGGCATAG-3' (SEQ ID No. 37)

This amplified DNA fragment (sometimes hereinafter referred to as Fragment A) then was digested with Xhol and Clal, which cleaves at the native 25 Clal site (bp 917), and ligated to the Xhol and Clal sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.

PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an EcoRI restriction site. The primers which 30 were employed were as follows:

5' end, Ad5 bp 3323-3360:

-77-

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID No. 38);

and

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC

5 -3' (SEQ ID No. 39).

This amplified DNA fragment (sometimes hereinafter referred to as Fragment B) was digested with BgIII, thereby cutting at the Adenovirus 5 BgIII site (bp 3,382) and EcoRI, and ligated to the BgIII and EcoRI sites of pSE280-AE to reconstruct the complete E1a and E1b region from Adenovirus 5 bp 552 through 4,090. The resulting plasmid is designated pSE280-E1.

A construct containing the intact E1a/b region under the control of the synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was excised from pSE280-E1, which was modified previously to contain a BamHI site 3' to the E1 gene, by digesting with Xhol and BamHI. The Xhol to BamHI fragment containing the E1a/b fragment was cloned into the unique Xhol and BamHI sites of pGRE5-2/EBV (U.S. Biochemicals, Cleveland, Ohio) to form pGRE5-E1).

Bacterial transformants containing the final construct were identified. Plasmid DNA was prepared and purified by banding in CsTFA prior to use for transfection of cells.

**Construction of plasmid including Adenovirus 5 E2A sequence.**

The Adenovirus 5 genome was digested with BamHI and SphI, which cut at bp 21,562 and 27,080, respectively. Fragments were separated on an agarose gel and the 5,518 bp BamHI to SphI fragment was isolated. The 5,518 bp BamHI to SphI fragment was digested further with SmaI, which cuts at bp 23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI.

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites.

The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

-78-

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID No. 40);

3' end, Ad5 bp 23,912-23,934:

5'-CACCCCGGGGAGGC GGCGGCGACGGGGACGGG-3' (SEQ ID No. 41)

This amplified DNA fragment was digested with SmaI and EcoRI, and  
5 ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the  
complete E2a region from Ad5 bp 24,730 through 21,562. The resulting  
construct is pSE280-E2a.

In order to convert the BamHI site at the 3' end of E2a to a Sall site, the  
E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and  
10 recloned into the unique BamHI and NheI sites of pSE280. Subsequently, the  
E2a region was excised from this construction with NheI and Sall in order to  
clone into the NheI and Sall sites of the pMAMneo (Clonetech, Palo Alto, CA)  
multiple cloning site in a 5' to 3' orientation, respectively. The resulting  
construct is pMAMneo E2a.

15 Bacterial transformants containing the final pMAMneo-E2a were  
identified. Plasmid DNA was prepared and purified by banding in CsTFA.  
Circular plasmid DNA was linearized at the XmnI site within the ampicillin  
resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform  
extraction and ethanol precipitation prior to use for transfection of cells.

20 Transfection and selection of cells.

In general, this process involved the sequential introduction, by calcium  
phosphate precipitation, or other means of DNA delivery, of two plasmid  
constructions each with a different viral gene, into a single tissue culture cell.  
The cells were transfected with a first construct and selected for expression of  
25 the associated drug resistance gene to establish stable integrants. Individual cell  
clones were established and assayed for function of the introduced viral gene.  
Appropriate candidate clones then were transfected with a second construct  
including a second viral gene and a second selectable marker. Transfected cells  
then were selected to establish stable integrants of the second construct, and  
30 cell clones were established. Cell clones were assayed for functional expression  
of both viral genes.

-79-

A549 (ATCC Accession No. CCL-185) were used for transfection.

Appropriate selection conditions were established for G418 and hygromycin B by standard kill curve determination.

**Transfection of A549 cells with plasmids including E1 and E2a regions.**

5 pMAMNeo-E2a was linearized with XmnI with the Amp<sup>R</sup> gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, and visualizing by immunofluorescence. E2a function was 10 screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1, which contains the GRE5 promoted 15 E1a/b region plus the hygromycin<sup>R</sup> gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus 20 establishing the expression of E1a/b and E2a in the positive cell clones.

A transfected A549 ( A549 (ATCC Accession No. CCL-185);) cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

25 **G. Preparation of Adenoviral Vectors Containing Ad5.βgal.ΔF Genome in S8 Improved Fiber-Complementing Cell Lines**

To prepare adenoviral vectors containing Ad5.βgal.ΔF (Ad5.βgal.ΔF has been deposited the ATCC under accession number VR2636) in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5.βgal.ΔF in 30 211B cells was followed with the exception of pretreatment with 0.3 μM dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless

-80-

Ad5. $\beta$ gal. $\Delta$ F genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5. $\beta$ gal. $\Delta$ F genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

Thus, these viral preparations, prepared as described herein are useful for targeting delivery of the Ad5. $\beta$ gal. $\Delta$ F, Ad5.GFP. $\Delta$ F, or other similarly constructed fiberless genome with either wild-type or modified fibers. Preferably for purposes herein the fibers are from an Ad serotype D virus, more preferably from Ad37.

#### EXAMPLE 6

10        **Pseudotyping and Infectivity of Recombinant Adenoviral Vectors  
Produced with Improved Fiber-Complementing Cell Lines**

A.        **Pseudotyping of Ad5. $\beta$ gal. $\Delta$ F**

To verify that adenoviral vectors were produced had altered tropisms, viral particles were purified from either 633 or 644 cells and were then Western blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects the Ad5 and chimeric 5T3H fiber proteins).

B.        **Infectivity of Cells with 633 or 644 Generated Virus Particles** The cell lines, 633 or 644, prepared as described above, were infected with the indicated number of particles/cell of Ad5. $\beta$ gal. $\Delta$ F and virus particles produced. Virus was then used to infect selected cell lines, including 211B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light microscopy where all experiments were done in triplicate.

The results indicated that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber proteins. Particles containing either fiber were equally infectious on 211B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.

## EXAMPLE 7

## Transient Transcomplementation

The ability of adenovirus type 5 (Ad5) to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it was thought that it would be difficult to use adenoviruses to deliver genes to specific cell types. A system for testing modified fiber genes to identify tropisms of interest is described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000). An *in vitro* system has been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate modified fibers expressed on a viral particle. This system can be used to produce therapeutic quantities of adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

Plasmids used were pDV60 and pDV55 were prepared as described herein and in U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000). pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5. $\beta$ gal. $\Delta$ F and 211B are described above. 293T cells are identical to 293 cells except they express an integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and  $\alpha_v$  integrins; HDF cells express  $\alpha_v$  integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine serum.

The fiber deletion mutation of Ad5. $\beta$ gal. $\Delta$ F is complemented in *trans* by passaging virions through 211B, a cell line that stably expresses functional Ad5.

-82-

fiber. The present system was designed to complement Ad5. $\beta$ gal. $\Delta$ F by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5. $\beta$ gal. $\Delta$ F genome that does not require propagation of 5 the virus.

The feasibility of transcomplementation of Ad5. $\beta$ gal. $\Delta$ F with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists 10 for at least six days. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5. $\beta$ gal. $\Delta$ F passaged through 211B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber 15 expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility 20 for quickly evaluating a bank of modified fibers for other binding properties, including new tropisms and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. $\beta$ gal. $\Delta$ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent 25 advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber for complementation with Ad5. $\beta$ gal. $\Delta$ F. Because the Ad5. $\beta$ gal. $\Delta$ F is deleted in E1, E3 and fiber, there is an additional 30 gene deletion, which should render it very suitable for gene therapy. In addition, the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. A single Ad vector preparation can be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

-83-

### EXAMPLE 8

#### Preparation of Adenoviral Gene Delivery Vectors Containing the Ad37 fiber protein

This example describes construction of packaging cell lines expressing the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as Ad5. $\beta$ gal. $\Delta$ F) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would efficiently bind the Ad5 penton base in these vectors.

##### A. Materials and methods

**Cell lines and wild-type adenovirus.** Human A549 lung carcinoma epithelial cells and human Chang C conjunctival cells (American Type Culture Collection) were maintained in complete Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum. Wild-type Ad19p and Ad37 (ATCC) were propagated in A549 cells and purified by banding on CsCl<sub>2</sub> density gradients as previously described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Viral protein concentration was determined by the Bio-Rad Protein Assay, and was used to calculate the number of viral particles based on the known molecular weight of Ad2 virions (1  $\mu$ g = 4  $\times$  10<sup>9</sup> particles).

##### B. Construction of the Ad37 fiber expressing cell lines and the recombinant Ad37 knob protein.

###### 1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)

The plasmid designated pDV80 (see, SEQ ID No. 42) prepared for expression of the Ad37 fiber protein in mammalian cells, uses the same regulatory elements as the elements in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines. It was constructed in two steps.

First, the Ad37 fiber open reading frame was amplified from Ad37 genomic DNA using synthetic oligonucleotide primers, L37: 5' TGT CCT GGA TCC AAG ATG AAG CGC GCC CGC CCC AGC GAA GAT GAC TTC 3' (SEQ ID NO. 43) and 37FR: 5' AAA CAC GGC GGC CGC TCT TTC ATT CTT G 3' (SEQ ID NO. 44). L37 contains nucleotides (underlined) that differ from the Ad37

-84-

genomic sequence in order to add a unique *Bam*H1 site (bold) before the start codon (italicized) and to create point mutations that make the N-terminal sequence of the fiber more closely match the N-terminal sequence of the Ad5 fiber protein as follows:

5 Ad37 MSKRLRVEDDFNPVYPY (SEQ ID No. 45)  
↓↓↓↓↓  
KRARPS (SEQ ID No. 46)

Ad5 MKRARPSEDTFNPVYPY (SEQ ID No. 47).

37FR also incorporates a unique *Not*1 site (bold). The PCR product was inserted  
10 into the *Bam*H1 and *Not*1 sites of pCDNA3.1zeo(+) (Invitrogen) to create  
pDV78. The correct sequence of the Ad37 fiber protein, including inserted  
changes, was confirmed by sequencing.

Two point mutations in the fiber gene in the 705 line, S356 to P356 and  
I362 to T362, were discovered by the sequencing. The mutations are not in the  
15 receptor binding domain in Ad37 fiber gene in the 705 cell line. They are buried  
in the knob trimer interface. To confirm that these mutations do not affect  
receptor binding, the Ad37 fiber protein with the correct sequence was recloned,  
and 293T cells transfected with the virus and subsequently infected with  
Ad5.GFPΔF to produce Ad37 pseudotyped virus. The results were the same as  
20 the results of the experiments with Ad37 pseudotyped virus produced from line  
705 (see, Wu *et al.* (2001) *Virology* 279:78-89).

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5  
tripartite leader was excised from pDV55 (see EXAMPLE 3) and inserted into the  
25 *Bam* H1 site of pDV78 to create pDV80 (SEQ ID No 42). Plasmid pDV80 has  
been deposited in the ATCC under accession number PTA-1147.

## 2. Construction of the recombinant Ad37 knob protein

Recombinant Ad37 knob protein containing an N-terminal T7•Tag was  
produced in *E. coli* using the PET expression system (Novagen). Ad37 fiber DNA  
(GenBank accession number U69132) was PCR amplified from wild-type Ad37  
30 genomic DNA using the following primers (SEQ ID Nos. 48 and 49):  
5' GGATCCATGGGATACTTGGTAGCA 3' (*Bam*H1 site underlined and  
5' GCAACTCGAGTCATTCTTGGGCAATATAGG 3' (Xhol site underlined).

-85-

The PCR reactions were performed at 94 °C (denaturation), 55 °C (annealing), 72 °C (extension, 30 cycles) using *Taq* DNA polymerase (Qiagen). The amplified DNA fragments, which contained residues 172 to 365 of the Ad37 fiber protein with the addition of an N-terminal start codon (italicized), were

5 purified and subcloned into the pCR-TOPO vector using the TA-Cloning Kit (Invitrogen). No replication errors were found by DNA sequencing. Plasmids from cultured transformed colonies were purified and digested with *Bam*HI and *Xhol*. The fragment was inserted into the *Bam*HI and *Xhol* sites of the bacterial expression vector, pET21a (Novagen), and transformed into (DE3)pLYS S 10 expression cells (Invitrogen). Colonies were selected for knob expression by induction with 1 mM IPTG for four hours at 37 °C and knob expression was determined by SDS-PAGE. The colony displaying highest knob expression was used for large-scale knob expression and induced with 0.5 mM IPTG at 30 °C for four hours.

15 The recombinant T7•Tagged Ad37 knob protein was purified from sonicated bacteria using the T7•Tag Affinity Purification Kit as recommended by the manufacturer (Novagen). Recovered protein was analyzed for purity by SDS-PAGE followed by Coomassie staining or Western blotting with an HRP-conjugated  $\alpha$ -T7•Tag monoclonal antibody as described by the manufacturer 20 (Novagen) or an  $\alpha$ -Ad37 fiber rabbit antibody.

### 3. Preparation of Cell Lines that Express the Ad37 fiber protein

Plasmid pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (see Examples herein; see also, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178; 25 and Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468). Stable clones were selected with 600  $\mu$ g/ml zeocin (Invitrogen).

Clones were expanded and were screened for fiber expression by indirect immunofluorescence (Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468) using a rabbit polyclonal antibody directed against the Ad37 fiber ( $\alpha$ -Ad37 fiber 30 rabbit antibody) raised by immunizing rabbits with recombinant Ad37 fiber protein. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected.

-86-

### EXAMPLE 9

#### Production of Pseudotyped Ad Vector Particles

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately 5 1000 particles/cell) with Ad5.βgal.ΔF or with Ad5.GFP.ΔF.

#### Materials and methods

##### Ad5.βgal.ΔF

The construction of Ad5.βgal.ΔF is described in Example 2 (it has been deposited on January 15, 1999, with the ATCC as listed above under accession 10 number VR2636; see also, Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; copending U.S. application Serial No. 09/482,682 filed January 14, 2000, and also International PCT application No. PCT/US00/00265, filed January 14, 2000).

##### Ad5.GFP.ΔF

15 Ad5.GFP.ΔF was constructed by recombination in bacteria using a modification of the AdEasy System (see, U.S. Patent No. 5,922,576; see, also He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the system is publicly available from the authors and other sources).

First, a fiber-deleted genomic plasmid was constructed by removing the 20 fiber gene from pAdEasy-1 (see, U.S. Patent No. 5,922,576; and He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the AdEasy system and vectors are publicly available from He *et al.* at Johns Hopkins University). Plasmid pAdEasy-1 contains the entire Ad5 genome, except for nucleotides 1- 25 3,533, which encompass the E1 genes, and nucleotides 28,130-30,820, which encompass the E3 gene.

Plasmid pDV43 (see Example 2; see, also Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608) was digested with *Pac*1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated to produce plasmid pDV76. The resulting plasmid pDV76 is identical to 30 pDV43 except for loss of the *Pac*1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.23 kb fragment from pDV76 was amplified using the oligonucleotide primers (SEQ ID Nos. 50 and 51:

5' CGC GCT GAC TCT TAA GGA CTA GTT TC 3', including the unique *Spe*1 site in the Ad5 genome (bold); and 5' GCG CTT AAT TAA CAT CAT CAA TAA TAT ACC TTA TTT T 3', including a new *Pac*1 site (bold) adjacent to the right Ad5 ITR. Hence the resulting PCR amplified fragment contains nucleotides 5 27,082 to 35,935 of the Ad5 genome with deletions of nucleotides 28,133 to 32,743 (the E3 and fiber genes), and was used to replace the corresponding *Spe*1/*Pac*1 fragment of pAdEasy 1 (see, U.S. Patent No. 5,922,576) to create pDV77.

Second, *E. coli* strain BJ5183 was electroporated with a mixture of 10 pDV77 and *Pme*1-linearized pAdTrack as described (U.S. Patent No. 5,922,576; He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete Ad5 genome with E1-, E3-, and fiber-deletions with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full length 15 Ad chromosome was isolated by *Pac*1 digestion, and transfected into the E1- and fiber-complementing 633 cells (Von Seggern *et al.* (2000) *J. Virol.* 74:354-362). The 633 cells were produced by electroporating pDV67 (SEQ ID No. 30, deposited under ATCC accession number PTA-1145) into the E1-2a S8 cells, described above. The recovered virus Ad5.GFP.ΔF was then plaque purified by 20 plating on 633 cells and virus stocks were prepared by freeze-thawing cell pellets.

#### Ad5-pseudotype particle production

##### Particles with Ad5 fiber

Ad5-pseudotyped particles were generated by virus growth in 633 cells, 25 which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients (Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C)). For analysis of viral proteins, ten µg of the purified particles were electrophoresed on 8-16% gradient gels and the protein 30 transferred to nylon membranes. The resulting blot was probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells.

**Particles with Ad37 fiber**

Cells from the Ad37 fiber producing cell line 705 were infected at approximately 1000 particles/cell with Ad5. $\beta$ gal. $\Delta$ F or with Ad5.GFP. $\Delta$ F. Viral particles were isolated and purified over CsCl gradients. The bands were 5 harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C.

**Viral protein analyses**

For analysis of viral proteins, 10  $\mu$ g of purified Ad5. $\beta$ gal. $\Delta$ F particles with no fiber (grown in 293 cells), the Ad5 fiber (grown in 633 cells), or the Ad37 10 fiber (grown in 705 cells) were electrophoresed by 8-16% polyacrylamide gradient SDS-PAGE and the proteins were transferred to nylon membranes. The blot was then probed with  $\alpha$ -Ad37 fiber rabbit antibody. Ad5 fiber and penton base were detected by reprobing the blot with polyclonal antibodies raised 15 against recombinant proteins expressed in baculovirus-infected cells (Wickman *et al.* (1993) *Cell* 2:309-319).

**Adenovirus infection and cell binding assays**

Adherent Chang C and A549 cells were infected with GFP expressing Ad5 vectors containing the Ad5 fiber (Ad5.GFP. $\Delta$ F/5F) or the Ad37 fiber (Ad5.GFP. $\Delta$ F/37F) at 10,000 particles per cell for 3 hours at 37°C, 5% CO<sub>2</sub> in 20 DMEM, 10% FCS. Cells were washed twice with saline and then cultured overnight at 37°C, 5% CO<sub>2</sub>. The next day, the cells were detached with buffer containing 0.05% (w/v) trypsin and 0.5 mM EDTA (Boehringer Mannheim) for 5 minutes at 37°C. Suspended cells were washed once with PBS and then 25 resuspended in phosphate-buffered saline (PBS), pH 7.4. GFP fluorescence was measured with a FACScan flow cytometer. A threshold established by the fluorescence of uninfected cells was used to distinguish cells expressing GFP. To assess the role of CAR in Ad infection, 10,000 attached cells were pre-incubated with 180  $\mu$ g/ml RmcB, a function-blocking anti-CAR monoclonal antibody (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), in complete DMEM for 1 30 hour at 4°C. A small volume containing Ad5.GFP. $\Delta$ F/5F or Ad5.GFP. $\Delta$ F/37F was then added at 10,000 particles per cell. The cells were infected for 3 hours, cultured overnight, harvested, and analyzed for GFP expression. Percent

cells expressing GFP was determined by the percent of cells detected above a threshold set by the fluorescence of uninfected Chang C cells.

To measure adenovirus binding to cells, wild type Ad37 was labeled with <sup>125</sup>I using Iodogen (Pierce) according to manufacturer instructions and separated from free <sup>125</sup>I by gel filtration as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Binding of radiolabeled wild type Ad37 on Chang C cells was then quantitated as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Non-specific binding was determined by incubating cells and labeled Ad37 particles in the presence of 100-fold concentration of unlabeled Ad37. Specific binding was calculated by subtracting the non-specific binding from the total cpm bound. To examine if divalent cations are required for binding, 10 mM ethylenediaminetetraacetic acid (EDTA) or various concentrations of CaCl<sub>2</sub>, or MgCl<sub>2</sub> were added to cells before incubation with labeled virus. To examine if the receptor for Ad37 is a protein, cells were pretreated with 10 µg/ml trypsin (GIBCO), subtilisin (Sigma), proteinase K (Boehringer-Mannheim), and bromelain (Sigma) at 37 °C for 1 hour, then washed twice with complete DMEM before adding labeled virus. Cells were >95% viable after protease treatment.

Ad37 binding to conjunctival cells is calcium-dependent. Specific <sup>125</sup>I-labeled Ad37 binding to Chang C cells was measured in the presence of 10 mM EDTA and in the presence of varying concentrations of calcium chloride or magnesium chloride. Specific binding was determined by subtracting the nonspecific counts in the presence of 100-fold excess unlabeled virus from the total counts.

Pretreatment of conjunctival cells with proteases inhibits Ad37 binding. Chang C cells were pretreated with various proteases for 1 hour before binding <sup>125</sup>I-labeled Ad37 to the cells. Nonspecific binding was measured by adding 100-fold unlabeled Ad37 to cells with <sup>125</sup>I-labeled Ad37 and subtracting from total counts for specific binding. Percent inhibition represents the difference in specific binding of untreated cells and pretreated cells as a percentage of the specific binding of untreated cells.

-90-

**Virus overlay protein blot assay (VOPBA)**

For VOPBA of human conjunctival membrane proteins probed with Ad37 in the presence of EDTA or calcium chloride, Chang C membrane fractions were separated by 8% SDS-PAGE and transferred to a PVDF membrane. The 5 membrane was subsequently probed with or without whole Ad37 particles, a polyclonal antibody against Ad37 fiber, and finally a horseradish peroxidase conjugated anti-rabbit antibody, in the presence of EDTA or calcium chloride. Transferred Chang C membrane proteins were probed with recombinant Ad37 knob protein, instead of Ad37 knob, in the presence of calcium chloride.

10 Confluent monolayers of Chang C and A549 cells were detached by scraping, pelleted by centrifugation, and then resuspended in 250 mM sucrose, 20 mM HEPES, pH 7.0, 1 mM EDTA, and 2  $\mu$ g/ml aprotinin and leupeptin. Cells were transferred into a dounce homogenizer and disrupted with 30 strokes. Organelles and nuclei were pelleted at 500g for 15 min. Plasma membrane 15 fragments were then pelleted from the supernatant of cell lysates at 200,000g for 1 hour and then resuspended in 10 mM Tris•Cl, pH 8.1, 10  $\mu$ g/ml aprotinin and leupeptin.

Cell membranes of Chang C or A549 cells were incubated (1:1) with a 2% SDS, non-reducing buffer and separated on an 8% polyacrylamide gel 20 without boiling. Membrane proteins were then electroblotted onto a PVDF membrane (Immobilon-P) and blocked in 5% (w/v) milk in PBS, pH 7.4, 0.02% Tween-20 (PBS-T). After blocking, the membrane was incubated with 1  $\mu$ g/ml wild-type Ad19p or Ad37 in 0.5% (w/v) milk in PBS-T, 1 mM  $\text{CaCl}_2$ , for 1 hour at room temperature. The membrane was then washed once with phosphate-buffered saline, pH 7.4 (PBS), 1 mM  $\text{CaCl}_2$ , and incubated with 1:500 dilution of  $\alpha$ -Ad37 fiber rabbit antibody in 0.5% (w/v) milk in PBS-T, 1 mM  $\text{CaCl}_2$ , for 30 minutes at room temperature. The membrane was washed again with PBS, 1 mM  $\text{CaCl}_2$ , and incubated with 1:5000 dilution of horseradish peroxidase (HRP) conjugated  $\alpha$ -rabbit antibody (Sigma) in 0.5% (w/v) milk in PBS-T, 1 mM  $\text{CaCl}_2$ , for 30 minutes at room temperature. The membrane was washed four times in PBS, 1 mM  $\text{CaCl}_2$ , once with PBS-T, 1 mM  $\text{CaCl}_2$ , and once in 1 mM  $\text{CaCl}_2$ . The blot was developed with enhanced chemiluminescence reagents (Pierce) for 5

minutes and placed onto a piece of Biomax film (Kodak) for 5 seconds to 1 minute. For divalent metal cation experiments, membranes were incubated in the presence of 2 mM EDTA instead of 1 mM CaCl<sub>2</sub> in all solutions. To assay fiber knob binding to cell membrane proteins, membrane filters were incubated 5 with 1 µg/ml purified T7-tagged Ad37 knob protein in Tris-buffered saline, 0.1% Tween-20, 1 mM CaCl<sub>2</sub>, for 1 hour at room temperature.  $\alpha$ -Ad37 fiber rabbit antibody and HRP-conjugated anti-rabbit antibody were applied and the membrane was developed with substrate solution as described above.

10 **Results: Comparison of adenovirus infection of human conjunctival and lung epithelial cells with virus particles retargeted with Ad5 or Ad37 fiber proteins**

Packaging cell lines producing the Ad37 fiber protein were generated. Since the N-terminal amino acid sequences of the Ad5 and Ad37 fiber proteins differ significantly, and to ensure that the Ad37 fiber would be efficiently incorporated into Ad5 vector particles, several residues in the wild-type Ad37 15 fiber were mutated to more closely match the Ad5 sequence. Stable cell lines producing this fiber under control of the CMV promoter and the adenovirus type 5 tripartite leader were then generated and screened for fiber expression by indirect immunofluorescence. One clone (line 705), which expressed the Ad37 fiber at a high level, was selected for further study.

20 Cells from one cell line 633, which expresses the wild-type Ad5 fiber protein, and line 705 were infected with a fiber-deleted Ad5 vector carrying a  $\beta$ galactosidase reporter gene. The resulting vector particles contained the Ad5 fiber protein (Ad5. $\beta$ gal. $\Delta$ F/5F) and the Ad37 fiber protein (Ad5. $\beta$ gal. $\Delta$ F/37F), respectively. Incorporation of the correct fiber protein into viral particles was 25 verified by Western blotting. Adenoviral vectors containing the GFP reporter gene, Ad5.GFP. $\Delta$ F/5F and Ad5.GFP. $\Delta$ F/37F, were created in the same fashion.

Infection of a variety of cell types using the retargeted adenovirus 30 particles was examined. As assayed by GFP fluorescence, Ad5.GFP. $\Delta$ F/5F exhibited good gene delivery to lung epithelial (A549) and conjunctival cells (Chang C). In contrast, Ad5.GFP. $\Delta$ F/37F efficiently delivered GFP to Chang C cells, but exhibited very poor gene delivery to A549 cells. Although CAR is expressed on the surface of A549 cells, as indicated by AD5.GFP. $\Delta$ F/5F

-92-

infection, Ad5.GFP.ΔF/37F was unable to infect these cells efficiently. This experiment shows that the Ad37 fiber protein can confer preferential infection of human conjunctival cells, but not CAR-expressing human lung epithelial cells.

Hence CAR is not the primary receptor for Ad37. Recent studies reported 5 that expression of CAR on the surface of chinese hamster ovary (CHO) cells did not improve Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 does not use CAR as a primary receptor. In order to verify this on human conjunctival cells, A549 and Chang C cells were pretreated with RmcB (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), a function-blocking monoclonal 10 antibody against CAR. The RmcB antibody inhibited infection of A549 cells by Ad5.GFP.ΔF/5F, but it had little effect on infection of Chang C cells by Ad5.GFP.ΔF/37F. This indicates that CAR is not the primary receptor for Ad37 on Chang C conjunctival cells.

Ad37 binding to conjunctival cells requires divalent metal cations. It has 15 been proposed (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) that a combination of fiber binding to CAR and penton base binding to  $\alpha_v$ -integrins allows some adenovirus serotypes to attach to cells. Although  $\alpha_v$ -integrin binding to the RGD motif of the adenovirus penton base is of relatively low affinity (Wickman *et al.* (1993) *Cell* 2:309-319), it may nonetheless contribute to viral attachment to the 20 cell surface. Ad37 shows a particularly strong affinity for binding to integrin  $\alpha_v\beta_5$  (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675), suggesting that integrin  $\alpha_v\beta_5$  might be a primary receptor for Ad37. Binding of the RGD motif by  $\alpha_v$ -integrins requires the presence of divalent cations, such as calcium or magnesium (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531). In contrast, no divalent cations were 25 required for binding in the CAR-Ad12 knob complex (Bewley *et al.* (1999) *Science* 286:1579-1583).

To investigate the potential role of  $\alpha_v$ -integrins and divalent metal cations in Ad37 receptor binding,  $^{125}$ I-labeled Ad37 binding to Chang C cells was examined in the absence or presence of EDTA. EDTA inhibited Ad37 binding to 30 conjunctival cells but did not alter Ad5 binding. These findings suggest a requirement for divalent metals for Ad37 binding.

The presence of either calcium or magnesium ions helps  $\alpha_v\beta_5$  organize in focal contacts (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531), suggesting that calcium and magnesium aid in integrin  $\alpha_v\beta_5$  function. To further test the potential role of integrin  $\alpha_v\beta_5$  in Ad37 cell attachment,  $^{125}\text{I}$ -labeled Ad37 binding to Chang C cells was measured in the presence of varying concentrations of calcium or magnesium chloride. Magnesium ions had little effect on Ad37 binding to Chang C cells. In contrast, calcium ions dramatically enhanced Ad37 binding to Chang C cells. The optimal concentration of calcium chloride for Ad37 binding was 1 mM, while higher concentrations of calcium actually decreased virus binding to cells. The fact that calcium, but not magnesium, promoted Ad37 attachment is not consistent with integrin  $\alpha_v\beta_5$  as the primary receptor for viral attachment to the cells since either metal will support ligand binding to integrin  $\alpha_v\beta_5$ . Moreover, A549 cells express abundant  $\alpha_v$ -integrins (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675) but were unable to support efficient binding of Ad37.

Wild-type Ad37 particles bind to three conjunctival membrane proteins. Recent studies reported that protease treatment of CHO cells abolished Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 bound to a protein receptor on CHO cells. Scatchard analysis of Ad37 binding to Chang C cells showed that each cell expresses approximately 24,000 fiber binding sites (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). To determine if the Ad37 binding site on human conjunctival cells is also a protein, Chang C cells were treated with different proteases prior to measuring binding of  $^{125}\text{I}$ -labeled Ad37. Digestion of surface proteins by all four proteases inhibited Ad37 binding to Chang C cells by greater than 50%. This finding showed that Ad37 also binds to a protein receptor on Chang C cells.

Virus overlay protein blot assays (VOPBAs) were used to identify candidate viral protein receptors. This Western blot technique uses intact viral particles in place of antibodies to probe viral-receptors interactions. VOPBA was used herein to identify Chang C membrane proteins that bind to Ad37. In the absence of Ad37 particles, no protein bands were observed, while addition of virus in the absence of calcium revealed binding to a single 45 kDa protein. In

the presence of 1 mM calcium chloride, Ad37 reacted with three proteins with approximate molecular weights of 45, 50 and 60 kDa. The same three proteins were detected using a recombinant Ad37 fiber knob alone, indicating that Ad37-receptor interactions are fiber mediated and do not involve interactions of other 5 capsid proteins such as the penton base. The size of the calcium-independent protein (45 kDa) is very similar to the known molecular weight of CAR. A direct comparison of the Ad37 VOPBA and a CAR Western blot showed that the 45 kDa receptor co-migrates with CAR on SDS-PAGE. Moreover, two other members of subgroup D adenoviruses, Ad9 and AD15, have been shown to bind 10 to CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915).

Since CAR does not appear to mediate Ad37 binding on intact Chang C cells, the possibility that the 50 or 60 kDa protein serves this function was tested by examining an adenovirus serotype that does not bind to Chang C cells. Ad19p, a closely related subgroup D adenovirus, binds poorly to Chang C cells 15 (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) and Ad19p recognition of the Ad37 receptor is therefore unlikely. Ad19p particles bound to the 45 and 60 kDa receptors in the VOPBA, but did not bind to the 50 kDa receptor. Moreover, the 50 kDa receptor is expressed on Chang C cells, but not A549 cells, which only support low levels of Ad37 binding and infection. Taken 20 together, these data indicate that the 50 kDa protein is a primary candidate receptor for Ad37 on human conjunctival cells.

#### Discussion

The identification of the CAR protein as a major adenovirus receptor does not explain why certain subgroup D members, such as Ad37, preferentially 25 infect ocular cells. A 50 kDa human conjunctival cell membrane protein is identified herein as a primary candidate for the receptor for Ad37. This 50 kDa protein is not present on A549 lung epithelial cells. Ad37 binding to this receptor is calcium-dependent, which is consistent with Ad37 binding and infection experiments. Ad37 also bound to a 60 kDa protein that is present on human 30 conjunctival and lung epithelial cells. It does not, however, appear to be serotype specific. The molecular weights of MHC class I heavy chain, which has been proposed as a receptor for Ad5, and  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins, receptors for

the penton base, are distinct from the 50 or to kDa receptor characterized in this study.

The studies of Ad37-receptor interaction using VOPBAs are consistent with previous studies showing that subgroup D adenoviruses can bind to the 5 extracellular domain of CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). Biochemical and structural studies on knob-CAR interactions indicate that the CAR binding site is located on the AB-loop of the fiber knob. Alignment of the fiber sequences of Ad37 and other adenoviruses reveals that the AB-loop of Ad37 is similar to those of Ad12 and Ad5. Moreover, a phylogenetic tree of 10 adenovirus knobs (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) shows that fiber proteins of subgroup D are similar to those of subgroup C and E, which use CAR as their primary receptor. Ad37 does not, however, appear to effectively use CAR as a primary receptor, as demonstrated by virus binding and infection studies on Chang C conjunctival cells and A549 lung epithelial cells.

15 It has been reported that Ad37 uses sialic acid as a receptor on chinese hamster ovary (CHO) cells and human lung carcinoma (A549) cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). Human conjunctival cells were not studied. Human corneal epithelial (HCE) cells were the only ocular cell line studied and Ad37 binds relatively poorly to these cells, compared to binding on A549 cells 20 (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). In addition,  $8.4 \times 10^7$  wheat germ agglutinin molecules per cell were required to significantly inhibit Ad37 binding to sialic acid on sialic acid positive CHO cells (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), three orders of magnitude higher than the number of Ad37 receptors on Chang C conjunctival cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802).

25 Clearly, sialic acid is not the only factor responsible for Ad37 binding to the cell surface and its influence on Ad37 tropism is unclear.

The results herein show that Ad37 selects a 50 kDa cellular receptor for binding to conjunctival cells, but it is possible that sialic acid also plays a role in this interaction. The characterization and identification of the Ad37 receptor 30 have therapeutic implications and also explain the different tropism of Ad37. The 50 kDa receptor for Ad37 may also be the receptor for other subgroup D adenoviruses that cause severe cases of EKC, Ad19a and Ad8. Ad19p is a

-96-

nonpathogenic variant of Ad19 (Arnberg *et al.* (1998) *Virology* 227:239-244) while Ad19A, along with Ad8 and Ad37, are major causes of EKC. Ad19a and Ad37 have identical fiber proteins (Arnberg *et al.* (1998) *Virology* 227:239-244) and have similar tropism in vivo. Ad8, Ad19a, and Ad37 agglutinate dog and 5 guinea pig erythrocytes more effectively than four other serotypes that are associated with less severe forms of conjunctivitis (Arnberg *et al.* (1998) *Virology* 227:239-244), implying that the receptors of Ad18, Ad19A, and Ad37 have similar characteristics. Hence, this 50 kDa receptor is an attractive drug target against EKC caused by adenoviruses to provide therapeutic intervention of 10 ocular diseases associated with these viruses.

#### EXAMPLE 10

##### Targeting of the Ad5 vector to photoreceptor cells

The fiber-deleted adenovirus vector Ad5.GFP.ΔF was propagated in 705 cells, which express a modified Ad37 fiber protein. Viral particles 15 (Ad5.GFP.Δf/37F) were harvested, CsCl-purified and dialized into 0.9% NaCl, 10 mM Tris, pH 8.1, and 10% glycerol. Two to three  $\mu$ l of the resulting solution, containing approximately  $1 \times 10^9$  particles/ $\mu$ l was injected into the vitreous chamber of a mouse eye. Seven days post-injection, eyes were harvested, fixed with paraformaldehyde and cryo-sectioned. Sections were stained with an anti-20 rhodopsin antibody to identify photoreceptor cells and with DAPI to show all cell nuclei. The resulting sections showed red anti-rhodopsin staining in the photoreceptors, blue DAPI-stained nuclei, and green GFP staining in any transduced cells. The results revealed substantially exclusive transduction of photoreceptors. Co-localization of rhodopsin staining and GFP expression 25 indicated selective transduction of photoreceptor cells.

As a control, contralateral eyes were injected with a stock of the fiber-deleted vector AD5.βgal.ΔF grown in the same Ad37 fiber-expressing cells. Since this virus (Ad5.βgal.ΔF/37F) produces βgal rather than GFP, the green staining is absent from the photoreceptors.

30 Additional experiments using the AD37 fiber for targeting to the photoreceptor cells have been performed. Subretinal and intravitreal injection have been used in mouse models and the results demonstrate targeting to the

-97-

photoreceptors. As with intravitreally injected eyes, the major cell type infected via subretinal administration was the photoreceptor.

As noted, Ad5.GFP.ΔF /37F infected Chang C cells efficiently, but A549 cells poorly. Ad37 fiber protein confers preferential infection on human conjunctival cells, but not CAR-expressing human lung epithelial cells. Binding to conjunctival cells requires divalent cations.

5 Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-98-

**WHAT IS CLAIMED IS:**

1. An isolated nucleic acid molecule, comprising:  
adenovirus inverted terminal repeat sequences; an adenovirus packaging signal operatively linked thereto; and a photoreceptor-specific promoter.
- 5 2. The isolated nucleic acid molecule of claim 1, further comprising a nucleic acid encoding a therapeutic product operatively linked to the promoter.
3. The isolated nucleic acid molecule of claim 1, wherein the promoter is a rhodopsin promoter.
4. The nucleic acid molecule of claim 1, wherein the adenovirus 10 genome does not encode a functional fiber protein such that packaging the nucleic acid requires complementation in a packaging cell.
5. A recombinant adenovirus vector, comprising the nucleic acid molecule of any of claims 1-4 packaged therein.
6. A recombinant adenovirus vector of claim 5, wherein inverted 15 terminal repeat sequences (ITR) and a packaging signal are derived from adenovirus type 2 or adenovirus type 5.
7. A recombinant adenovirus vector of claim 5, wherein the virus comprises a fiber protein.
8. A recombinant adenovirus vector of claim 7, wherein the fiber 20 protein selectively binds to photoreceptors in the eye of a mammal.
9. A recombinant adenovirus vector of claim 7, wherein the fiber is a chimera composed of N-terminal sequences from adenovirus type 2 or type 5, and a sufficient portion of an adenovirus serotype D fiber for selective binding to photoreceptors in the eye of a mammal.
- 25 10. A method for targeted delivery of a gene product to the eye of a mammal, comprising:  
administering a recombinant adenovirus virus that comprises heterologous DNA encoding the gene product or resulting in expression of the gene product, wherein the recombinant virus comprises a fiber protein that specifically or 30 selectively binds to receptors that are expressed on cells in the eye.

-99-

11. The method of claim 10, wherein the cells are photoreceptors.
12. The method of claim 10, wherein administration is effected by intraocular delivery.
13. The method of claim 10, wherein administration is effected by a 5 method selected from subretinal injection, intravenous administration, periorbital administration, and intravitreal administration.
14. The method of claim 10, wherein the recombinant virus comprises a fiber protein from an adenovirus type D serotype.
15. The method of any of claims 10-14, wherein the fiber protein is an 10 adenovirus type 37.
16. The method of any of claims 10-14, wherein the fiber is a chimeric protein containing a sufficient portion of the N-terminus of an adenovirus type 2 or type 5 fiber protein for interaction with an adenovirus type 2 or type 5 penton, and a sufficient portion of an adenovirus serotype D knob portion of the 15 fiber for selective binding to photoreceptors in the eye of a mammal.
17. The method of any of claims 10-16, wherein the recombinant virus is an adenovirus type D serotype.
18. The method of any of claims 10-17, wherein the encapsulated nucleic acid comprises a photoreceptor-specific promoter operatively linked to a 20 nucleic acid comprising the therapeutic product.
19. The method of claim 18, wherein the therapeutic product is selected from the group consisting of a trophic factor, an anti-apoptotic factor, a gene encoding a rhodopsin protein, a wild-type Stargardt disease gene (STDG1), an anti-cancer agent and a protein that regulates expression of a photoreceptor- 25 specific gene product.
20. The method of any of claims 10-19, wherein delivery is effected for treatment of an ocular disease.
21. The method of claim 20, wherein the disorder is a retinal degenerative disease.
- 30 22. The method of claim 20, wherein the disease is retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, or retinoblastoma.

-100-

23. The method of any of claims 10-22, wherein the mammal is a human.
24. The method of any of claims 10-22, wherein the viral nucleic acid comprises:
  - 5 an adenovirus inverted terminal repeat (ITR) sequences; and an adenovirus packaging signal operatively linked thereto.
  25. The method of claim 24, wherein the ITRs and packaging signal are derived from an adenovirus serotype B or C.
  26. The method of claim 24, wherein the ITRs and packaging signal 10 are derived from an adenovirus type 2 or 5.
  27. The method of claim 24, wherein the viral nucleic acid further comprises a photoreceptor-specific promoter.
  28. A method of targeted gene therapy, comprising: administering a recombinant viral vector that comprises an adenovirus 15 type 37 fiber protein or portion thereof, whereby the vector selectively transduces photoreceptors and delivers a gene product encoded by the recombinant viral vector; wherein the portion is sufficient for selective binding to photoreceptors.
  29. The method of claim 28, wherein the vector is administered into 20 the eye.
  30. The method of claim 28, wherein the vector is administered to the vitreous cavity of the eye.
  31. The method of claim 28, wherein administration is effected by subretinal injection, intravenous administration, periorbital administration or 25 intravitreal administration.
  32. The method of any of claims 10-31, wherein at least about  $10^7$  plaque forming units of virus are administered.
  33. The method of any of claims 10-31, wherein about 1 plaque forming unit to about  $10^{14}$  plaque forming units of virus are administered.

## SEQUENCE LISTING

<110> VON SEGGERN, DANIEL  
NEMEROW, GLEN R.  
FRIEDLANDER, MARTIN

<120> VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY

<130> 756.1PCT/NOV0205P

<140>

<141> 2001-05-01

<150> 09/562,934

<151> 2000-05-01

<160> 51

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1 30  
cggtacacag aattcaggag acacaactcc

<210> 2

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2 35  
gcctggatcc ggaaagtac gtaacgtggg aaaac

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 3 12  
cgcgatccg cg

<210> 4

<211> 8710

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

>400 > 4  
 caccttaaatt gtaagcgtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag 60  
 ctcattttt aaccataagg ccgaaatcg caaaatccct tataaatcaa aagaatagac 120  
 cgagataggg ttgagtgtt ttccagttt gaacaagagt ccactattaa agaacgtgga 180  
 ctccaacgtc aaaggggcgaaa aacccgtcta tcagggcgat gccccactac gtgaaccatc 240  
 accctaatca agtttttgg ggtcgagggt cgtaaagca ctaaattcgga accctaaagg 300  
 gagcccccgga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaagggaa 360  
 gaaagcgaaa ggagcgggccc cttagggcgt ggcagaatgtt gccggtcagc tgcgctaaac 420  
 caccacaccc gcccgcgtta atgcggccgt acaggcgcg gtttttttttccccc cattcaggct 480  
 ggcgaactgt tgggaagggc gatcggtgc ggccttttgc ctattacgccc agctggcgaa 540  
 agggggatgt gctgcaaggc gattaagggtt ggttaacgcga ggggtttccc agtcacgacg 600  
 ttgtaaaaacg acggccaggc aattgtataa cgactcacta tagggcgaat tgggtaccgg 660  
 gccccccctc gaggtcgacg gtatcgataa gcttgatatac gaattcagga gacacaactc 720  
 caagtgcata ctctatgtca ttttcatggg actgttctgg ccacaactac attaatgaaa 780  
 tatttgcac atctcttac acttttcatc acatttgccta agaataaaagg atcggttgc 840  
 ttatgttca acgtgtttat ttttcaattt cagaaaattt caagtattttt ttcattcagt 900  
 agtataggcc caccaccaca tagttatc acatcaccgt accttaatca aactcacaga 960  
 acccttagtat tcaaccctgcc acctccctcc caacacacag agtacacagt ccttctccc 1020  
 cggctggcct taaaaagcat catatcatgg gtaacagaca tatttttagg tgttatattc 1080  
 cacacgggtt cctgtcgagc caaacgctca tcagtgatata taataaaacte cccgggcagc 1140  
 tcacttaagt tcatgtcgct gtccagctgc tgagccacag gctgtgtcc aacttgcgtt 1200  
 tgcttaacgg gggcgaagg agaagtcac gcctacatgg ggttagagtc ataatgtgc 1260  
 atcaggatag ggggtgggtt ctgcagcgc ggcgaataa actgctggcg cccggctcc 1320  
 gtctcgagg aataacaatcat ggcagtggc tcctcagcga tgattcgcac cggccgcagc 1380  
 ataaggcgcc ttgtcctccg ggcacagcag cgcacccctga tctcaactaa atcagcacag 1440  
 taactgcagc acagcaccac aatattgttc aaaaatccac agtgcacaggc gctgtatcca 1500  
 aagctcatgg cggggaccac agaaccaccac tgccatcat accacaaggc cagtagat 1560  
 aagtggcgac ccctcataaa cacgtggac ataacattttt ccttttttgg catgttgaa 1620  
 ttcaccaccc cccggatcca tataaaaccc tcatttttttggccatc caccaccatc 1680  
 ctaaaccaggc tggccaaaac ctgcccggc gctatacact gcagggaacc gggactggaa 1740  
 caatgacagt ggagagccca ggactctgtaa ccatggatca tcatgtctgt catgatatac 1800  
 atgttggcac aacacaggca cacgtgcata cacttccctca ggattacaag ctcccccgc 1860  
 gttagaacca tatcccaggg aacaaccatc tcctgaatca gcttaatcc cactatgcag 1920  
 ggaagacctc gcaactgtaact cagtttgc tcatttttttggccatc gggcagcagc 1980  
 ggtatgtcc ccagttatggt agcgcgggtt tctgtctcaa aaggaggtag acgatcccta 2040  
 ctgtacggag tgcggcggaga caaccggagat cgtttggtc ttagtgcatttccactct 2100  
 acggccggacg tagtcatatt tcctgaagca aaaccagggtg cggggcgtgac aaacagatct 2160  
 gcgctccgg ttcggccgtc tagatcgctc tggtagtagt ttgttagtata tccactctt 2220  
 caaagcatcc aggccggccccc tggcttccggg tttatgtaa acgtgttgcatttccactt 2280  
 cctgataaca tcaccaccac cagaataaggc cacaccccgac ggtttttttt ttttatttcca 2340  
 cgagtccac acggggaggag cggggaggac tggagaaggc aacccctacatccatcgtcc 2400  
 aaagattatc caaaacctca aaatgaagat ctattaatcc cctccggatgttgcac 2460  
 cgtggtaaaa ctctacagcc aaagaacaga taatggcatt tgtaatgttgcacatgg 2520  
 ctccaaaag gcaaacggcc ctcacgttca agtggacgtt aacaaatccatccatcgtcc 2580  
 gaatctctc tataaaatcc ccagccatc caaccatccatcgtcc aaaaatttccatccatcgtcc 2640  
 accttctca tatattctca agcaaatccc gaatattaaatcc tccggccatt gtaaaaatct 2700  
 gtcggagac gcccctccacc ttccagctca agcagcgaat catgatttgc aaaaatttccatccatcgtcc 2760  
 ttctctacag acctgtataa gatttttttggccatc gtttttttttccatccatcgtcc 2820  
 taggtccctt cgcaggggcca gctgaacata atcgtgcagg tctgcacggc ccagcggccg 2880  
 cacttccccc ccaggaacct tgacaaaaga accacactgtt attatgacatccatcgtcc 2940  
 agctatgcta accagcgttag ccccgatgtt agcttttttggccatc gatataaaatccatccatcgtcc 3000  
 gcaagggtgt gtcaaaaaaaaa tcaggccaaatccatcgtcc gatataaaatccatccatcgtcc 3060  
 catgtctcatcag cagataaaagg caggttaagct cccggaaaccac aaaaaggaaaggc acatcgtagt 3120  
 ttctctcaatccatcgtcc ggttttgcataa taaaacacaaaataaaatccatcgtcc 3180  
 ttaaacatca gaaaggctgtc ttacaacagg aaaaacaaccatccatcgtcc 3240  
 tacggccatc cccggcgtgac cgtaaaaaaa ctgggtcaccgt tgataaaaaaatccatcgtcc 3300  
 cagctccctcg gtcatgtccg gagtccataatccatcgtcc gtaagactgttgcataaaccatccatcgtcc 3360  
 catcggtcag tgctaaaaaaatccatcgtcc cggccaaatccatcgtcc aaaaacccgggggaaatccatcgtcc 3420  
 gagacaaacatccatcgtcc atagggaggttgcataaaccatccatcgtcc aatccatcgtcc 3480  
 aaacacccatccatcgtcc tggcttgcataaaccatccatcgtcc cttccggctcc agaacaacatccatcgtcc 3540

acagcgcttc acagcgccag cctaacagtc agccttacca gtaaaaaaaga aaaccttatta 3600  
 aaaaaacacc actcgacacg gcaccagctc aatcagtac agtgtaaaaa agggccaagt 3660  
 gcagagcgag tatatatagg actaaaaaaat gacgtaacgg ttaaagtcca caaaaaacac 3720  
 ccagaaaacc gcacgcaac ctacgcccag aaacgaaagc caaaaaaccc acaacttcct 3780  
 caaatcgta cttccgttt cccacgttac gtaacttccc ggatcccgcc cattcacagt 3840  
 tctccgcaag aattgatgg ctccaaatct tggagtgggt aatccgttag cgaggtgccg 3900  
 ccggcttcca ttcaggtcga ggtggcccg ctccatgcac cgcgacgca cgccccggg 3960  
 cagacaaggat atagggcgcc gcctacaatc catgccaacc cgttccatgt gctcgccgag 4020  
 gcccataaa tcgcccgtac gatcagcggt ccagtgtatcg aagttaggct gtaagagcc 4080  
 gcgagcgatc cttgaagctg tccctgtatgg tcgtcatcta cctgccttga cagcatggcc 4140  
 tgcaacgcgg gcatcccgat gccggccgaa gcgagaaagaa tcataatggg gaaggccatc 4200  
 cagccctcgcg tcgcaacgcg cagcaagacg tagccccagcg cgccggccgc catgcccctgc 4260  
 ttcatccccg tggcccggtt ctcggtttt ctggcggtgt ccccgaaaga aatataattt 4320  
 catgttcttgc ttctatgt gacacaaacc ccccccagcg tttgtcatt ggcgaattcg 4380  
 aacacgcaga tgcagtcggg gcggcgccgt cccaggcttca cttcgcataat taaggtgacg 4440  
 cgtgtggctt cgaacaccga gcgaccctgc agcgaccgc ttaacagcgtaacacgcgt 4500  
 ccgcagatcc cgggcaatga gataaaaaaa acgttcaactt caccgcgacg tctgtcgaga 4560  
 agtttctgtat cggaaatgttcc gacacgttcc cccacgtat gacgctctcg gaggggcgaag 4620  
 aatctcgatc tttcagcttcc gatgttaggg ggcgtggata tgcctgcgg gtaaatagct 4680  
 gcccgtatgg tttctacaaa gatcgatgt tttatcgca ctttgcatacg gcccgcgtcc 4740  
 cgattccggat agtgcttgcg attggggat tcaagcgagag cctgcacatc tgcatactccc 4800  
 gcccgtcaca ggggttcacg ttgcacagacc tgcctgaaac cgaactgcgg gtttgcgtc 4860  
 agccggctcgcc ggaggccatg gatcgatcg ctggcgccg tcttagcccg acgagcggtt 4920  
 tcggccctt cggaccgcgg ggaatcggtt aatacactac atggcgatgt ttcataatcg 4980  
 cgattgtcgatc tccccatgttatactggc aactgtatgg ggcgtatcg gtcagtgcgt 5040  
 ccgtcgccgca ggctctcgat gagctgtatgc tttggccga ggactgcccc gaagtccggc 5100  
 acctcgatca cggggatttcc ggcttcaaca atgtcctgtac ggacaatggc cgcataacac 5160  
 cggtcattgtatc ctggagcgag gcgatgttcc gggatccca atacgaggatc gccaacatct 5220  
 tcttctggag gccgtgggtt gtttgcgttgg agcagcagatc ggcgtatcc gaggcgaggc 5280  
 atccggagatc tgcaggatcg cccggctcc ggggtatcgat gtcacttcggc 5340  
 aactctatca gagctgtttt gacggcaatt tgcgtatgc agcttggcg cagggtcgat 5400  
 gcgacgcaat cgtccgtatcc ggagccggga ctgtcgccg tacacaaatc gcccgcagaa 5460  
 gcccggccgtt ctggaccatg ggctgtgttag aagtaacttcg cgtatagtgg aaccgcgc 5520  
 ccagcactcg tccgaggggca aaggaaatgg ggcgtatcgat gggatgggg gaggtaactt gaaacacgg 5580  
 aggagacaat accggaaatgg accccgcgtt ggcgtatcgat gggatgggg gggatgggg 5640  
 acgggtgttg ggtcggttgc tcatcaacgc ggggttcgtt cccaggctg gactctgtc 5700  
 gataccccatc cggagaccatc ttggggccaa tgcgtatcgat ggggttcgtt tttcttcctt 5760  
 cacccccccaa gttcgggtatc agggccaggg tgcgtatcgat ggggttcgtt tttttatgg 5880  
 gccatagcca ctggccccgtt gggtagggca tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 5940  
 tctgtggggat tattatgg tggcgttgcgtt ggggttcgtt tttttatggt 6000  
 cagaccatcgatc gttttgtatc ggcgttgcgtt ggggttcgtt ccacactgg actgagcaga 6060  
 cccggcgtctt gtggctgcca aacaccccccgc tgcgtatcgat ggggttcgtt tttttatggt 6120  
 cggcccgatgtc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6180  
 gcccctgacgg gcttgcgtc tccggcatacg ggggttcgtt ccacactgg actgagcaga 6240  
 gagctcgatc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6300  
 taatcagcca taccacatc tgcgtatcgat ggggttcgtt tttttatggt 6360  
 cctgaacatcgaa acacataaaa tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6420  
 taatgttac aaataaaatcgatc tgcgtatcgat ggggttcgtt tttttatggt 6480  
 gcatgtatcgatc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6540  
 gttcttagatc gggccgcacc ggcgttgcgtt ggggttcgtt tttttatggt 6600  
 atttcgatcgatc tggcgatatc atgtcgtatcgat ggggttcgtt ccacactgg actgagcaga 6660  
 acaattccaa acacataatcgatc tgcgtatcgat ggggttcgtt tttttatggt 6720  
 gtgagctaac tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6780  
 tcgtccgatcgatc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6840  
 cgcgttccgc tttccatcgatc tgcgtatcgat ggggttcgtt tttttatggt 6900  
 gttatcgatcgatc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 6960  
 aagaacatcgatc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 7020  
 gcttccatcgatc tgcgtatcgat ggggttcgtt ccacactgg actgagcaga 7080  
 aggtggcgaa accccgacagg actataaaaga taccaggatcgat tttttatggt 7140  
 gtgcgttccgc tttccatcgatc tgcgtatcgat ggggttcgtt tttttatggt 7200  
 ggaagcgatgg cgcgttccgc tttccatcgatc tgcgtatcgat ggggttcgtt tttttatggt 7260

ggtaactatc gtcttgagtc caaccggta agacacgact tatcgccact ggcagcagcc 7320  
 actggtaaca ggatttagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg 7380  
 tggcttaact acggctacac tagaaggaca gtatggta tctgcgtct gctgaagcca 7440  
 gttaccttcg gaaaaagagt tgtagtct tgatccggca aacaaaccac cgctggtagc 7500  
 ggtggtttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaagatc tcaagaagat 7560  
 ccttgatct ttctacggg gtctgacgct cagtggaaacg aaaactcactg ttaagggatt 7620  
 ttggcatga gattatcaa aaggatcttc accttagatcc tttaaatta aaaatgaagt 7680  
 tttaatcaa tctaaagttat atatgatcaa acttggtctg acagttacca atgcttaatc 7740  
 agtggggcac ctatctcagc gatctgtcta ttgcgttcat ccatagttgc ctgactcccc 7800  
 gtcgtgtaga taactacgat acggggaggc ttaccatctg gccccgtgc tgcaatgata 7860  
 ccgcgagacc cacgcgtcacc ggctcagat ttagtgcggtaa taaaccagcc agccggaagg 7920  
 gcccggcgca gaagtgggtc tgcaacttta tccgcctcca tccagtttat taattgttgc 7980  
 cggggagcta gagaatgg ttcgcgtt aatagttgc gcaacgttgc tgccattgtc 8040  
 acaggcatcg tgggtgtacgg ctgcgtcgat ggtatggctt cattcagctc cggttcccaa 8100  
 cgatccaaggc gagttacatg atccccatg ttgtgcggaa aagcggttag ctcccttcgg 8160  
 cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatgt tatggcagca 8220  
 ctgcataatt ctcttactgt catgcgttcc gtaagatgtt tttctgtgac tggtagtac 8280  
 tcaaccaagt cattctgaga atatgtatg cggcgaccga gttgcgttgc cccggcgtca 8340  
 atacgggata ataccgcggc acatagcaga actttaaaag tgctcatcat tgaaaaaacgt 8400  
 tcttcggggc gaaaactctc aaggatcttgc cccgtgttgc gatccagttc gatgtaaacc 8460  
 actcggtcac ccaactgtatc ttgcgttcc tttactttca ccagcgttgc tgggtgagca 8520  
 aaaacaggaa ggcggaaaatgc cgccaaaaaag ggaataaggg cgacacggaa atgttgaata 8580  
 ctcatactct tccttttca atattattgtc agcattttatc agggttatttgc ttcgttgc 8640  
 ggatatacatat ttgtatgtat ttggaaaaat aaacaaatag gggttccgcg cacatttccc 8700  
 cggaaaatgtc 8710

&lt;210&gt; 5

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 5

atggatcca agatgaagcg cgcaagaccg

30

&lt;210&gt; 6

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 6

cataaacgcgg ccgttctttt attcttgggc

30

&lt;210&gt; 7

&lt;211&gt; 7148

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: plasmid

&lt;400&gt; 7

 gacggatcg ggatctccc gatccccat ggtcgactct cagttacaatc tgctctgtat 60  
 ccccatagtt aagccagtat ctgtccctg cttgtgtt ggaggtcgct gatgtgtcg 120  
 cgagcaaaat ttaagctaca acaaggcaag gcttgcggca caattgcgtc aagaatctgc 180

tttagggttag gcgaaaaatcgcttgcg ctgcttcgcttgcg atgtacgggc cagatatacg cggttgcacatt 240  
 gattattgac tagttatcaa tagtaatccaa ttacggggtc attagttcat agcccatata 300  
 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccc cccaaacgacc 360  
 ccccccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420  
 atgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480  
 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540  
 atgcccagta catgacccctt tgggactttc ctacttggcc gtacatctac gtattagtca 600  
 tcgctattac catggtgatg cgggtttggc agtacatcaa tggcgcttgcg tagcggttt 660  
 actcacgggg atttccaatg ctccacccca ttgacgtcaa tggaggtttt tttggcacc 720  
 aaaatcaacg ggactttcca aatgtcgta acaactccgc cccattgacg caaatggcg 780  
 gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca 840  
 ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagacccaa gcttggtacc 900  
 gagctcgat ccaagatgaa ggcgcgaaga cccgtctgaag atacccctaa ccccggttat 960  
 ccatatgaca cggaaacccg tcccttcaact gtgccttttctt ttactctcc ctttgtatcc 1020  
 cccaaatgggt ttcaagagatc tccccctggg gtactcttt tgcccttctc cgaacctctta 1080  
 gttacccctca atggcatgt tgcgtctaaa atgggcaacg gcctctctc ggacgaggcc 1140  
 ggcaccccta cttcccaaaa tgtaaccact gtgagcccac ctctcaaaaaa aaccaagtca 1200  
 aacataaacc tggaaatatac tgcaacccctc acagttactt cagaacccctt aactgtggct 1260  
 gcccggcac ctctaattgt cgcgggcaac acactcacca tgcaatcaca gggcccgctt 1320  
 accgtgcacg actccaaact tagcattggc acccaaggac ccctcactatg gtcagaagg 1380  
 aagctagccc tgcaaaacatc aggccccctc accaccaccc atagoagttac ctttactatc 1440  
 actgcctcac cccctctaaac tactggcaact ggtagcttgg gcattgtactt gaaagagccc 1500  
 atttatacac aaaatggaaa actaggacta aagtacgggg ctcccttgca tgtaacagac 1560  
 gacctaaaca ctttgaccgt agcaactggg ccaggtgtga ctattataa tactttcttg 1620  
 caaaactaaag ttactggagc cttgggtttttaa gatttgcataa gcaatatgca acttaatgt 1680  
 gcaggaggac taaggatgtatc ttctccaaac agacgcctta tacttgcattt tagttatccg 1740  
 tttgtatgctc aaaaccaactt aatctaaga cttagcagg gccctttttt tataaactca 1800  
 gccaccaact tggatattaa ctacaacaaa ggcctttact tgtttacagc ttcaaaacaat 1860  
 tccaaaaaagc ttgaggttaa cctaaagcaact atggcttcaac gcaagggggt tgatgttga cgctacagcc 1920  
 atagccatta atgcaggaga tgggcttggaa gatattgttcaac ctaatgcacc aaacacaat 1980  
 cccctcaaaa caaaaatgg ccattggccca agacgcctta tacttgcattt tatggttctc 2040  
 aaacttagggc ctggcccttag ttttgacagc acagggtgcca ttacatgggaa acacaaaaat 2100  
 aatgataaggc taactttgtt gaccacacca gctccatctc ctaactgttag actaaatgca 2160  
 gagaagatg ctaaaactcac ttttgttctt aaaaaatgtg gcagtcaaat acttgcataa 2220  
 gtttcagttt tggctgttaa aggagtttg gctccaatat ctggaacagt tcaaaatgt 2280  
 catcttatta taagatttgca cgaaaatggaa gtgctactatc aacaaacccctt cctggacc 2340  
 gaatattggc acttttagaaa tggagatctt actgaaggca cagctataac aaacgcttt 2400  
 ggatttatgc ctaacccatc agtttatcca aatctcagc gtaaaactgc caaaagtaac 2460  
 attgtcagttt aagtttactt aaacggagac aaaactaaac ctgtaaactt aaccattaca 2520  
 ctaaaacggta cacagggaaac aggagacaca actccaatgt catactctat gtcatttca 2580  
 tggacttgcg ctggccacaa ctacattat gaaatatttg ccacatcttc ttacactttt 2640  
 tcatacattt cccaaagata aagaagccgc cgctcgagca tgcatctaga gggccctatt 2700  
 ctatagtgtc acctaaatgc tagagtcgc tgatcaggtt ccactgttgc ttcttagttc 2760  
 cagccatctg ttgtttggcc ctccccctgt cttcccttgc cccttggagg tgccactccc 2820  
 actgtccttt ctaataaaaaa tgagggaaatt gcatcgatt gtctgagtag gtgtcattt 2880  
 attctggggg gtgggggtggg gcaggacagc aagggggagg attggaaaga caatagcagg 2940  
 catgctgggg atgcgggtggg ctctatggct tctgaggccgaa aaaaacccatc ctggggctct 3000  
 agggggatc cccacgcgc ctgtagccgc gcatggacgc cgggggtgt ggtgtttaac 3060  
 cgcagcgtga cccgtacttgc tggcagccgc tcgttccctcg cccttttgc ttcttagttc 3120  
 tcctttctcg ccacgttgc cggctttccc cgtcaagtc taaatcgggg catcccttta 3180  
 gggttccgat ttgtgtttt acggcacctc gaccccaaaa aacttgatta ggggtatgg 3240  
 tcacgtatgtt gcccattcgcc ctgatagacg gtttttgc gtttgcgtt ggagtccac 3300  
 ttctttaata gtggacttgc ttccaaaact tcacccctat ctcgggttat 3360  
 tcttttgcatt tataaggat tttggggatt tcggcctatt ggtttaaaaa tgagctgatt 3420  
 taacaaaaat ttaacgcgaa ttaattctgt ggaatgtgtg tcagtttaggg tttatgcaga 3480  
 ccccaggctc cccaggcagg cagaagttatg caaagcatgc atctcaatta gtcagcaacc 3540  
 aggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 3600  
 tagtcagcaa ccatacgccc gcccctaact cggcccatcc cggccctaaac tccggccctgt 3660  
 tccgccccatt ctccgccccca tggctgacta atttttttt tttatgcaga gggccggg 3720  
 gcctctgcct ctgagctatt ccagaagttatg tgaggagct ttttggagg cttaggctt 3780  
 tgcaaaaaggc tccggggaggc ttgttatatcc attttgcatt ctgatcaaga gacaggatga 3840  
 ggatcggttc gcatgattga acaagatgga ttgcacgcag gtttgcggc cgcttgggt 3900

gagaggctat tcggctatga ctgggcacaa cagacaatcg gctgctctga tggccggcgtg 3960  
 ttccggctgt cagcgcaggc ggcgcgggtt ctttttgcata agaccgaccc gtcgggtgcc 4020  
 ctgaatgaac tgcaggacca ggcaggcggc ctatcggtc tggccacgac gggcgttcct 4080  
 tgcgcagctg tgctcgacgt tgcactgaa gcggaaagggg actggctgtc attggcgaa 4140  
 gtgcggggc aggatctcct gtcatctcact cttgctctgt ccgagaaaagt atccatcatg 4200  
 gctgatgaa tgcggcggtt gcatacgctt gatccggctt cctgcccattt cgaccaccaa 4260  
 gcgaaacatc gcatcgagcg agcactactt cggatggaaagg ccggctttgtt cgatcaggat 4320  
 gatctggacg aagagatca ggggtcgcc cagccgaac ttttcggcag gctcaaggcg 4380  
 cgcacggcccg acggcgaggc ttcgtcgatg accccatggcc atgcctgtt gccgaatata 4440  
 atggggaaa atggcgctt ttctggattt atcgactgtt gccggctggg tggccggac 4500  
 cgctatcaggc acatagcggtt ggctaccgtt gatattgtctt aagagcttgg cggcgaatgg 4560  
 gctgaccgct tcctcggtt ttacggatc ggcgtctcccg attcgcagcg catcgcccttc 4620  
 tattcgccctt ttgacgaggc ttctcgatc ggactctggg ttgcggatg accgaccaag 4680  
 cgacgcccacaa cctggccatca cgagatctg attcacccgc cgccttctat gaaagggttgg 4740  
 gcttcggaaat ctgtttccgg gacggccggc gtatgttccctt ccagcgcggg gatctcatgc 4800  
 tggaggatctt cggccaccccc aacttttttta ttgcagcttta taatgtttac aaataaaagca 4860  
 atagcatcac aaatttcaca aataaaagcat ttttttactt gcattctatg tgggtttgt 4920  
 ccaaactcat caatgtatct tattatgtt gataccgtt gacctttagc tagagcttgg 4980  
 cgtaatcatg gtcatacgctt ttctcggtt gaaatttttta tccgttccaca attccacacaca 5040  
 acatacgacg cggaaagcata aagttaaaag cttgggggtgc ctaatgatgtt agctaactca 5100  
 cattaaatgtt gttgcgttca ctgcggccgtt tccagtcggg aaacctgtcg tgccagctgc 5160  
 attaaatgttgc cggccaaacgc gccccggagag gcccgttgcg tattgggcgc tcttccgctt 5220  
 cctcgctcac tgactcgatc cgctcgatc ttccggatc ggcggatgttgc tcaagctact 5280  
 caaaggcggtt aatacggtt tccacacaaat caggggatataa cgcggaaag aacatgttgg 5340  
 caaaaaggcca gcaaaaggcc aggaaccgtt aaaaaggccgc gttgtggcg tttttccata 5400  
 ggctccgccc ccctgacgag catcacaatc atcgacgttc aagtcaagggg tggcgaaacc 5460  
 cgacaggactt aataaagatc cggcggtttc cccctggaaat ctcctcgatc cgctctctgt 5520  
 ttccgaccctt gccgcttacc ggataacctgtt ccgccttttcccttcgggaa agcgtggcgc 5580  
 tttctcaatgtt ctcacgtgtt aggtatctca gttcggttgc ggtcggttgc tccaaagctgg 5640  
 gctgtgttca cgaacccccc gttcagcccg accgctgtgc cttatccgtt aactatcgatc 5700  
 tttagtccaa cccggtaaga caccactt cgcactgtc cagatgttttgcgaaatc 5760  
 tttagcagacg gaggatgttgc ggcgtgtca cagatgttttgcgaaatc 5820  
 gctacactat aaggacatgtt tttgttatctt ggcgtctgtt gaaaggccatgtt accttcggaa 5880  
 aaagagttgg tagctcttgc tccggcaaaac aaaccaccgc tggttagcggtt ggtttttttt 5940  
 ttttcaagca gcaaggatccg cgcagaaaaaa aaggatctca agaaggatccctt tgatctttt 6000  
 ctacgggggtc tgacgtcttagt tggaaacgaaaactc acacgttca agggattttgc tcatagat 6060  
 tataaaaaaaat gatcttaccat tagatcctttt taaaataaaaaaat aatgatttt aatcaatct 6120  
 aaagatataat tggatataat tggatgttgcata gttaccaatgtt cttatcgtt gaggcaccta 6180  
 ttcacgatc ctgtcttaccat cgttccatccat tagttgcctt actccccgtc gtgttagataa 6240  
 ctacgatacg ggagggttca ccattctggcc ccagtgttgc aatgatccgc cgagacccac 6300  
 gctcaccggc tccagatattt tcagcaatata accaggccatc cggaggccgc gagcgcggaaa 6360  
 gtgtctgtc aactttatcc gcctccatcc agtcttattaa ttgttgcggg gaagcttagag 6420  
 taatgttgc gccagttat agtttgcata acgttgcgtt cattgttaca ggcacatgttgc 6480  
 tggatgttgc gtcgtttgtt atggcttcat tcagctccggg ttccaaacgc tcaaggcgag 6540  
 ttacatgtatc ccccatgtt tgcaaaaaaaat cggtagtgc ttcgtgttccctt ccgatcgatgt 6600  
 tcagaagttaa gttggccgca gtgttacatc tcatgttccat tggcagactgc cataatttc 6660  
 ttactgtcat gccatccgtt agatgtttt ctgtgacttgc tgagacttca accaagtcat 6720  
 ttcgttgc gccagttat agtttgcata acgttgcgtt cattgttaca ggcacatgttgc 6780  
 ccgcggccaca tagcagaactt taaaatgttccat tcatcatttttggaaaacgttctt tggggcgaa 6840  
 aactctcaag gatcttaccgtt ctgttgcgtt ccagttcgat taaacccactt cgtgcacccca 6900  
 actgtatcttccatc agcatctttt actttccatca gcttttctgg gtgttgcggaaaatc 6960  
 aaaatgcgcgca aaaaaaggaaataaggccgaa caccggaaatgtt gtaatacttc atactttccatc 7020  
 tttttcaata ttattgttgcattatcagg gttattgttccat gtcggccgaa tacatatttttgc 7080  
 aatgttatttttgc gaaaaataaaa caaatagggg ttccgcgcac atttcccgaa aaagtgcac 7140  
 ctgcacgttgc 7148

&lt;210&gt; 8

&lt;211&gt; 7469

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: plasmid

&lt;400&gt; 8

gacggatcg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60  
 ccgcatagtt aagccagtat ctgcctccctg cttgtgtgtt ggagggtcgct gagtagtgcg 120  
 cgagcaaaat ttaagctaca acaaggcaag gcttgcacca caattgcatg aagaatctgc 180  
 ttagggtagt gcggtttcgct ctgcctcgat atgtacgggc cagatatacg cggtgacatt 240  
 gattattgac tagtttataa tagtaatcaa ttacgggtc attagttcat agcccatata 300  
 tggagttccg cgttacataa cttacggtaa atggcccggc tggctgaccg cccaaacgacc 360  
 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420  
 attgacgtca atgggtggac tattacggt aaatgccca cttggcagta catcaagtgt 480  
 atcatatgcc aagtacggcc cctattgacg tcaatgacgg taaaatggccc gcctggcatt 540  
 atgcccaga catgacccat tggggatcc ctacttggca gtacatctac gtattagtca 600  
 tcgttattac catgggtatg cggtttggc agtacatcaa tggggcgtgga tagcgggttt 660  
 actcacgggg atttccaagt ctccacccca ttgacgtcaa tggggatttg ttttggcacc 720  
 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccatggacg caaaatggcg 780  
 gtaggcgtgt acgggtggag gtctatataa gcagactctt ctggcttaact agagaaccca 840  
 ctgttactg gcttacatcgaa attaatacgca ctcactatag ggagacccaa gcttggtacc 900  
 gagtcggat ctgaattcga gtcgtgtt gggctcgccg ttgaggacaa actcttcgcg 960  
 gtcttccag tacttcttgc tcggaaaccc gtcggctccg gaacggtaact cccgcacccg 1020  
 gggaccttag cgagtcgcga tcgacccggat cggaaaacct ctcgagaaag gctgtcaacc 1080  
 agtcacagtc gcaaggtagg ctgacgcacccg tggcgggggg cagcgggtgg cgggtcgggt 1140  
 tggggctggc ggaggtgtcg ctgtatgtt aattaaatgtt ggcggctttt agacggcgga 1200  
 tgggtcgaggt gagggtgtgc agggttggaa tccaaatgtt aacgcgcacccg accgtctgaa 1260  
 gataccatca accccgtgtt tccatatgtt acggaaaccc gtcctccaaatc tggccctttt 1320  
 cttaacttca cttttgtatcc ccccaatggg tttcaagaga gtccttctgg ggtactctt 1380  
 ttggccctat ccgaacccatc agttacatcc aatggcatgc ttgcgtcaaa atggcaac 1440  
 ggctctctc tggacggggc cggcaacccctt acctcccaaa atgtaaaccac tggagccca 1500  
 cctctcaaaa aaaccaagtc aaacataaaac ctggaaatccctt ctcgacccctt cacagttacc 1560  
 tcagaagccc taactgtggc tgccggcga ccttataatgg tcgccccggaa cacactcacc 1620  
 atgcaatcac agggcccgat aaccgtgcac gactccaaac tttagtattgc caccacaagg 1680  
 cccctcacag tgcagaagg aaagcttagcc ctgcaacat caggccccctt caccaccacc 1740  
 gatagcgtt cccttactat cactgcctca cccctctttaa ctactgcaccc tggtagctg 1800  
 ggatttgcgtt tggaaagagcc cattataca caaaatggaa aacttaggact aaagtacggg 1860  
 gctccttgc atgtaaacaga cggactaaac acttttgcgtt tggacccatcc tccaggtgtg 1920  
 acttataata atacttcctt gcaactaaa gtttgcgtt tggatatttactacaacaa aggcctttac 1980  
 ggaatatgc aacttaatgtt agcggaggaa ctaaggatttgcattcaatggg cagacgcctt 2040  
 atacttgcgtt ttagttatcc gtttgcgtt ctaaggatttgcattcaatggg caaaaccaac taaatctaag actaggacag 2100  
 ggccctctt ttataaaactc agcccacaac ttggatatttactacaacaa aggcctttac 2160  
 ttgtttacag cttcaacacaa ttccaaaaag cttggatatttactacaacaa aggcctttac 2220  
 ttgtatgtttt acgtctacgc catagccatc aatgcggagat tgggttgcattcaatggg caccatggcctt 2280  
 cctaattgcac caaacacaaaa tccccctcaaa tcaaaaatgg gccatggcctt agaatttgcattcaatggg 2340  
 tcaaaaacagg ctatggttcc taaaacttagga actggccctt tgggttgcattcaatggg caccatggcctt 2400  
 attacatgtt gaaacaaaaaa taatgtataag ctaactttgtt ggaccacacc agctccatct 2460  
 cctaactgtt gactaaatgc agagaaagat gctaaactca ctttgcgtt aacaaaatgtt 2520  
 ggcagtcaaa tacttgcgtt agtttcgtt ttggatatttactacaacaa aggcctttac 2580  
 tctggaaacag ttcaaaatgtt tcatactttt aataatggg ctaactttgtt ggaccacacc agctccatct 2640  
 aacaatttcctt tcctggaccc agaatattgg ctaactttgtt ggaccacacc agctccatct 2700  
 acgcctata caaaatgtt ttcaacttattt aacttttagaa atggagatct tggatatttactacaacaa 2760  
 ggtaaaactg ccaaaaatgtt cattgtcagt ctaactttgtt ggaccacacc agctccatct 2820  
 cctgttaacac taaccattac actaaacgggtt ttggatatttactacaacaa aggcctttac 2880  
 gcataactcta tgcattttc atgggactgg tctggccaca actacattaa tggatatttactacaacaa 2940  
 gcccacatctt ttacactttt tcatactttt gcccaagaat aaagaagccg cggctcgagc 3000  
 atgcgtttagt agggccctt tctatagttt cacctaaatg ctagagctcg ctgatcagcc 3060  
 tgcgttgc cttctatgtt ccagccatctt gttgtttgccttcccttgcgtt gcttccttgc 3120  
 acccttggaaag gtgcacttcc cactgtcctt tcataataaa atgaggaaat tgcatcgcatt 3180  
 tgcgttgcgtt ggtgttgcattt tattctgggg ggtgggggtgg ggcaggacac caagggggag 3240  
 gattggaaag acaatagcag gcatgtcgat gatgcgggtgg gctctatggc ttctgagggcg 3300  
 gaaagaacca gctggggctc taggggtat cccacgcgc cctgttagccg cgcattaaac 3360  
 gggcgccgggtg tgggtgttac ggcgcggcgtt accgcctacac ttggccagccg cctagccccc 3420  
 gtcctttcg ctttcttcc ttcccttctc gccacgttgc ccggctttcc cctgtcaagct 3480

ctaaatcggg gcatccctt agggatccga tttagtgcct tacggcacct cgaccccaaa 3540  
 aaacctgatt agggtgatgg ttcacgtagt gggccatcgc cctgatagac ggttttcgc 3600  
 ccttgcgt tggagtcac gttcttaat agtggactct tggatccaaac tggacaaca 3660  
 ctcaacccta tctcggtcta ttctttgtat ttataaggga ttttggggat ttcggcctat 3720  
 tggtaaaaaa atgagctgat ttaacaaaaa tttaacgcga attaattctg tgaatgtgt 3780  
 gtcagttagg gtgtggaaag tccccaggct ccccaggcag gcagaagtat gcaaaggatg 3840  
 catctcaatt agtcagcaac cagggtgtgg aagtccccagc gtcggcctatc aggcagaagt 3900  
 atgcaagca tgcattcaat ttatgcgca accatagtcc cgcccttaac tcggccatc 3960  
 cggccctaa ctccggccag ttccggccat tctccgcccc atggctgact aattttttt 4020  
 atttatgcag agggccgaggc cgcctctgcc tctgagctat tccagaagta gtgaggaggc 4080  
 tttttggag gcctaggctt ttgaaaaag ctccggggag cttgtatata cattttcgga 4140  
 tctgatcaag agacaggatg aggatgttt cgcattatc aacaagatgg attgcacgc 4200  
 ggttctccgg cccgtgggt ggagaggcta ttccggctatc actggcaca acagacaatc 4260  
 ggctgtctg atgcccggc tttccggctg tcaagcggagg ggcccccgt tcttttgc 4320  
 aagaccgacc tgcgggggtc cctgaatgaa ctgcaggacg aggacgcgcg gctatcgtgg 4380  
 ctggccacga cgggggttcc ttgcgcagct gtgcgcacg ttgtcaactga agcgggaagg 4440  
 gactggctgc tattggcga agtggccggg caggatctcc tgcatactca ctttgcct 4500  
 gcccggaaaat tatccatcat ggctgtatcga atgcggccgc gacatagcgt tgatccggct 4560  
 acctggccat tcgaccacca agcggaaatc cgcacgcacg gacacgtac tcggatggaa 4620  
 gccggcttg ctgcacggg tgatcggac gaagagcatc aggggctcgc gccagccgaa 4680  
 ctgttcgcca ggctcaaggc ggcgcacccc gacggcgagg atctcgctg gaccatggc 4740  
 gatgcctgtc tgccgaatat catgtggaa aatggccgt tttctggatt catcgactgt 4800  
 ggcggcgtgg gtgtggcgga cccgtatcag gacatagcgt tggctaccgg tgatattgt 4860  
 gaagagctt gccggcgttgg ggcgtaccgc ttcctcgatc tttacggat cggcgtcccc 4920  
 gatcgacgc gcatcgccct ctatcgccctt ttgcacgtt tcttcgtggc gggactctgg 4980  
 ggttcgaaat gaccgacca ggcgcacccc acctgcaccc acgagattt gattccaccc 5040  
 cccgcttcta tggaaagggtt ggcttcggaa tggatcccg tggatcccg tggatgatcc 5100  
 tccagcgcgg ggcattcatg ctggaggatct tggccaccc caacttgtttt attgcagctt 5160  
 ataatggta caaataaaatc aatagcatca caaatttcac aaataaagca tttttttcac 5220  
 tgcattctcgat ttgtgggtt tccaaactca tcaatgtatc ttatcgatc tgcgtatccgt 5280  
 cgacctctcgat ctagagcttgc gctatcatc gtttcgtgt tgaaattgtt 5340  
 atccgctcac aattccacac aacatacgag cccgaaggat aagtgtaaa gcctgggggt 5400  
 cctaattgagt gagctaactc acattaaatttgc tggccgtc actgcggcgt ttcagtcgg 5460  
 gaaacctgtc gtggccgttgc cattaatgaa tcggccaaacg cggggggaga ggcgggttgc 5520  
 gtattggcgct ctcttcgctc tcctcgctca ctgcactcgct ggcgcgttc gttcggctgc 5580  
 ggcgagcggt atcagctcac tcaaaaggcg tcaatcgatc tttccacagaa tcaggggata 5640  
 acgcaggaaa gaacatgtga gcaaaaggcc acggaaaaggc caggaaccgt aaaaaggccg 5700  
 cgttgcgtggc gtttttccat aggctccggc cccctgacga gcatcacaaa atcgacgtc 5760  
 caagtccagag gtggcgaaac ccgcacaggac tataaagata ccaggcgatc cccctggaa 5820  
 gtccttcgt ggcgttcctt gttccgaccc tggatccctc cggatccctg tccgccttgc 5880  
 tcccttcggg aaggctggcg ctttctcaat gtcacgcgt taggtatctc agttcggtgt 5940  
 aggtcggtcg ctccaaatgc ggcgtgtgc acgaaaaacc cgttcacccc gaccgtcgc 6000  
 ccttattccgg taaatatcgat ttgtatcgc acccggtaa acacgacttac tcggcaactgg 6060  
 cagcagccac tggtaacagg attacgagag cgaggatgtt aggcgggtct acagagttct 6120  
 tgaagtggtg gcctaactac ggctacacta gaaggacagt atttggatc tgcgtctgc 6180  
 tgaagccagt taccttcggg aaaagagttt gtagatcttgc atccggcaaa caaaccacccg 6240  
 ctggtagccgg tggttttt gtttgcacgc acgcaggatc ggcgcggaaa aaaggatctc 6300  
 aagaagatcc ttgtatccat ttcacgggtt ctgcacgtca gtggaaacgaa aactcacgtt 6360  
 aagggatttt ggtcatgaga ttatcaaaaaa ggatcttccac ttagatccctt taaaattaaa 6420  
 aatgaagttt taaatcaatc taaatgtatc atgatcaatc ttggatcgac agttaccaat 6480  
 gcttaatcag tgaggcacct atctcagcga gggagggtt accatctggc cccagtgcgt 6540  
 gactccccgt cgtgtatata actacgatc cttccatggc atcagacata aaccagccac 6600  
 caatgatacc ggcggacca cgcctcaccgg caactttatc cgcctccatc cagtcattaa 6720  
 ccggaaaggc cggcgcaga agtggctgtc ggcgcgttta tagttgcgc aacgttgg 6780  
 atttggccg ggaagctca gtaatgtttt cgtcggttgc tatggcttca ttcagctccg 6840  
 ccattgtcac aggcatcgat gtcacgcgt ccccatgtt gtgcggggggatc atcatgggtt 6900  
 gttcccaacg atcaaggcga ttacatgtatc gggggggatc agtggccgc agtggatcc 6960  
 ccttcggtcc tccgatcgat gtcacgttgc tgccatccgt aagatgtttt tctgtgactg 7020  
 tggcagcaact gcatcaatttcttactgtca agtgtatgcg ggcggcgttgc tgcgtcttgc 7080  
 gtgagttactc aaccaatgc ttctgagaat atagcagaac tttaaaatgt ctcattatc 7140  
 cggcgtcaat acgggataat accgcgcac ggcgttacc ggcgttgcgaa tccagttca 7200

tgtaaccac tcgtgcaccc aactgatctt cagcatctt tactttcacc agcggttctg 7260  
ggtagcaaa aacaggaagg caaaatgcgg caaaaaaaaagg aataagggcg acacggaaat 7320  
gttgaatact catactcttc cttttcaat attattgaag catttatcg gtttattgtc 7380  
tcatgagcg 7440  
cattcccccgg 7469  
aaaagtccaa cctgacgtc

<210> 9  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 9  
tgcttaagcg gcccgcgaagg agaagtcc

28

<210> 10  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 10  
ccgagctagc gactgaaaat gag

23

<210> 11  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 11  
cctctcgaga gacagcaaga cac

23

<210> 12  
<211> 11152  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: plasmid

<400> 12  
aagcttgggc agaaatggtt gaactcccga gagggtccctt cacctagggg agaagcagcc 60  
aagggttgtt ttcccacca ggacgacccg tctgcgcaca aacggatgg cccatcgac 120  
aaagacatat tcattctcg ctgaaaactt ggcatacgctc tgctttgcct ggggcttattg 180  
ggggaaatgg cgggttcgtgc tgcggggct ctcacccttg actctttaa tagcttct 240  
gtgcaagatt acaatctaaa caattcgag aactcgacct tcctcctgag gcaaggacca 300  
cagccaaactt cctcttacaa gcccgcacatcgat ttttgcctt cagaaataga aataagaatg 360  
cttgcataaa attatatttt taccataaag accaatccaa tagtagattt attatgttact 420  
atgttaagaa atgaatcatt atcttttagt actatttta ctcaattca gaagtttagaa 480  
atggaaatag aaaaatagaaa gagacgctca acctcaatgg aagaacaggt gcaaggacta 540  
ttgaccacag gccttagaagt aaaaaggaa aaaaagatgg tttttgtcaa aataggagac 600  
aggtgggtggc aaccaggagc ttatagggaa ccttacatct acagaccaac agatgcccc 660  
ttaccatata caggaagata tgacttaaat tggataggt gggtagt 720

aaagtgttat atagatccct ccctttcgt gaaagactcg ccagagctag acctccttgg 780  
 ttagatgtgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatattttat 840  
 ctaggaacag gaatgcactt ttggggaaag atttccata ccaaggaggg gacagtggct 900  
 ggactaatag aacattattc tgcaaaaaact catggcatga gttattatga atagccttta 960  
 ttggcccaac cttgcgttc ccagggctta agtaagttt tggttacaaa ctgttcttaa 1020  
 aacgaggatg tgagacaagt ggttccctga cttggtttg tatcaaaggt tctgatctga 1080  
 gctctgagtg ttcttatttc ctatgttctt ttgaaattta tccaaatctt atgtaaatgc 1140  
 ttatgtaaac caagatataa aagagtgtg atttttgag taaaatgtca acagtcctaa 1200  
 cattcaccctc ttgtgttgc ttgtgttgc gccatcccg ctccgctgt cacttatctt 1260  
 tcactttcca gagggtcccc ccgcagaccc cggcggccct caggtggcc gactgcggca 1320  
 gctggcgccc gaacaggagc cctcggataa gtgaccctg tctctatttc tactatttgg 1380  
 tgggtgtctt gtattgtctc tttcttgcgt ggctatcatc acaagagcgg aacggactca 1440  
 ccatagggac caagctagcg actgaaaatg agacatatta tctgcccacgg aggtgttatt 1500  
 accgaagaaa tggccggccag tctttggac cagctgtcg aagaggtact ggctgataat 1560  
 cttccaccctc ctggccattt tgaaccctt acccttcacg aactgtatga tttagacgtg 1620  
 acggcccccg aagatccaa cgaggaggcg gtttgcaga ttttcccga ctctgtatg 1680  
 ttggcggtgc aggaaggat tgacttactc atttttccgc cggcggccgg ttctccggag 1740  
 cccgcctcacc ttccccggca gcccggcagc cggagcaga gacgcttggg tccggtttct 1800  
 atgccaaacc ttgttacccga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860  
 agtgacgacg aggatgaaga gggtgaggag tttgtttag attatgtgg acaaaaaagg 1920  
 cacgggtgca ggtcttgcata ttatcaccgg aggaatacgg gggaccagg tattatgtgt 1980  
 tcgctttgtc atatgaggac ctgtggcatg tttgtctaca gtaagtggaa attatggca 2040  
 gtgggtgata gagtggggg tttgggtgtgg taattttttt ttaattttt acagttttgt 2100  
 ggtttaaaga atttgtatt gtgattttt taaaagggtcc tttgtctgaa cctgagccctg 2160  
 agcccgagcc agaaccggag cctgcaagac ctaccgcgg tcctaaaatg ggcctgtcta 2220  
 tcctggagacg cccgacatca cctgtgtcta gagaatgca tagtagtacg gatagctgtg 2280  
 actccgggtcc ttctaaacaca cctcctgta tacaccccggt gtcggctgt tgccccattha 2340  
 aaccaggatgc cgtgagagtt gttggggcgtc gccaggctgt ggaatgtatc gaggacttgc 2400  
 ttaacgagcc tggggcaacct ttggacttga gctgtaaacg ccccaaggcca taagggtgtaa 2460  
 acctgtgatt gctgtgtgg ttaacgcctt gtttgcgtga atgagttgat gtaagtttaa 2520  
 taaagggtga gataatgttt aacttgcattt gctgtttaaa tggggcgggg cttaaagggt 2580  
 atataatgcg ccgtgggcta atcttggttt catctgcactt catggaggct tgggagtgtt 2640  
 tggaaagatgtt ttctgtctgt ctgtaacttgc tggaaacagag ctctaaacagt acctcttgg 2700  
 tttggaggtt tctgtggggc tcatcccagg caaagtttagt ctgcagaattt aaggaggatt 2760  
 acaagtggga atttgaagag cttttgaaat cctgtgggtga gctgtttgat tctttgaatc 2820  
 tgggtcaccga ggcgttttc caagagaagg tcatcaagac tttggatttt tccacaccgg 2880  
 ggcgcgctgc ggctgtgtt gctttttgtt gttttataaa ggataaatgg agcgaagaaa 2940  
 cccatctgag cgggggggtac ctgtggatt tctctggccat gcatctgtgg agagcggtt 3000  
 tgagacacaa gaatcgctg ctactgtgtt cttccgtcc cccggcgata ataccgacgg 3060  
 aggagcagca gcagcaggcg gaggaaagcca gatgttgcata cagggtggctg aactgtatcc 3180  
 acccgagagc cggcctggac cctcggaaat ggatgggcag gggctaaagg gggtaaagag 3240  
 agaactgaga cgcattttga caattacaga ggcttaggaat cttagtttgc gcttaatgtac 3300  
 ggagcgggggg gcttggagg ctacagagga acatgtcaag gataatttgc ctaatgaggt 3360  
 cagacaccgt cctgaggttta ttaattttca gcaatgttgc gtcagccagg 3420  
 tgatctgtcg ggcgagaatg attccataga. gcaactgcactt gtcggatgttgcacttgc 3480  
 ggatgatttt gaggaggcta ttagggtata gatgttgc tttttttttt gcaatgttgc 3540  
 gtacaagatc agcaaacttg taaatatcg ggcctttaga tgtagcatga taaatatgtg 3600  
 cgagggtggag atagatacgg aggatagggt tattatgtat gtaagggttta ctggccccaa 3660  
 gccccgggtg cttggcatgg acgggggtgtt caacatttac ctacacgggtg taagcttcta 3720  
 ttttagcggt acgggtttcc tggccataac gaccgatgtt ggttccggg gctgtgcctt 3780  
 tgggttaac aatacctgtg tggaaaggctg ccccaaaaggc agggcttcaa ttaagaaaatg 3840  
 ttactgtcg tggaaaggggg tgggtgtgtc gtctgagggt aactccaggg tgccgcacca 3900  
 cctctttgaa aggtgtaccc tgggtatctt gtttgcgttgc gtttgcgttgc ttaagcataa 3960  
 tggggctcc gactgtgtt gcttcatgtctt cttctcgatg ctgacccgtctt cggacggccaa 4020  
 catgtatgtt ggcactgtcg aggacaggcc cagccactt cgcaaggccg gggcagtgtt 4080  
 ctgtcacctg ctgaagacca ttcactgtcg gcatgttgcgtt gacggagggg ggggtttctt 4140  
 tgagcataac atactgaccc gctgtccctt gcatgttgcgtt gatattgtt gacggagggg 4200  
 accttaccaa tgcaatttga gtcacactaa gatattgtt gacggagggg gcatgtccaa 4260  
 ggtgaacctg aacgggggtgt ttgacatgac catgaagatc tggaaagggtgc tgagggtacga 4320  
 tgagacccgc accagggtca gaccctgcga gtttgcgttgcgtt aaacatatta ggaaccaggcc 4380  
 tggatgtcg gatgtgaccg aggagcttag gcccgtatc tttttttttt gctgcacccg 4440  
 cgctgagttt ggctctagcg atgaagatc agattgaggt actgaaatgtt gtttgcgttgc

cttaagggtg	ggaaaagaata	tataagggtgg	gggtctttagt	tagttttgtta	tctgttttgc	4500
agcagccgcc	gcccgcattga	gcaccaactc	gtttagtgg	agcattgtga	gctcatattt	4560
gacaacgcgc	atgccccccat	ggggccgggt	gcgtcagaat	gtgatgggt	ccagcattga	4620
tggtcggccc	gtctctggcccg	caaactctac	taccttgacc	tacgagaccg	tgtctggaaac	4680
gcccgttggag	actgcagcct	ccggccgcgc	ttcagccgt	gcagccacccg	cccgccggat	4740
tgtgactgac	tttgccttcc	tgagcccgct	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgtatgac	aagttgacgg	ctcttttgc	acaatggat	tctttgaccc	ggaaacttaa	4860
tgtcgtttct	cagcagctgt	tggtatctcg	ccagcaggtt	tctggccctga	aggcttcctc	4920
ccctcccaat	gcccgtttaaa	acataaataa	aaaaccagac	tctgtttgg	tttgatcaa	4980
gcaagtgtc	tgtgtctct	cgagggatct	ttgtgaagga	accttacttc	tgtgggtgt	5040
cataatggta	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgtttaaacta	ctgatttcaa	ttgtttgtgt	attttagatt	ccaaacctatg	5160
gaactgatga	atgggagcag	tggtgaaatg	cctttatga	ggaaaacctg	ttttgtctag	5220
aagaaatgcc	atctagtgtat	gatgaggcta	ctgctactc	ttaacattct	actctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttcttc	agaattgtca	agtttttga	5340
gtcatgtgt	gttttagtaat	agaacttctt	cttgcttgc	tatttacacc	acaaggaaaa	5400
aagctgcact	gctataaca	aaaattatgg	aaaatatttc	tgtaacctt	ataagttagc	5460
ataacagttt	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgctg	5520
ctattaaataa	ctatgctcaa	aaaattgtgt	cctttatgg	tttaattttgt	aaagggttta	5580
ataaggaataa	tttgatgttat	agtgccttga	ctagagatca	taatcagccca	taccacattt	5640
gttagaggtt	tacttgcctt	aaaaaaccc	ccacaccccttcc	ccctgtaccc	gaaacataaa	5700
atgaatgc	ttttgtgtgt	taacttgc	attgcagctt	ataatggtt	caaataaagc	5760
aatagcatca	caaattttcac	aaataaaga	tttttttcac	tgcattctag	tttggtttt	5820
tccaaactca	tcaatgtatc	ttatcatgtc	ttggatccggc	tgtgtatgt	gtgtcagtt	5880
gggtgtggaa	agttccccagg	ctcccccagca	ggcagaagta	gtcaaaagat	gcacatcaat	5940
tagtcagcaa	ccaggtgtgg	aaagtcccc	ggctccccag	caggcagaag	tatgcaaaag	6000
atgcacatc	attagtgcagc	aaccatagtc	ccgccccctaa	ctccgccccat	cccggcccta	6060
actccggcca	gtttccggcca	ttctccggcc	catggctgac	taattttttt	tatttatgca	6120
gaggccgagg	ccggctcgcc	ctctgtggta	ttccagaagt	agtggaggag	cttttttgg	6180
ggccttaggct	tttgcaaaaaa	gcttggacac	aagacaggct	tgcagat	gtttgagaat	6240
accactttat	cccgcgctcg	ggagggagg	tgcttttttttt	gacgcggact	catgtgaat	6300
actggttttt	agtgcgcccag	atctctataa	tctcgcgca	ccttattttc	cctcgaacac	6360
tttttaagcc	gtagataaaac	aggctggac	acttcacatg	agcggaaaat	acatcgta	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgtatc	tttctgaaca	6480
atggaaaggc	attatttgcg	taagccgtt	cggtctgtt	ccgggtgcgt	tactggcg	6540
tgaactgggt	atttcgtatg	tcgatacc	ttgttatttcc	agctacgatc	acgacaacca	6600
gcfgcagctt	aaagtgtgt	aacgcgcaga	aggcgtatgc	tcgttatttgc	tcgttatttgc	6660
tgacctgggt	gataccgggt	gtactgcgtt	tgcgattcgt	gaaatgtatc	caaaagcgc	6720
ctttgtcaacc	atcttcgca	aaccggctgg	tcggtccgt	gtttagtact	atgtttgtt	6780
tatcccgc	gataccgtt	ttgaacagcc	gtggatatg	ggcgtcgat	tcgtcccgcc	6840
aatctccgg	cgctaatctt	ttcaacgcct	ggcactgcgc	ggcgtgttgc	tttttaactt	6900
caggcgggtt	acaatagttt	ccgatagta	ttctggggc	tgcatccat	acacaggca	6960
acctgagcga	aaccctgttc	aaaccccgct	ttaaacatc	tgaaacctcg	acgcttagc	7020
gcccgtttaa	tcacggcga	caaccgcctg	tgcatcgcc	cctttagtgg	aaaacccatcc	7080
ctcaactgtt	tcgcatgatt	aaccgtctga	tgtggatctg	gcccggcatt	gaccacacgc	7140
aaatctccga	cgtccaggca	cgtattgtt	tgaggcgatgc	cgaaacgtacc	gacgatgatt	7200
tatacgtatc	gggtatttgc	taccgtggcg	gcaactggat	ttatgtgtt	gccccggatc	7260
tttgcgttgg	aaaccttactt	ctgtgtgtt	acataattgg	aaaacaaatcc	tacagagat	7320
taaagctcta	aggttaatata	aaaatttttta	agtgtataat	gtgtttaact	actgtattct	7380
attgtttgtt	tatttttagat	tccaacctat	ggaactgtat	aatggggaga	gtgggtttaat	7440
gcctttaatg	aggaaaaacct	gttttgcctt	gaagaaaatgc	catctagtgt	tgatgaggct	7500
actgtctact	ctcaacatc	tactcttcc	aaaagaaga	gaaaggtaga	agaccccaag	7560
gactttctt	cagaattgt	aagtttttt	agtcatgtgt	tgttttagt	tagactctt	7620
gcttgcttt	ctattttacac	cacaaggaa	aaagctgcac	tgcttatacaa	gaaaattatg	7680
aaaaaatatt	ctgtaacctt	tataagttag	cataacagtt	ataatcataa	catactgtt	7740
tttcttactc	cacacaggca	tagagtgtct	gcttataata	actatgtctc	aaaattgtgt	7800
acctttagct	tttttaatttgc	taaagggggtt	aataaggaat	attttagtgc	tagtgcctt	7860
actagagatc	ataatcagcc	ataccacatt	tgttaggggtt	ttacttgcctt	aaaaaaacct	7920
cccacaccc	ccccctgaa	tgaacatcaa	aatgaatgc	attgttgttt	ttaacttgc	7980
tattgcagct	tataatgggt	acaataaaag	caatagcatc	acaatatttc	caaataaagc	8040
attttttca	ctgcattctt	gttgggttt	gtccaaactc	atcaatgtat	cattatctgt	8100
ctggatcccc	aggaagctcc	tctgtgtct	cataaaaccc	acacccctct	acttgagaaqq	8160

acattccaat cataggctgc ccatccaccc tctgtgtcct cctgtaatt aggtcaactt 8220  
 aaaaaaagga aatgggttag gggttttca cagaccgctt tctaagggtt attttaaaat 8280  
 atctggaaag tcccttccac tgctgtgtc cagaagtgtt gtaaacacgc ccacaaatgt 8340  
 caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaacaccc tgctcatcaa 8400  
 gaagcactgt gggtgctgtg ttagtaatgt gaaaaacagg aggcacattt tccccacctg 8460  
 ttaggttcc aaaatatacta gtgtttcat ttttacttgg atcaggaacc cagcaacttca 8520  
 ctggataagc attatcctta tccaaaacag ccttgggtc agtggatcatt tgctgactgt 8580  
 caactgtac atttttggg gttacagtt gaggcaggata tttggctctg tagttgcta 8640  
 acacaccctg cagtcacaaa gtttccac caacagcaaa aaaatgaaaaa ttggccctt 8700  
 gaatgggtt tccagcacca ttttcatgg tttttgtgt ccctgaatgc aagtttaaca 8760  
 tagcagttac cccaaataacc tcagtttaa ctaaacagg tttccacattt aaaaatattt 8820  
 cacaggttaa gtcctcattt aaatttagga aaggaaatct tgaagacgaa agggcctcgt 8880  
 gatacgceta tttttatagg ttaatgtcat gataataatg gtttctttaga cgtcagggtgg 8940  
 cactttcgg ggaatgtgc ggggaaaccc tatttggta ttttcttaa tacattcaaa 9000  
 tatgtatccg ctcatgagac aataaccctg ataaatgtttt caataatattt gaaaaaggaa 9060  
 gagtatgagt attcaacattt tccgtgtcgc ctttattttt tttttgcgg cattttgcct 9120  
 tcctgtttt gtcacccag aaacgcgtt gaaagaaaaa gatgctgtgg atcagttggg 9180  
 tgcacgagtg gtttacatcg aactggatct caacagcggt aagatcctt agagtttcg 9240  
 ccccgaaagaa cttttccaa ttagtggacac ttttaaagtt ctgtatgtt ggcgggtatt 9300  
 atccccgtt gacggccggc aagagcaact cgggtccgc atacactattt ctcagaatga 9360  
 cttgggttag tactcaccag tcacagaaaaa gcatcttacg gatggcatga cagtaagaga 9420  
 attatgcagt gtcgcataaa ccatgagtg taacactgcg gccaacttac ttgtgacaac 9480  
 gatcgagga cggaaaggagc taaccgtttt tggcacaac atggggatc atgtactcg 9540  
 ccttgatcgt tgggaaaccgg agctgaatga agccatacca aacgacgacg gtgacaccac 9600  
 gatgcctgca gcaatggcaa caacgttgcg cttttttttt cttttttttt 9660  
 agcttcccg caacaattaa tagactggat ggaggcgat aaagttgcag gaccacttct 9720  
 ggcgcggcc cttccggctg gttttttt tggatataa tctggagccg gtggcggtgg 9780  
 gtctcggtt atcattgcag cactggggcc agatggtaaag ccttcccgta tcgttagttat 9840  
 ctacacgacg gggagtcagg caactatgg tggatggat gacatggatc ctggatagg 9900  
 tgcctcactg attaaggatt ggtaactgtc agaccaagtt tactcatata tacttttagat 9960  
 tgattnaaaaa cttcattttt aattttaaaag gatcttagtg aagatccttt ttgataatct 10020  
 catgacaaaaa atcccttaac gtggatttt gttccactga gctcagacc ccgtagaaaaa 10080  
 gatcaaaaggaa tcttctttag atctttttt tggcgcgtt atctgtgtt tgcaaaacaaa 10140  
 aaaaccaccc ctaccaggg tggatggat gggatcaa gagtacccaa ctctttttcc 10200  
 gaaggtaact ggcttcagca gagcgcagat accaaataact gtccttcttag tggcggtt 10260  
 gttaggccac cacttcaaga actctgtacg accgcctaca tacctcgctc tgctaatct 10320  
 gttaccagtg gtcgtgcgca gtggcgatata gtcgtgtt accgggttgg actcaagacg 10380  
 atagttaccg gataaggcgc acgggtcgcc ctgaacgggg gtttgcgtca cacagccag 10440  
 cttggagcga acgactaca cggaaactgag atacatcag cgtgagatcat gagaagcgc 10500  
 cacgcttccc gaaggagaa agcgccgacag gtatccggta acggccggg tggaaacagg 10560  
 agagcgcacg agggagcttc caggggggaa cgcctggat ctttataatgc tggcggtt 10620  
 tgcgcaccc tggatgtt gtcgatgtt gtatgttgcg tcaagggggc ggagccat 10680  
 gaaaaacccgg agcaacgcgg ctttttttacg gtttgcgtt ttttgcgtt cttttgcgtca 10740  
 catgttctt cttgttttccctgttcc tggatgttgcg cttttttttt 10800  
 agctgatacc gtcggccgca gccaacgcac cgacgcgcac gatgttgcgtt gtcgttgcgtt 10860  
 ggaagagcgc ctgtatgcgtt atttttctt tggatgttgcg tggatgttgcgtt 10920  
 atgggtgcact ctcagttacaa tctgtctgtt gtcgatgttgcg tggatgttgcgtt 10980  
 ctatcgctac gtgactgggt catggctgcg cccggacacc cgccaacacc cgctgacg 11040  
 ccctgtacggg cttgtctgtt cccggatcc gtttacagac aagctgttgcg cttttttttt 11100  
 agctgcgtt gtcagaggat ttcaccgtca tcaccgaaac ggcggaggca gc 11152

&lt;210&gt; 13

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 13

gacggatcgg gagatctcc

<210> 14  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 14  
 ccgcctcaga agccatagag cc

22

<210> 15  
 <211> 14455  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: plasmid

<400> 15  
 aagcttgggc agaaaatgggtt gaactcccga gagggtccta cacctagggg agaaggcagcc 60  
 aagggggtgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgg cccatcagac 120  
 aaagacatat tcatttcgtc ctgcacactt ggcatacgctc tgcttgcct ggggctattt 180  
 gggaaatggt cggttcgtgc tcgcagggtct ctcaccctt actctttaa tagctcttct 240  
 gtcaagatt acaatctaaa caattcggag aactcgaccc tcctcctgag gcaaggacca 300  
 cagccaaactt cctcttacaa gccgcacatcga ttttgcctt cagaaataga aataagaatg 360  
 cttgctaaaa attatattt taccataaa accaataag tagtagattt attagttact 420  
 atgttaagaa atgaatcatt atctttatg attatttta ctcaaaattca gaagtttagaa 480  
 atggaaatag aaaatagaaa gagacgctca acctcaattt aagaacagggt gcaaggacta 540  
 ttgaccacag gcctagaatg aaaaaaggaa aaaaagagggt tttttgtca aataggagac 600  
 aggtgggtgc aaccagggtac ttatagggtt ctttacattt acagaccaac agatgcccc 660  
 ttaccatata caggaagata tgacttaat tggtagatgtt gggtagatgtt caatggctat 720  
 aaagtgttat atagatccct cccttttgcgtt gaaagactcg ccagagctag acctccctgg 780  
 tggatgtgtt ctcaagaaga aaaaagacgc ataaaacaaac aggtacatga ttatattttat 840  
 ctggaccacag gaatgcactt ttggggaaag attttccata ccaaggaggg gacagtggct 900  
 ggactaatag aacattattt tgcaaaaactt catggcatga gtttattatg atagccctta 960  
 ttggcccaac cttgcgggtt ccagggtctt agtaatgtt tggtagatgtt ctgttcttaa 1020  
 aacgaggatg tgagacaatg gtttccctga cttgggttttgcgtt tccaaatctt atgttaatgc 1140  
 gctctgatgtt ttcttattttc ctatgttctt ttggatattt tccaaatctt atgttaatgc 1140  
 ttatgttaaac caagatataa aagatgtctt attttttgatg taaaatgtca acagtccctaa 1200  
 cattcacttc ttgtgtgtt gtgtctgtt gccatccctt ctccgctgtt cacttattct 1260  
 tcactttcca gagggtcccc ccgcagaccc cggcgaccc caggtcgcc gactgcggca 1320  
 gctggcgccc gaacagggtac cctcggatata gttttccctt tctcttatttttgcgtt 1380  
 tgggtgtctt gtattgtctt ttgtgtctt ggctatcatc acaagagccgg aacggactca 1440  
 ccataggac caagctacgtt actggaaaatg agacatattt tctgccacgg aggtgttatt 1500  
 accgaagaaa tggccggccat tctttggatc caggtgtatgtt aagaggatct ggctgataat 1560  
 ctteccacatc ttagccattt tgaaccaccc acccttccacg aactgtatgtt ttttagacgtt 1620  
 acggcccccg aagatccaa cggggaggccg gtttcccgat ttttcccgat ttttcccgat 1680  
 ttggcggtgc aggaaggat tgacttactc acttttcccgat cggggccccggg ttctccggag 1740  
 ccgcctcacc ttcccggcc gcccgagccg cggggccggat gggcccttggg tccgggtttct 1800  
 atgccaaacc ttgttacccggat ggtgtatgtt cttacctccg acggggctgg ctttccaccc 1860  
 agtgcacgttccg aggtgtatgtt ggggtggat gtttgcgtttag attatgttgcgtt gcaaaaaa 1920  
 cacgggtgc ggttttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 1980  
 tcgctttgtctt atatgttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2040  
 gttttttttttttaatgttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2100  
 gttttttttttttaatgttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2160  
 agcccgaccc agaaccggat ctttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2220  
 tcctgatgttccg cccgacatca ctttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2280  
 actccggatcc ttctaaacaca ctttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2340  
 aaccaggatgc ctttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2400  
 ttaacggatgc ttttgcgttccg ttatcaccgg aggaataccgg gggacccaga ttttcccgat 2460

acctgtgatt gcgtgtgtgg ttaacgcctt tgtttgcgtga atgagttgat gtaagttaa 2520  
 taaagggtga gataatgtt aacttgcgt gcggttaaa tggggcgggg cttaaagggt 2580  
 atataatgcg ccgtgggcta atcttggta catcgacct catggaggct tgggagtgtt 2640  
 tggaaagattt ttctgtgtg cgttaacttg catggacagag ctctaacagt acctcttggt 2700  
 ttggaggtt tctgtgggc acaagtgggaa atttgaagag ctttgaaat cctgtggta gctgtttgat tctttgaatt 2760  
 tgggtcacca ggcgttttca caagagaagg tcatcaagac ttggatattt tccacacgg 2820  
 ggcgcgtgc ggctgtgtt gctttttaa gtttataaa ggataaaatg aaggaggatt 2880  
 cccatcttag cgggggggtac ctgtggat cttccgtccg cccggcgata ataccgacgg 2940  
 tgagacacaa gaatcgctg aggacgacca gacgacgagg cctcggaaat gatgttgc gctgttttttggat 2990  
 acccgagagc cggcctggac agaactgaga cgcatgttca gatgttgc gctgttttttggat 3050  
 ggacgggggg gcttgtgagg cagacaccgt ctgtgtgttca acatgttca acatgttca gataattggc 3120  
 ttagggatccatcg gatgttgc gacgtgttca acatgttca acatgttca gataattggc 3180  
 gatataatcg gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 3240  
 cgagggttggag atagatacgg gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 3300  
 gccgggggtg ctggcatgg ttagggatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3360  
 tgggttaaac aatacctgtg ttagggatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3420  
 ttactgtc tggaaaggggg tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3480  
 cctcttggaa aggtgttccatcg gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 3540  
 tggggctcc gactgtgtt gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 3600  
 catggatgtt ggcactgtcg tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3660  
 ctgtcacctg ctgaagacca tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3720  
 tgagcataac atactgtcg tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3780  
 accttacca tgcataatggg gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 3840  
 ggtgaacctg aacgggggtt gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 3900  
 tgagacccgc accaggtgca tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 3960  
 tggatgtcg gatgtgaccc gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 4020  
 cgctgagttt ggtcttagcg tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 4080  
 cttaaagggtg gggaaagataa tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 4140  
 agcagccgcg gccggatcg tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 4200  
 gacaacccgc atgccccccat gggccggggg gatgttgc gatgttgc gatgttgc gatgttgc 4260  
 tggtcgcccc gtcctggccg caaactctac taccttgc gatgttgc gatgttgc gatgttgc 4320  
 gccgttggag actgcagcc tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 4380  
 tggactgac ttgtgtttcc tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 4440  
 ccgcgtatgac aagtgtacgg ctcttttgc gatgttgc gatgttgc gatgttgc gatgttgc 4500  
 tggctttct cagcagctgt gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 4560  
 ccctcccaat gcggtttaaa acataaataaa aaaaccagac tgggtatccatcg gatgttgc gatgttgc 4620  
 gcaagtgtct tgctgtctct cgagggatct ttgtgaaggaa tgggtatccatcg gatgttgc gatgttgc 4680  
 cataattggc caaactacatc acagagattt aaactgtcg tgggtatccatcg gatgttgc gatgttgc 4740  
 gtgtataatg tgtaaaacta ctgttcttgc acaattggat tgggtatccatcg gatgttgc gatgttgc 4800  
 gaactgtatg atggggacgg tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 4860  
 aagaatgtc atctgtgtt gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 4920  
 aaaagaagag aaaggtagaa gaccccaagg atcttgc tgggtatccatcg gatgttgc gatgttgc 4980  
 gtcatgtgt gtttagtaat agaacttgc ctgtgtttgc tgggtatccatcg gatgttgc gatgttgc 5040  
 aagctgcact gctatacaag aaaaatattt gatgttgc gatgttgc gatgttgc gatgttgc 5100  
 ataacagtttta taatcataac atactgttgc ttgttactcc acacaggcat agagtgtctg 5160  
 ctattaataa ctatgtctca aaaaatgttgc ctttagtgc ttttgc gatgttgc gatgttgc 5220  
 ataaggatgtt ttgtgtgtat agtgccttgc tgggtatccatcg gatgttgc gatgttgc 5280  
 gttagggttt taactgtgtt aaaaacctc ccacacctcc tgggtatccatcg gatgttgc gatgttgc 5340  
 atgaatgca ttgtgtgtt taactgtgtt attgcgttgc tgggtatccatcg gatgttgc gatgttgc 5400  
 aatagcatca caaatttccatc aaataaagca ttttttgc gatgttgc gatgttgc gatgttgc 5460  
 tccaaactca tcaatgtatc ttatcatgtc tgggtatccatcg gatgttgc gatgttgc gatgttgc 5520  
 gggtgtggaa agtccccagg ctccccaggca ggcagaagtg tgggtatccatcg gatgttgc gatgttgc 5580  
 tagtcagcaa ccagggtggaa aagttccccca ggctccccag cggcagaagtg tgggtatccatcg gatgttgc 5640  
 atgeatctca attagtccatc aaccatagtc cccggccctaa tgggtatccatcg gatgttgc gatgttgc 5700  
 actccggcca gttccggcca ttctccggcc catggctgac tgggtatccatcg gatgttgc gatgttgc 5760  
 gaggccgagg cccgcctcgcc ctctgagctt tttccagaagtg tgggtatccatcg gatgttgc gatgttgc 5820  
 tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 5880  
 tgcaaaagcat gcatctcaat tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 5940  
 tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 6000  
 ctccggccat cccggccctaa tgggtatccatcg gatgttgc gatgttgc gatgttgc gatgttgc 6060  
 taattttttt tattatgtca agtggagg gtttttttggaa 6120  
 gaggccgagg cccgcctcgcc ctctgagctt tttccagaagtg tgggtatccatcg gatgttgc gatgttgc 6180



tgcctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tacttttagat 9960  
 tgatttaaaa cttcattttt aattttaaaag gatcttagtg aagatcctt ttgataatct 10020  
 catgacccaa atcccttaac gtgagtttc gtccactga gcgtcagacc ccgtagaaaa 10080  
 gatcaaaggta tcttcttgag atccttttt tctgcgcgta atctgctgct tgcaaacaaa 10140  
 aaaaccacccg ctaccagcgg tggttgttt gccggatcaa gagctaccaa ctcttttcc 10200  
 gaaggtaact ggcttcagca gagcgcagat accaaataact gtccttctag tgtagccgta 10260  
 gttaggccac cacttcaaga actctgttgc accgccttaca tacctcgtc tgctaatcct 10320  
 gttaccagtg gtcgtgcgc gtcgtgttgc accgggttgg actcaagaa 10380  
 atagttaccg gataaggcgc acggcgtggg ctgaacgggg gttctgtca cacagccccag 10440  
 cttggagcga acgacactaca ccgaacttag atacctacag cgtgagctat gagaagcgc 10500  
 cacgttccc gaagggagaa aggccggacag gtatccggta agcggcaggg tcggaaacagg 10560  
 agagccacg aggaggcttc cagggggaaa cgcctgttat ctttatagtc ctgtcgggtt 10620  
 tcgcacccctc tgacttgagc gtcgattttt gtatgtctcg tcaggggggc ggagcctatg 10680  
 gaaaaacgccc agcaacgcgg ccttttacg gttctggcc ttttgcgtcc ctttgtctca 10740  
 catgttctt cctgcgttcc cccctgattc tggatataac cgtattaccg cctttgagtg 10800  
 agctgatacc gtcgcccga gccaacgcac cgagcgcagc gagtcgtga gcgaggaagc 10860  
 ggaagagcgc ctgtgcgtt attttcttctc tacgcatactg tgccgttattt cacaccgcatt 10920  
 accgcctcag aagccataga gcccacgcac tccccagcat gcctgttattt gtcttcccaa 10980  
 tcctccccctc tgctgtccgt ccccacccca ccccccagaa tagaatgaca cctactcaga 11040  
 caatgcgtat caatccctc atttttag gaaaggacag tggagtgcc accttccagg 11100  
 gtcaagggaa gcacggggga gggccaaaca acagatggct ggcaactaga aggcacagtc 11160  
 gaggctgtc acgcgtctc agcatttagg tgacactata gaataggcc ctctagatgc 11220  
 atgctcgacg gggcgttct ttatttttgg gcaatgtatg aaaaagtgtg agaggatgtg 11280  
 gcaaatattt cattaatgtt gtttggcca gaccgtccc atgaaatgtg catagatgt 11340  
 gcacttggag ttgtgtctcc ttgttctgtgtt gtaatgggtt gttatgtt tagtgttaca 11400  
 ggtttagttt tttgttccgtt taatggaaatc tgactgatcc ttgttactttt ggcagttttt 11460  
 ccgttagatt ttggatatacg tgataggta ggcataaaatc caacagcgtt tttataggct 11520  
 gtgcatttcg taagatctcc attttctaaag ttccaaatattt ctgggtccag gaaggaattt 11580  
 ttttagtagca ctccattttc gtcaatctt ataataagat gggactttt aactgttcca 11640  
 gatattggag cccaaactgccc tttaaacagcc aaaactgaaa ctgtacaaag tttttgactg 11700  
 ccacattttgc ttaagacccaa agtggattttta gcatcttttctc ctgcatttttgc ttttttgc 11760  
 ggagatggag ctgggtgtgg ccacaaatggcc ttgtgttgc ttgttgcattt ttttttgc 11820  
 atggcacctg tgctgtccaa actaaggccca gttcctaggat taggaaccat agccttgc 11880  
 gaatcaaattt ctaggccatg gccaattttt gttttgaggg gattttgtt ttttttgc 11940  
 ggtgaaccaa attcaagccc atctctgtca gtttgcattt ttttttgc ttttttgc 12000  
 aaccccttgg cagtgccttgc gtttgcattt aatggatggcc ttgtgttgc ttgtgttgc 12060  
 aagtaaaaggc ctttgcattt gtttgcattt aatggatggcc ttgtgttgc ttgtgttgc 12120  
 cccctgtccca gtcttagatt ttttttgc ttgtgttgc ttgtgttgc ttgtgttgc 12180  
 ataaggcgcc ttttttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12240  
 ctttgcatttgc cccaaacccaa ggctccatgtt gtttgcattt ttttttgc ttgtgttgc 12300  
 gtacacacccg gaccagggttgc tacggatccaa gtttgcattt ttttttgc ttgtgttgc 12360  
 gccccgtact ttagtgcattt ttttttgc ttgtgttgc ttgtgttgc ttgtgttgc 12420  
 cccaaactcact ctttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12480  
 tcgggtgtgg tgagggggcc tgatgttttgc ttgtgttgc ttgtgttgc ttgtgttgc 12540  
 ggttgcatttgc ttttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12600  
 atttgtgttgc ttttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12660  
 gaggttaactg tgagggggcc agatattttcc ttgtgttgc ttgtgttgc ttgtgttgc 12720  
 ggtgggtctca ctttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12780  
 ccgttgcatttgc ttttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12840  
 aaagagatg ccccgagggg actcttcttgc ttgtgttgc ttgtgttgc ttgtgttgc 12900  
 agaaaaggca ctttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 12960  
 tcctcagacgg gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13020  
 catccgcgtt ctttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13080  
 caaaccggccg ctttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13140  
 ctgggttagac gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13200  
 cttcgggtggc gggatccatgt tgccggggcc acgggtttcc gatccaaatggcc ttgtgttgc 13260  
 acccgcaaga gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13320  
 tcgggtacca gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13380  
 agtgggttct ctttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13440  
 accggccattt gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13500  
 ttgggtgcattt gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13560  
 gtttgcatttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc ttgtgttgc 13620

gatgactaat acgttagatgt actgccaagt aggaaagtcc cataaggcata tgtactggc 13680  
 ataatgccag gcggggcatt taccgtcatt gacgtcaata gggggcgtac ttggcatatg 13740  
 atacattga tgtactgcca agtggcagt ttaccgtaaa tagtccaccc attgacgtca 13800  
 atggaaagtc cctattggcg ttactatggg aacatacgtc attattgacg tcaatggcg 13860  
 ggggtcggtt ggcggtcagc caggcgggccc atttaccgtt agttatgtaa cgcggaaactc 13920  
 catatatggg otatgaacta atgacccgtt aatgttac tattaataac tagtcaataa 13980  
 tcaatgtcaa cgcgtatata tggccgtac atcgcgaagg agcgcaaaac gcctaaccct 14040  
 aagcagatcc ttcatgcaat tgcggcataa gccttgcctt gtttagttaa aaattttgc 14100  
 cgcgtactc tcaagcgtact ccaacacaca agcaggggagc agataactggc ttaactatgc 14160  
 ggcgtcagag cagattgtac tgagactgca ccatagggga tcgggagatc tcccgatccg 14220  
 tctatggtgc actctcagta caatctgtc tgatggcgc tagttaaaggc agtatacact 14280  
 ccgcgtatcgc tacgtgactg ggtcatggct gcggccggc acccggcaac acccgctgac 14340  
 ggcgcctgac gggctgtct gtcggcataa tccggttaca gacaagctgt gaccgtctcc 14400  
 ggcgcctgac gggctgtct gtcggcataa tccggttaca gacaagctgt gaccgtctcc 14455  
 gggagctgca tgtgtcagag gtttcaccg tcatcaccga aacgcgcgag gcagc

&lt;210&gt; 16

&lt;211&gt; 10610

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>  
<223> Description of Artificial Sequence: plasmid

<400> 16  
 gacggatccgg gagatcccg cggtacacag aattcaggag acacaactcc aagtgcatac 60  
 tctatgtcat tttcatggg ctggctggc cacaactaca ttaatggaaat atttgcacaca 120  
 tcctcttaca ctttttccata cattgcccga gaataaagaa tcgtttgttat tatgtttcaa 180  
 cgtgtttatt tttcaattgc agaaaaatttc aagtcttatt tcatttgcata gtatagcccc 240  
 accaccacat agttatataca gatcaccgtt ccttaatcaa actcacagaa cccttagtatt 300  
 caacctgcca cttccctccc aacacacaga gtacacagtc cttttccccc ggctggccctt 360  
 aaaaagcatc atatcatggg taacagacat attcttaggt gttatattcc acacggtttc 420  
 ctgtcgagcc aaacgctcat cagtgatatt aataaactcc cggggcagct cacttaagtt 480  
 catgtcgctg tccagctgtc gagccacagg ctgtgttcca acttgcgggt gcttaacggg 540  
 cggcgaaggga gaagtccacg cctacatggg ggttagatgc taatctgtca tcaggatagg 600  
 gcggtgttgc tgcagcgcg cgcaataaaa gtttcgcacc gcccgcagca taaggcgcct 660  
 atacaatcatg gcagtggctt cctcagcgtt ctcacttaaa tcagcacagtt aactgcagca 720  
 tgcgtcccg gacagcagc gcacccctgtt gtgcgaaggcg ctgtatccaa agctcatggc 780  
 cagcaccacaa atattgttca aaatcccaca ccacaaggcgc aggttagatta agtggcggacc 840  
 ggggaccacaa gaacccacgt ggcacatcata cttttttggc atgtgtat tcaccaccc 900  
 cctcataaaac acgtgtgaca taaacattac cgggtccatcata accaccatcc taaaccatgt 960  
 cgggtccatcata accaccatcc cgggtccatcata accaccatcc taaaccatgt 1020  
 ggcggccatc accaccatcc cgggtccatcata accaccatcc taaaccatgt 1080  
 ggcggccatc accaccatcc cgggtccatcata accaccatcc taaaccatgt 1140  
 tgcgtcccg gacagcagc gcacccctgtt gtgcgaaggcg ctgtatccaa agtggcggacc 1200  
 acacaggcac acgtgcatac acttcctcgtc gttacatcg ggcacccatcc taaaccatgt 1260  
 atccccaggaa acaaccatt cctgttgcatac cgggtccatcata accaccatcc taaaccatgt 1320  
 cactgttgcatac cgggtccatcata accaccatcc taaaccatgt 1380  
 cgggtccatcata accaccatcc taaaccatgt 1440  
 ggcggccatc accaccatcc taaaccatgt 1500  
 agtcataattt cctgttgcatac cgggtccatcata accaccatcc taaaccatgt 1560  
 ctcggccgtt agtcgttgcatac cgggtccatcata accaccatcc taaaccatgt 1620  
 ggcggccatc accaccatcc taaaccatgt 1680  
 ccaccacccgc agaataagcc acacccagcc tgggtttttt ttttattccaa aagattatcc 1740  
 cgggaggagc gggaaagatc ggaagaacca tgggtttttt ttttattccaa aagattatcc 1800  
 aaaacctcaa aatgaagatc tattaaatgtt aacgcgttccctt ctcgggtggc gtggtcaaac 1860  
 tctacagccaa aagaacatgtt aatggcattt gtaatgtt gtcacatggc ttccaaaagg 1920  
 caaacggccc tcacgttccaa gttggacgtt aacgttccatcc ttttccatcc ctttctcaat 1980  
 ataaaacattc cagcacccatcc aaccatgtttt ttttattccaa aacgttccatcc ctttctcaat 2040  
 atatctctaa gcaaaatcccg aatattaatgtt cgggtccatcc ttttattccaa aacgttccatcc ctttctcaat 2100  
 ccctccacccatcc tcaatgttccatcc gcaacatggc aatattaatgtt cgggtccatcc ttttattccaa aacgttccatcc ctttctcaat 2160  
 cctgttataag attcaaaaatcccg ggaacatggc aaaaatacc gcaacatggc aatattaatgtt cgggtccatcc ttttattccaa aacgttccatcc ctttctcaat 2220  
 gcaacatggc tcaatgttccatcc gcaacatggc aaaaatacc gcaacatggc aatattaatgtt cgggtccatcc ttttattccaa aacgttccatcc ctttctcaat

caggaacacctt gacaaaagaa cccacactga ttatgacacg catactcgga gctatgctaa 2280  
 ccagcgttagc cccgatgtaa gctttgttc atggcgccg atataaaatg caagggtctg 2340  
 ctcaaaaaat cagggaaagc ctcgcgaaa aaagaagca catcgtagtc atgctcatgc 2400  
 agataaaaggc aggtaaagtc cggaccacc acagaaaaag acaccattt tctctaaac 2460  
 atgtctcgcc gtttctgcataa acacacaaaaaaa taaaataaca aaaaacattt taaaacattt 2520  
 aaggctgtct tacaacagga aaaacaaccc ttataagcat aagacggact acggccatgc 2580  
 cggcgtgacc gtaaaaaaaatc tggtcacccgt gataaaaaaag caccaccgac agtccctcg 2640  
 tcatgtccgg agtcataatg taagactcggt taaaacacatc aggttatttc atcggtcagt 2700  
 gctaaaaaggc gaccgaaata gccccgggaa atacataccg gcaggcgtag agacaacatt 2760  
 acagccccca taggaggtat aacaaaatta ataggagaga aaaacacata aacacctgaa 2820  
 aaaccctctt gcctaggca aatagcacc tcccgctca gaacaacata cagcgcttca 2880  
 cagggcggcgc ctaacagtc aacccatcgc taaaacatc gacccatgc aacacatc 2940  
 ctcgcacacgg caccagctca atcagtccca gttttttttt gggccaatgg cagagcgagt 3000  
 atatatagga ctaaaaaatg acgttaacccgt taaaatccac aaaaacacccaa cagaaaaaccg 3060  
 cacgcgaacc tacgcccaga aacggaaagcc aacccatcgc caacttcctc aaatcgtaac 3120  
 ttccgttttc ccaacgttgc taacttcccg gatctctcc cgatccccca tggtcgactc 3180  
 tcagtaacaat ctgcctgtat gccgcataatc taagccagta aacaaggccaa ggctgaccgg 3240  
 tggaggtcgc tgtagtgc gcgagaaaaa tttaaagctac gctgttccgat gatgtacggg 3300  
 acaattgtcat gaagaatctg cttagggtta ggcgttgc atagtaatca attacggggt 3420  
 ccagatatac gctgtgacat tgattattga ctgttattaa acttacggta aatggcccg 3480  
 cattagttca tagcccatat atggaggatcc gctttacata aatgacgtat gttccatag 3540  
 ctggctgacc gcccaacgac cccgcctat tgacgtcaat ctatttacgg taaactgccc 3600  
 taacgccaa atggactttc cattgacgtc aatgggtggg cccttattggc gtcataatgc 3660  
 acttgcgtat acatcaagtgc tatcatatgc caagtacgcg atgggactt cctacttggc 3720  
 gtaaatggcc cgcctggcat tatgcccagt acatgacctt gcccaccc 'attgacgtca 3780  
 agtacatcta cgtattatgc atgccttata ccatggtgat tctccaccc 3840  
 atgggctgtt atagcggtt gactcaggg gatttcaag aaaaatgtctg aacaactccg 3900  
 atgggatgtt gtttggcactt gggactttcc ggtctatata aattaaatcg actctata 3960  
 ccccatggc gcaaatgggc ggtaggctg tacgggtggg aattaaatcg actctata 4020  
 tctggtaaca tagagaaccc actgttact ggcttattcg agtctcggtg tggctcgcg 4080  
 gggagaccca agcttggtac cgagcttggc tctgaatccg atcgaaacc cgtcggccctc 4140  
 gttgaggaca aactcttcgc ggtcttccca gttacttttcc gtcggccgcg atcgaccgg 4200  
 cgaacggta tccgcaccgg agggacttgc gogagtcggc gtcggccgcg 4260  
 tctcgagaaa ggcgtctaaatc cagtccatc acgttacttcc gtcggccgcg 4320  
 gcaggggtg ggggtcccccc ttgtttctgg cgaggtgtct gctgatgtat taattaaatcg 4380  
 aggcgtctt gagacggccgg atggtcgagg tgaggtgtgg caggcttgcg atccaatgt 4440  
 aagcgcgcaaa gaccgtctga agataccctc aacccctgtt atccatatga caccggaaacc 4500  
 ggtctccaa ctgtgcctt tcttacttcc ecctttgtat ccccaatgg gttcaagag 4560  
 agtccccctg gggtaacttcc tttgcttca tccgaacctc tagttaccc caatggcatg 4620  
 ctgcgctca aatggggcaaa cggctcttctt ctggacgagg cggcaaccc tacotccaa 4680  
 aatgttaacca ctgtgagcccc acctctcaaa aaaaccaatgt caaacataaa cctggaaata 4740  
 tctgcacccctt ctcagttac ctcagaagcc ctaactgtgg ctggccgcg acctctaattg 4800  
 gtcggggca acacactcac catgcaatca caggcccccc taacgggtca cgactccaa 4860  
 cttagcattt ccacccaagg acccttcaca gtgtccagaag gaaagcttgc cctgcaaaaca 4920  
 tcaggcccccc tcaccacccat cgatagcgtt acccttacta tcactgcctc accccctcta 4980  
 actactgcctt ctggtagttt gggcatttgc ttggaaagagcc ccatttatac aaaaaatgg 5040  
 aaacttaggac taaaatggcgg ggtcttccat catgttaacag acgaccctaaa cactttgacc 5100  
 gttagcaactt gtccagggtt gacttataat aataacttcc tgcaccaactt aattacttgc 5160  
 gccttgggtt ttgatttcaca aggcaatatg caacttataat tagcaggagg actaaggatt 5220  
 gatttctaaa acagacgcct tataacttgc ttgtttatc cttttgtatc taaaacccaa 5280  
 ctaaatctaa gacttagggca gggccctttt ttataaaactt cagccccacaa ctggatattt 5340  
 aactacaaca aaggccctt tttttttttt gtttcaaaatc attccaaaaaa gtttggatgtt 5400  
 aaccaatggca ctgccaagggg gttgtatgtt gacgctacag ccatagccat taatgcaggaa 5460  
 gatggcgtt aattttggttt acctaattgc caaaacacaa atccctcaaa aaccaaaaattt 5520  
 ggccatggcc tagaatttgc ttcaaaacaag gctatgtttt cttttacttgc aactggccctt 5580  
 agtttgcata gacaggttgc cattacaga gggaaacaaaataatgataa gctaactttt 5640  
 tggaccacac cagctccatc ttcttaactt gacgctacag cttttacttgc aactggccctt 5700  
 actttggctt taacaaaatg tggcgttcaaa atacttgcata cttttacttgc aactggccctt 5760  
 aaaggcgtt tggcttcaat atctggaaaca gttcaaaatgtt cttttacttgc aactggccctt 5820  
 gacggaaaatg gaggctactt aaacaatttcc ttctggacc cttttacttgc aactggccctt 5880  
 aatggagatc ttactgaagg cacagccatc aacaaacgcgtt ttggatattt gcttaaccta 5940  
 tcagttatc caaaatctca cggaaaaactt gccaaaaatgtt acatttgcac tcaagtttac

ttaaacggag acaaaaactaa acctgttaaca ctaaccatta cactaaacgg tacacagga 6000  
acaggagaca caactccaag tgcatactct atgtcatttt catgggactg gtctggccac 6060  
aactacatta atgaaaattt tgccacatcc tcttacactt ttcatacat tgcccaagaa 6120  
taaagaacg gccgctcgag catgcatcta gagggcccta ttctatagtg tcacctaataat 6180  
gctagagctc gctgatcagc ctcgactgtg ccttctagtt gccagccatc tggttgc 6240  
ccctcccccg tgcttcctt gaccctggaa ggtgccactc ccactgtcct tccttaataataat 6300  
aatgagaaaa ttgcatacgca ttgtctgagt aggtgtcatt ttatctggg ggttgggtg 6360  
ggcgaggaca gcaaggggga ggatggggaa gacaatagca ggcatacg 6420  
ggcttatgg ctcttgaggc gggaaagaagc agctggggct ctagggggta tccccacgcg 6480  
ccctgtacg ggcattaaag cgccggggtt gtgttgggta cgcgcagct gaccgcata 6540  
cttgcacg 6600  
gcccgttc cccgtcaagc tctaaatcg 6660  
ttacggcacc tgcaccccaa aaaacttgat taggtgtat taggtgtat 6720  
ccctgtataga cggttttcg cccttgacg ttgagttca cttcctttct 6780  
ttgttccaaa ctgaaacaac actcaacccat atctcggtct ttataaagg 6840  
attttgggaa ttccggctt ttgtttaaaa aatgagctga ttaacaaa 6900  
aattaattt ctgaaatgtg tgcgtttag ggtgtggaa gtcggcagg 6960  
ggcagaatg tgcataagcat gcatctcaat tagtcagcaa ccagggtgtgg 7020  
ggccccccag caggcagaag ctcggccatc acttcgttca 7080  
ccgccccctaa ctccggccat cccggccctt actccggg 7140  
catgggtgac taatttttt tattatgca gagggcggg 7200  
ttccagaagt agtgaggagg ctttttgg 7260  
gcttgatata tccatggcgg aggttctcg gcccgttgg 7320  
gaacaatgat gattgcacgc gggctgtct gatggccgg 7380  
gactgggcac aacagacaat caagacgc 7440  
gggcggccgg ttcttttgcg ggtatccgtg ctgtccgg 7500  
gaggcagcgc ggtatccgtg gtttttgg 7560  
gttgtactg aagcgggaaag gggccgttgc ctattgggg 7620  
ctgtcatctc acttgcgttgc tgccgagaaa gatccatca 7680  
ctgcatacgc ttgatccggc tacctggcc 7740  
cgagcacgta ctccggatgg 7800  
caggggctcg cgccagccga actttcgcc aggtcaagg 7860  
gatctgtcg tgaacccatgg cgatgcgtc ttggca 7920  
ttttctggat tcatcgactg tggccggcgt ggtgtggcgg 7980  
ttggtaccc gtatattgc tgaagagctt gggggcgaat 8040  
ctttaaggta tccggcgtcc cgattcgcag 8100  
ttcttcttag gggactctg gggttcgaaa tgaccgacca 8160  
cacgagattt cgattccacc gcccgttctt atgaaagg 8220  
gggacggcgg ctggatgatc ctccagcgc 8280  
ccaaatgtt tatttgcgt tataatgtt acaaataaaag 8340  
caaataaagc attttttca ctgcattcta gttgtggg 8400  
cttatacatgt ctgtataccg tgcaccccta gtagagctt 8460  
tggttctgt gtgaaattgt tattccgtca caattccaca 8520  
taaagtgtaa agcctgggtt gcctaatgag tgagtcact 8580  
caactggccgc tttccactg gggaaacctgt 8640  
gcccggggag agccgggttt cgtatggcc 8700  
tgccgtcggt ctggcgctg cggcgagcgg 8760  
tatccagaga atcaggggat aacgcaggaa agaacatgtg 8820  
ccaggaaccg taaaaaggcc gcgttgcgtt cttttccca 8880  
agcatcacaa aaatcgacgc tcaagtccaga ggtggcgaat 8940  
accaggcggt tccccctgga agctccctcg tgccgtctcc 9000  
ccggataacct gtccggctt ctccctccgg 9060  
gttagtatct cagttcggtg taggtcggtc gtcacccgtt 9120  
ccgttcagcc cgaccgtcg gccttacccg gtaactatcg 9180  
gacacgactt atcgccactg gcagcagcc 9240  
taggcgggtc tacagagtt ttgaagttt ggccttaacta 9300  
tatttggat ctgcgtctg ctgaaggcc 9360  
gatccggcaaa acaaaccacc gctggtagcg gtgggtttttt 9420  
cgccgagaaa aaaaaggatctt caagaagatc 9480  
agtggaaacg 9540  
ccttagatct tttaaattaa aaatgaagtt taaatcaat 9600  
cttggctcg 9660  
cagttaccaa tgcttaatca gtgaggcacc 9720  
tatctcagcg 9780  
atctgtctat 9840

ttcgttcatc catagttgcc tgactcccg tcgtgttagat aactacgata cgggagggt 9720  
 taccatctgg ccccagtgtc gcaatgatac cggagaccc acgctcacgg gctccagatt 9780  
 tatcagcaat aaaccagccaa gccggaaaggg ccgagcgcag aagtggctt gcaactttat 9840  
 ccgcctccat ccagtctatt aattgttgc gggaaagctag agtaagttagt tcgcccgtt 9900  
 atagttgcg caacgttgtt gccatgtcta caggcatcggt ggtgtcacgc tcgtcggtt 9960  
 gtatggcttc attcagctcc ggttccaaac gatcaaggcg agttacatgtc tccccatgt 10020  
 tgtgcaaaaa agcggttagc tccttcggc ctcgcgtc tgtagaaatg aagttggccg 10080  
 cagtgttattc actcatgggtt atggcagccatc tgataattc tcttactgtc atgcccattcg 10140  
 taagatgtt ttctgtgact ggtgagtagt caaccaagtc attctgagaa tagtgtatgc 10200  
 ggcgaccgag ttgtcttgc cccgcgtcaa tacggatata taccgcgcac catagcagaa 10260  
 cttaaaaatg gtcatcatt gaaaaacgtt cttcgccggc aaaactctca agatcttac 10320  
 cgctgtttagt atccagttcg atgtaaacccaa ctcgtgcacc caactgtatc tcagcatctt 10380  
 ttactttcac cagcgtttctt gggtagccaa aaacaggaa gcaaaaatgcc gcaaaaaaagg 10440  
 gaataaggc gacacggaaa tgtagataatc tcatacttctt ccttttcaa tattattgaa 10500  
 gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgttatt tagaaaaata 10560  
 aacaaatagg ggttccgcgc acatttcccc gaaaagtgc acctgacgtc 10610

&lt;210&gt; 17

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt; Description of Artificial Sequence: Primer

<223> Description of Artificial Sequence: Primer  
tgtacaccgg atccggcgca cacc

24

&lt;210&gt; 18

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Primer

&lt;400&gt; 18

cacaacgagc tcaattaattt aattgccaca tcctc

35

&lt;210&gt; 19

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; adenovirus

&lt;400&gt; 19

Thr Leu Trp Thr

1

&lt;210&gt; 20

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; adenovirus

&lt;400&gt; 20

Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser  
1 5 10

&lt;210&gt; 22

&lt;211&gt; 327

&lt;212&gt; DNA

<213> adenovirus

<210> 23

<211> 32480

<212> DNA

<213> adenovirus

ctttcgttac ctggagagac ggcggcgtg atcccttgcg aatacgccca cgcgatgggt 2820  
 aacagtcttgc ggggttgc taaaacttgg caggcggttc gtcagtatcc ccgtttacag 2880  
 ggcggcttcg tctgggactg ggtggatcatcg tcgctgatta aatatgtatga aaacggcaac 2940  
 ccgtggtcgg cttacggcgg tgattttggc gatacggcga acatgcgc aatctgtatg 3000  
 aacggcttgg tctttggcga cggcacggc catcggcgc tgacggaa gaaaacaccag 3060  
 cagcagttt tccagttccg tttttttttt caaaccatcg aatgtggatgg 3120  
 ttccgtatca gcgataacga gtcctgcac tgatgttgg aacagttgtatca 3180  
 gcaaggcggtg aagtgcctct ggtatgtcgct ccacaaggta cagtgccgt 3240  
 gaactaccgc agccggagag cggggggca ctctggctca agtacgcgt 3300  
 aacgcgaccg catggcaga aacccggcac atcagcgct ggcagcagt 3360  
 gaaaacctca gtgtgacgct cccggcccg tccccacgca tcccgatct 3420  
 gaaatggatt tttcatcgat gctgggtaat aagcggttgc aatttacccg 3480  
 ttcttccatc agatgttggat tggcgataaa aacaaactgc ccaatccg 3540  
 ttcacccgtg caccgtggaa taacgacccat ggcgttaatgt aagcgcaccg 3600  
 aacgccttgg tgcgaaacgctg gaaggcggcg ggcattacc tcccgatct 3660  
 cagtgacacgg cagatacact tgcgtatgcg gtgtgttgcg aatggcgtca 3720  
 catcaggggga aaaccttatt tgcgtatgcg aaaaacttacc cccggcccg 3780  
 atggcgatata cccgttgcgt tgaagtggcg agcgatatac cccggcccg 3840  
 ctgaatgcctc agtggcgca ggttgcagag cgggttttttgcg 3900  
 gaaaacttcc cccggccct gacatgtata cccgttgcgt gctggatgttgc 3960  
 gacatgtata cccgttgcgt ttttttttttgcg gctggatgttgc 4020  
 ttgaattatg gcccacacca caacagcaac tgatggaaac tcaatccatcg 4080  
 ctgaatatcg acggtttcca ttttttttttgcg acggatgttgc 4140  
 tccggcgaat tccagcttag ttttttttttgcg gctggatgttgc 4200  
 taataataac cgggcaggcc ttttttttttgcg gctggatgttgc 4260  
 tatttttttttacacaaactt ttttttttttgcg gctggatgttgc 4320  
 atggggacct attttccgtt ttttttttttgcg gctggatgttgc 4380  
 agtgatacgg gtatttttttgcg ttttttttttgcg ttttttttttgcg 4440  
 ttttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 4500  
 aaagcaatag catcacaat ttttttttttgcg ttttttttttgcg ttttttttttgcg 4560  
 gtttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 4620  
 aggggtggaa agaataatata aggtgggggt ttttttttttgcg ttttttttttgcg 4680  
 gccggccggc ccatgagcac caactcttgcg ttttttttttgcg ttttttttttgcg 4740  
 acgcgcacgc ccccatggcc cgggggtgcgt cttactacc ttttttttttgcg 4800  
 cggccggcc tggccgttgcg ttttttttttgcg ttttttttttgcg 4860  
 ttggagactg cggccgttgcg ttttttttttgcg ttttttttttgcg 4920  
 actgacttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 4980  
 gatgacaatgg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5040  
 gtttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5100  
 cccaaatgcgg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5160  
 gtgtcttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5220  
 cggcgatgttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5280  
 agggggggatgttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5340  
 agggggggatgttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5400  
 agggggggatgttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5460  
 ttttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5520  
 gatcacttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5580  
 gatcacttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5640  
 agggggggatgttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5700  
 ttttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5760  
 atggggccac gggggggggatgttgcg ttttttttttgcg ttttttttttgcg 5820  
 ttttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5880  
 ttttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 5940  
 ttttttttttgcg ttttttttttgcg ttttttttttgcg ttttttttttgcg 6000  
 cccaaatccgc ttttttttttgcg ttttttttttgcg ttttttttttgcg 6060  
 cccaaatccgc ttttttttttgcg ttttttttttgcg ttttttttttgcg 6120  
 cccaaatccgc ttttttttttgcg ttttttttttgcg ttttttttttgcg 6180  
 cccaaatccgc ttttttttttgcg ttttttttttgcg ttttttttttgcg 6240  
 cccaaatccgc ttttttttttgcg ttttttttttgcg ttttttttttgcg 6300  
 cccaaatccgc ttttttttttgcg ttttttttttgcg ttttttttttgcg 6360  
 atatcccttc gtttttttttgcg ttttttttttgcg ttttttttttgcg 6420  
 ccagacggggc cagggtcatgc ttttttttttgcg ttttttttttgcg 6480

tcacggtaa ggggtgcgt cggggctgca cgctggccag ggtgcgttg aggctggtcc 6540  
 tgctggctc gaagcgctgc cggcttcgc cctgcgcgtc ggccagtag catttgacca 6600  
 tggtgtata gtccagcccc tccgcggcgt gccccttggc ggcgcgttg cccttggagg 6660  
 aggcgcgcga cgagggggcag tgcagacttt tgagggcgt aagcttggc gcgagaaata 6720  
 ccgattccgg ggagtaggca tccgcgcgc agggccgcga gacggctcgt cattccacga 6780  
 gccaggtgag ctctggccgt tcgggtcaa aaccagggt tccccatgc tttttgatgc 6840  
 gttcccccgtc tctgggtttcc atgagccgtt gtcacgcgtc ggtgacaaa aggtgtccg 6900  
 tgcgttccatc tagacttgcgtt agaggcgtt ctcgcgttcc ggcgcacg aaggaggcta 7020  
 atagaaaactc ggaccactt gagacaagg ctcgcgttca ggcgcacg aaggaggcta 7080  
 agtggggaggg gtagcggtcg ttgtccacta ggggttccac tcgcgttccagg gtgtgaagac 7140  
 acatgtcgcc ctcttcggca tcaaggaagg tgattgtttt gtatgttag gccacgtgac 7200  
 cgggttcc tgaagggggg ctataaaagg ggggtggggc ggcgttcc tcactcttca 7260  
 cgcgcgtgtc gtctcgagg ggcgcgtt ggggtgagta ctcgcgttca aagcggggca 7320  
 tgacttctgc gtaagatgtt tcgcgttcaaaaacgaggaa ggatttgata ttcacctggc 7380  
 cgcgggtgtat gccttggagg gtggcgcgtt ccatctgtc agaaaagaca atcttttgc 7440  
 tgtcaagctt ggtggcaaac gaccgtaga gggcgttggc cagcaactt ggcgttggc 7500  
 gcagggtttt gttttgtcgt cgatcgccgc gtccttggc cgcgttgcgtt agctgcacgt 7560  
 attcgccgc aacgcaccgc catttcggaa acacgggtt ggcgttgcgtt ggcaccagg 7620  
 gcacgcgc acccggttgc tgcagggtga caaggtcaac gctgggtgtt acctctccgc 7680  
 gttaggcgtc ttgttccagg cagaggcggc cgccttgcg cggcgttggc 7740  
 ggtctactgtc cgtctcggtt ggggggtctg cgtccacggt aaagaccccg ggcgttggc 7800  
 ggcgcgtgaa gtatgttata ttgcacgttca gcaagtctat cgcgttgcgtt ggcgttggc 7860  
 cggcaagcgc ggcgtcgat ggggtgtt ggggacccca tggcatgggg tgggtgagcg 7920  
 cggaggcgta catgcgcgaa atgtcgtaaa cgtagagggg ctctctgtt attccaagat 7980  
 atgttaggttgcatcttcc cgcggatgc tggcgcgcac gtaatgtat agttcggtcg 8040  
 agggagcgag gaggtcggttgc cggagggttgc tacggggggg ctgcgttgcgtt cggaaagacta 8100  
 tctgcctgaa gatggcatgt gagggttgcg atatgggttgg acgtgttgcgtt acgttgaagc 8160  
 tggcgtctgt gagaacctacc ggcgtacgcg cgaaggaggcgtt gtagggttgcgtt cgcagcttgc 8220  
 tgaccagctc ggcgtgttca tgcacgttca gggcgttca gtcacgttca gtttggggata aactcttcgc 8280  
 tgtcataactt atccgttcc tttttttcc acagctcggtt gtttggggata aactcttcgc 8340  
 ggtcttccatc gtacttggg atcgaaacc cgtcgccctc cgaacggtaa gggcttagca 8400  
 ttagaactt gttgacggcc tggtaggcgc agcatccctt ttctacgggtt agcgcgtatg 8460  
 cttcgccggc cttccggcgc gagggttggg tgagcgttcaaa ggtgtccctg accatgactt 8520  
 tgagggtactt gtatgttgcgt tcgcgttca cgcacgttcc tcgcgttccagg agcaaaaatg 8580  
 ccgtgcgtt tttggaaacgc ggttggcgtt gggcgttggc gacatgttgc agaggtatct 8640  
 ttcccgccgc aggcataaatc ttgttgcgttgc tgccggaggc tcccgccacc tccggacgggt 8700  
 tgtaattac ctggccggcgc agcacgtatc cgtcaaaaggc gtttgggttgcgtt agtttctctgt 8760  
 tgtaaaatgc caagaagcgc gggatggccat tgatggaaagg caattttttaa gtttgggttgcgtt 8820  
 aggtgagctc ttccaggggat ctgagccgtt gtcgttgcgtt ggcacgttca gcaagatgag 8880  
 ggttggaaagc gacgaatggat ctcacacggat ctcacacggat ctcacacggat tggatgttgcgtt 8940  
 gaaaggcttca aaatggccgc cctatggccca ttttttctgg ggttgggttgcgtt tggccccacaa 9000  
 gcggttcttgc ttcccgccgg tcccatccaa ggttgcgttcc tagtctcgc gccggcgttca 9060  
 cttagggctc atctccggcc aacttcatga ccacgttcaaa gggcacggcgtt tgcttccca 9120  
 agggccccat ccaagtatag gtctctacat cgttaggttgcgtt gacatgttgc acggagacgc 9180  
 gatgcgagcc gatcggttgcgtt aactggatct cccggccacca atggaggatc tggatgttgcgtt 9240  
 tgggtgaaa gtagaacttgcgtt ctgcgcgggg ggttgcgttcc ctcacacggat gtcgttgcgtt 9300  
 gtgcgcgttgcgtt ctggccggcgtt tgacgggttgcgtt gtcacacggat gtcgttgcgtt 9360  
 cgcgcacaag gaagcggatgtt gggatgttgcgtt gtcacacggat gtcgttgcgtt 9420  
 ctcttacttc ggttgcgttgcgtt ctttgcgttgcgtt gtcacacggat gtcgttgcgtt 9480  
 ggaccaccac ggcgcgcgc gccaaatgttgcgtt gtcacacggat gtcgttgcgtt 9540  
 tgacaacatc ggcgcgttgcgtt gtcacacggat gtcgttgcgtt 9600  
 gcggttgcgttgcgtt accttcgcgtt gtcacacggat gtcgttgcgtt 9660  
 gatacttaatc tttccaggggcgtt tggttgggttgcgtt gtcacacggat gtcgttgcgtt 9720  
 cccggccgc gacttgcgtt cccggccacca atggaggatc tggatgttgcgtt 9780  
 atgcatctaa aagcggttgcgtt gtcacacggat gtcgttgcgtt 9840  
 cggggaggggg ggcaggggccgtt ctcacacggat gtcgttgcgtt 9900  
 taggttgcgtt gtcacacggat gtcgttgcgtt 9960  
 gaagacgacgc gggccgggttgcgtt gtcacacggat gtcgttgcgtt 10020  
 gtcgttgcgtt gtcacacggat gtcgttgcgtt 10080  
 gatctccggcc atgaacttgcgtt ctcacacggat gtcgttgcgtt 10140  
 cacgggttgcgtt gtcacacggat gtcgttgcgtt 10200  
 tccctcggttgcgtt gtcacacggat gtcgttgcgtt

caccctgcgcg agattgagct ccacgtgccc ggcgaagacg gcgtagttc gcaggcgctg 10260  
 aaagaggtag ttgagggtgg tggcggtgt ttcgtccacg aagaagtaca taacccagcg 10320  
 tcgcacacgtg gattcgttga tateccccaa ggcctcaagg cgctccatgg cctcgttagaa 10380  
 gtccacggcg aagttgaaaa actgggagtt ggcgcggc acggtaact ctcctccatgg 10440  
 aagacggatg agctcggcga cagtgtcgcg caccctcgcc tcaaaaggcta cagggggcctc 10500  
 ttcttcttct tcaatctctt ctteccataag ggcctccctt tcttcttctt ctggcgccgg 10560  
 tgggggaggg gggacacgac ggcacacgac ggcgcacccggg aggccgtcgaa caaaggcgtc 10620  
 gatcatctcc cccggccgac ggcgcgttgc ctccgtgacg ggcggccgt tctcgtgggg 10680  
 ggcagttgg aagacggccg cccgtcatgtc ccggttatgg gttgggggg ggtgcccattg 10740  
 cggcaggatg acggcgctaa cgatgcatttca aacaattgt tggtaggttgc cccggccgc 10800  
 gagggacactg agcgactcg catcgaccgg atcggaaaaac ctctcgagaa aggcgcttcaa 10860  
 ccacgtcactg tcgcacggta ggctgacgac cgtgggggg ggcagccggc ggcgggtcg 10920  
 gttttctg ggggggtgc tgctgtatg taaattaaag taggcgttct tgagacggcg 10980  
 gatggtcacg agaaggaccca tgccttggg tccggcctgc tgaatgcga ggcggtcggc 11040  
 catgccccag gcttcgtttt gacatcgccg caggctttt tagtagtctt gcatgagcc 11100  
 ttcttacggc acttcttctt ctcccttc tttgttctgc tctctgtcat ctatcgctgc 11160  
 ggcggccggcg gagtttgggg gtaggtggcg cccttcttctt cccatcggt tgaccccgaa 11220  
 gcccctatc ggctgaagca ggcttaggtc ggcacacgac cgctccgtata atatggcctg 11280  
 ctgcacactg tgggggttag actgaagtc atccatgttcc acaaaggcggt ggtatgcgc 11340  
 cgtgttgcgt tgtaagtgac agttggccat aacggaccag ttaacggtctt ggtgacccgg 11400  
 ctgcgagagc tcgggttacc tgagacgcga gtaaggccctc gagtcacaaatc cgtagtcgt 11460  
 gcaagtccgc accaggtaact ggtatccac caaaaagggtc ggcggccggc ggcggtagag 11520  
 gggccacgtg agggtggccg gggctccggg ggcgagat tccaaatataa ggcgatgata 11580  
 tcccttagtg tacctggaca tccaggatg gccggccggc gtgggggggg cgcgcggaaa 11640  
 gtcgggacg cgggtccaga tggtggccag cggcaaaaag tgctccatgg tcgggacgc 11700  
 ctggccggc aaggcgccgc aatcggttac gctctagacc gtcggaaaagg agagcctgt 11760  
 agcgggcaact ctccctgtgt ctggggata aatttcgcac ggtatccatgg cggacgcac 11820  
 ggggtcgacg cccgtatccg gccgtccggc gtgatccatgg cggtaggc cggcgtgtc 11880  
 aaccagggtg tgcacgttca gacaacgggg ggttggcttcc ttccaggccgc 11940  
 ggcggctgtc ggcttaggtt tttttggccca tgccggccgc cagcgtaagc gtttaggctg 12000  
 gaaagcgaaa gcatcaatgt gctcgctccc tttttggccca ggggttattttt ccaagggttg 12060  
 agtcgggca ccccccgggtc gagtctcgga ccggccggac tgccggcgaac ggggggtttgc 12120  
 ctccccgtca tgcaagaccc cgctgcacaa ttccctccgaa aacaggggacg agcccccttcc 12180  
 ttgtttttcc cagatgcacg cgggtgtcgcc gcatgtgcgc cccccccttcc acgagcggca 12240  
 agagcaagag cagccggcaga catcgaggcc acccctccctt cctcttacccg cgtcaggagg 12300  
 ggcacatcc gcggttgcg cggcagccgaa tggttatttac gaaaccccccgc ggcggccggc 12360  
 cccgcaactac ctggacttgg aggagggcga gggctccggc cggctaggag cggccctctcc 12420  
 tgagcggtac ccaagggtgc agctgaagcg tgatcgcgt gaggcgatgc tgccggggca 12480  
 gaaacctgtt cgcgaccggc agggagagga gcccggaggat gtcggggatc gaaagggttcca 12540  
 cgcaggggcgc gagctggccg atggccttgc tgccggccgc ttggccggc aggaggactt 12600  
 tgagccggcgc gcgcaaccg ggtaggttcc acacatccatgg cggccggccgc cggccgaccc 12660  
 ggttaaccgcg taacggccg cggtaacca gggatataac ttccatggccgc acatgttcca 12720  
 ccacgtcggt acgcttgggg tccggccggc ggtggctata ggactgtgc atctgtggg 12780  
 ctttgcgtac ggcgtggccg aaaacccaaa tagcaagccg ctcatggccgc agctgttctt 12840  
 tatagtgcacg cacaggccgg acaacggggc attcaggatg ggcgtgttac acatagtaga 12900  
 gcccggggcgc cgctggcgc tggatgttgc aaacatccatgg cagacatgc tggtggccgg 12960  
 ggcgcacgtt acgctggccg acaagggtgc cccatcaac tttccatgc ttagccctggg 13020  
 caagttttac gcccggcaaga tataccatgc cccttacgtt cccatagaca aggaggtaaa 13080  
 gatcgagggg ttcttacatgc gcatggccgc gaaagggttcc accttggccgc acgacccctgg 13140  
 cgtttacatgc aacggccgc tccacaaggc ggcgtggccgc ggcgtggccgc cggaggttcca 13200  
 cgaccggcgag ctgtatgcaca gctgcacaa ggcgtggccgc ggcgtggccgc cggaggttcca 13260  
 agaggccggag tcctacttgc acggggccgc tgacccatccatgc ttagccctggg 13320  
 cctggaggca gctggggccg gacccatccatgc ggcgtggccgc cccggccggc ctggcaacgt 13380  
 cggccggcgatc gaggaaatgc acggggccgc tggttccatgc cggatccatgc ggcgtggccgc 13440  
 agccgtatgc tttctgtatca gatgtatgc gacccatccatgc ggcgtggccgc cggaggttcca 13500  
 ctgcacggcc acggcgatccatgc ggcgtggccgc ggcgtggccgc cggatccatgc ggcgtggccgc 13560  
 atcatgtcgcc tgactgtcgcc caatccatgc ggcgtggccgc ggcgtggccgc cggatccatgc ggcgtggccgc 13620  
 ctctccgcac ttcttggaaatgc ggttccatgc ggcgtggccgc ggcgtggccgc cggatccatgc ggcgtggccgc 13680  
 ctggcgatcg taaaacggccgtt ggcgtggccgc tggttccatgc ggcgtggccgc cggatccatgc ggcgtggccgc 13740  
 gtctacgcacg cggatccatgc ggcgtggccgc tggttccatgc ggcgtggccgc cggatccatgc ggcgtggccgc 13800  
 ctggaccggc tgggtgggggatgc tggccggccgc ggcgtggccgc acggccatccatgc ggcgtggccgc 13860  
 caggggcaacc tgggtgggggatgc tggccggccgc ggcgtggccgc acggccatccatgc ggcgtggccgc 13920

gtgcgcgggg gacaggagga ctacaccaac tttgtgagcg cactgcggct aatggtgact 13980  
 gagacaccgc aaagtgaggt gtaccagtct gggccagact atttttcca gaccagtaga 14040  
 caaggcctgc agaccgtaaa cctgagccag gctttcaaaa acttgcaggg gctgtggggg 14100  
 gtgcgggctc ccacaggcga ccgcgcgacc gtgtctagct tgctgacgccc caactcgcc 14160  
 ctgttgcgtc tgctaatacg gcccttcacg gacagtggca gctgtccccg ggacacatac 14220  
 cttaggtcaact tgctgacatc gtaccgcgag gccataggtc aggcgcacatg ggacgagcat 14280  
 acttccagg agattacaag tgcagccgc ggcgtggggc aggaggacac gggcagccctg 14340  
 gaggcaaccc taaaatccact gctgaccaac cggccggcaga agatccccctc ttgcacatgt 14400  
 ttaaacagcg aggaggagcg catttgcgc tacgtgcagc agagcgttag ccttaacctg 14460  
 atgcgcgacg gggtaaacgc cagcgtggcg ctggacatga ccgcgcgcaa catgaaaccc 14520  
 ggcatgtatg cctcaaaaccg gccgttata aaccgcctta tggactactt gatcgccg 14580  
 gcccgcgtga accccggta tttcacaat gccatcttga accccgactg gctaccgcoc 14640  
 cctgggtctc acacccgggg attcgggtg cccgagggtt acgtggatt cctctgggac 14700  
 gacatagacg acagcgtttt tcccccgaa ccgcagaccc tgcttaggtt gcaacagcgc 14760  
 gagcaggcgag aggccggcgt gcgaaaaggaa agtctccgca ggcacaaaggag cttgtccgat 14820  
 cttaggcgtc cggccccgcg gtcagatgtc agtagcccat ttccaaagctt gatagggtct 14880  
 cttaccagca ctgcacccac ccgcgcgcg ctgtggggc aggaggatg cttaaacaaac 14940  
 tcgctgtgc agccgcgcg cggaaaaaaac ctgcctccgg catttccaa caacgggata 15000  
 gagagccttag tggacaagat gatgtatgc aagacgtacg cgcaggagca cagggacgtg 15060  
 ccaggcccgcc gcccgcaccc cccgtctaa aggcacgacc gtcagcgggg tctgggttgg 15120  
 gagagcgtatg actcggcaga cgacagcgc gtcctggatt tggaggggag tggcaacccg 15180  
 tttgcgcacc ttgcgcaccag gctggggaga atgttttaaa aaaaaaaaaaag catgatgcaa 15240  
 aataaaaaaac tcaccaaggc catggcaccg acgcgtttt ttcttgatt ccccttagta 15300  
 tgccgcgcgc ggcgtatgtt gagaaggtc tccctccctt ctacggagat gttgtggacg 15360  
 cggcgcgcgtt ggcggccgcg ctgggttctc cttcgcatgc tcccctggac ccgcgcgttt 15420  
 tgccctccgcg gtacctgcgg cttaccgggg ggagaaacag catccgttac tctgagttgg 15480  
 cacccttatt cgacaccacc cgtgttacc ttgtggacaa caagtcaacg gatgtggcat 15540  
 ccctgaacta ccagaacgcg cacagcaact tccgcatttgc ctacggatgtt gttgtggac 15600  
 acagccccggg ggaggcaacg acacagacca tcaatcttgc tgcacccgtt cactggggcg 15660  
 gecacctgaa aaccatctg catacacaact tccaaatgtt gaacgatgtc atgtttacca 15720  
 ataagttttaa ggcgcgggtt atgggtgtcg gttgcctac taaggacaat caggtggagc 15780  
 tgaataacga gtgggtggag ttcaacgtgc cgcggccaa ctactcccgag accatgacca 15840  
 tagaccttat gaacaacgcg atcgtggagc actacttggaa agtgggcaga cagaacgggg 15900  
 ttctggaaag cgacatcggg gtaaaggttt acacccggaa cttcagactt gggtttgacc 15960  
 ccgtcactgg tcttgcactt cctgggttat atacaaacga agcctccat ccagacatca 16020  
 ttttgcgtcc aggtgcggg gtggacttca cccacaggcc cctgagcaac ttgtggggca 16080  
 tccgcaagcg gcaacccttc caggagggtt ttaggatcac ctacgtatgtt ctggagggtg 16140  
 gtaacattcc cgcactgtt gatgtggacg cctaccaggc gagttggaa gatgacacccg 16200  
 aacagggcggg gggtggcga ggcggcagca acagctgg cagccgcgcg gaagagaact 16260  
 ccaacgcggc agccgcggc atgcagccgg tggaggacat gaacgatcat gccatccgc 16320  
 ggcacaccc tggccacacgg gctggggaga agcgcgtga ggccgaagca gcccgcgaag 16380  
 ctggccccc cgcgtgcggc cccggggctc agaaggctca gaagaaaccc gtgatcaaac 16440  
 ccctgacaga ggacagaag aaacgcgtt acaacctaatt aagcaatgac agcaccttca 16500  
 cccagtagccg cagctggatc ttgcataca actacggcga ccctcagacc ggaatccgt 16560  
 catggaccct gctttgcact cctgacgtaa cctgcggctc ggacggatc tactggtcgt 16620  
 tgccagacat gatgcacagc cccgtgaccc tccgtccatc gcccagatc agcaacttca 16680  
 cgggtgtggg cggcgagctg ttggccgtc acttccaaagat ttcttacaac gaccaggccg 16740  
 totactccca actatccgc cagtttaccc ttctgaccca cgtttcaat cgcttcccg 16800  
 agaaccagat ttggcgcgc cggccagccc ccaccatcac caccgtcagt gaaaacgtt 16860  
 ctgcttcac agatcacggg acgttaccgc tgccaaacag catcgaggg gtcacggag 16920  
 tgaccattac tgacgcaga cggccgcaccc gcccctacgt ttacaaggcc ctgggcata 16980  
 tctgcgcgcg cgttccatcg agccgactt tttgagcaag catgtccatc ttatatcg 17040  
 ccagcaataa cacaggctgg ggctgcgtc tcccaagcaa gatgtttggc ggggccaaga 17100  
 agcgtccga ccaacaccca gtgcgcgtgc gggggcacta ccgcgcgcgg tggggcgcgc 17160  
 acaaacgcgg cgcactggg cgcaccaccg tcgatgacgc catcgacgcg gtgggtggagg 17220  
 aggccgcgaat ctacacgccc acggccaccc cagtgccatc agtggacgcg gccattcaga 17280  
 ccgtgggtcg cggagccccc cgttccatcg aaatgaagag acggccggagg cgcgttagac 17340  
 gtcgcaccc cggccgaccc ggactgcgc cccaaacgcgc gggccggcc ctgcttaacc 17400  
 gccgcacgtcg caccggccga cggggggccca tgccggccgc tcgaaggctg gccgcgggta 17460  
 ttgtcactgt gccccccagg tccaggccac gaggccgcgc cgcagcagcc gccgcattta 17520  
 gtgctatgac tcagggtgcg agggcaacg tttttttttt ggcgcactcg gttagcggcc 17580  
 tgccgcgtgcc cgtgcgcacc cggcccccgc gcaactagat tgcaagaaaa aactacttag 17640

actcgtaactg ttgtatgtat ccagcggcgg cggcgccaa cgaagctatg tccaagcgca 17700  
 aatcaaaga agagatgctc caggtatcg cggccggagat ctatggcccc ccgaagaagg 17760  
 aagagcagga ttacaagccc cgaagactaa agcgggtcaaa aagaaaaaaag aaagatgatg 17820  
 atgatgaact tgacgacgag gtggaaactgc tgcacgctac cgcgcccagg cgacgggtac 17880  
 agtggaaaagg tcgacgcgtaa aacagtgttt tgcaacccgg caccaccgta gtcttacgc 17940  
 ccggtgacgc ctccacccgc acctacaagg gcgtgtatga tgagggtgac ggcgacgagg 18000  
 acctgcttga gcagggcaac gaggcctcg gggagttgc ctacggaaag cggcataaag 18060  
 acatgctggc gttgccgtg gacgaggggca accaacacc tagctaaag cccgtaaacac 18120  
 tgcagcaggc gctgcccgcg cttgcacgtg cggaaagaaaa ggcggccta aagcgcgagt 18180  
 ctggtaactt ggacccaccgt gtgcagtgaa gaacctggc tggagcccgaa ggcggcgega ctggaaagatg 18240  
 tcttggaaaaa aatgaccgtg ggcgtcaga ccgtggacgt ggtccgcgtg cggccataca 18300  
 agcagggtgc gccgggactg acagaggggca tggagacaca tcaagatacc actaccaga 18360  
 gcaccaggat tgccaccgcg acagggtcg ctgcggccgc aacgtcccg gttgccttag 18420  
 cggtggcga tgccgcgtg caggcggcgtg cggccacccgg aacgtcccg gttgccttag 18480  
 tgcaaacggc cccgtggatg ttgcgttccg actatggccg aatatgcctc gtcggcggcgc 18540  
 agtacggcgc cccagcgcg acctacccgc ccagaagacg gccacacccgg attgcgccta 18600  
 ccccccggta tctgggtac acctacccgc ccagaagacg agcaactacc cgacgcccga 18660  
 ccacactgg aaccggccgc cggcgtcgcc gtcggcagcc cgtgctggcc cggatcccg 18720  
 tgcgcagggt ggctcgcaa ggaggcagga ccctgggtct gcaacacccgg egctaccac 18780  
 ccagcatcg taaaagccg gtctttgtgg ttcttgaga tatggccctc acatccctc 18840  
 tccgttccc ggtgcccgggaa ttccggagaa gaatgcaccg taggaggggc atggccggcc 18900  
 acggcctgac gggccggatg cgtcgtcgcc accacccggc gggcgcgcg tcgcaccgtc 18960  
 gcatggcgg cgtatccgt cccctctta ttccactgtat cgccggcggc atggccggc 19020  
 tgccggaaat tgcatccgtg gccttcgagg cgcagagaca ctgattaaaa acaagttca 19080  
 tggtaaaaaa tcaaaataaaa aagtctggac tctcacgctc gcttgggtct gtaactatt 19140  
 ttagaaatgg aagacatcaa ctttgcgtct ctggcccccgc gacacggctc gcggccgttc 19200  
 atggggaaact gcaagatata cggcaccagg aatatgacgc gttggcctt cagctggggc 19260  
 tgcgtgtgga gcccattaa aatttcggt tcaccgtta agaactatgg cagcaaggcc 19320  
 tggaaacacga gacaggcga gatgctgagg gataagttga aagagcaaaa tttccaacaa 19380  
 aagggttagg atggccctggc ctctggcatt aggggggtgg tggacctggc caaccaggca 19440  
 gtcaaaaata agatataacag taagcttgc ccccgccctc cctgtaggggca 19500  
 gccgtggaga cagtgtctcc agaggggcgt ggcggaaaagg gtcggccccc cgacaggggaa 19560  
 gaaactctgg tgacgcaaata agacgacgcct cctctgtacg aggaggact aagcaaggc 19620  
 ctgcccacca cccgtccatc cgcgcctatc gtcaccggag tgctggccca gcacacaccc 19680  
 gtaacgctgg actgtctcc cccggccgac acccagcaga aacctgtgtc gccaggcccc 19740  
 accgcctgg ttgtaccccg tcctagccgc gctccctgc gccgcgcgcg cagcggctcc 19800  
 cgatcggtgc ggccctgtac cagtggcaac tgccaaagca cactgaacac catctgggt 19860  
 ctgggggtgc aatccctgaa ggcggacga tgcttctgaa tagctaactg gtctgtatgt 19920  
 tgcgtatgtat gcttccatgt cggcccgaga ggagctgtct tgctggccca 19980  
 ccaagatggc tacccttcgc atgatggccgc agtggcttca catgcacatc tcggggccagg 20040  
 acgcctcgga gtacgtggc cccgggtgg tgcagttgc cgcgcacc gagaacgtact 20100  
 tcagctgtaa tacaagttt agaaacccca cggtgccgc tacgcacac gtagaccacac 20160  
 accggccca gctgttgcacg ctgcgttca tccctgtggc cctgtaggat atcgtgtact 20220  
 cgtacaaggc ggggttcacc ctgcgtgtgg gtgataaccc tggtggac atggcttcca 20280  
 cgtactttga catccgcggc gtgtggaca gggggccctac tttaaagccc tactctggca 20340  
 ctgcctacaa cggccctggc cccaaagggtg ccccaaatcc ttgcgaatgg gatgaagctg 20400  
 ctactgtct tggaaaataac ctagaagaaaggacatgacatc gaaacaaat ggtataaata 20520  
 agcaagctga gcaaaaaaaa actcacgat ttgggcaggg acctaataat gccgataaaaa 20580  
 ttacaaagga gggatttcaaa ataggtgtcg aaggtcaaaac cttttctcaa ctactgaggc gcttattct 20640  
 catttcaacc tgaacctcaa ataggagaat ctcaacttgc cggaaactgaa atgttacgtt tcaatatgca 20700  
 cagctgggag agtccttaaa aagactaccc caatgaaacc ttgttgcgtt gcaacaaaat gggaaagctag 20760  
 aaccacaaaa tggaaaatgg gggcaaggca ttcttgcgtt gttttctcaa ctactgaggc gaccgcaggc aatgggtata 20820  
 aaagtcaagt gggaaatggca tttttctcaa ctactgaggc gttttctcaa ctactgaggc gaccgcaggc aatgggtata 20880  
 acttgactcc taaaatggta ttgtacgtg aagatgtaga tataaaaacc ccaagacactc 20940  
 atatttctta catgcccact attaaggaag gtaactcaac agaactaatg gggccaaat 21000  
 ctatgccccaa caggcctaatt tacattgttt ttggggacaa ttttttgtt gttttttgtt ctaatgtatt 21120  
 acaacagcac gggtaataatg ggtttctgg cggggccaaatc tttttctcaa ctactgaggc gaccgcaggc aatgggtata 21180  
 tagatttgca agacagaaac acagacttcc tttttctcaa ctactgaggc gttttctcaa ctactgaggc gaccgcaggc aatgggtata 21240  
 atagaaccag gtactttct atgttgcgtt gggccaaatc tttttctcaa ctactgaggc gttttctcaa ctactgaggc gaccgcaggc aatgggtata 21300  
 gaatttatttga aatcatgtga atgaagatg aacttccaa ttactgtttt ccactggggag aacaggtcag gaaaatggat aataattttt 21360  
 gtgtgattaa tacagagact cttaccaagg taaaaccta aacaggtcag gaaaatggat aagagttggaa aataattttt 21360

ccatggaaat caatctaaat gccaacctgt ggagaaaattt cctgtactcc aacatagcgc 21420  
 tgtatggcc cgacaagcta aagtacagtc cttccaacgt aaaaatttct gataacccaa 21480  
 acacctacga ctacatgaac aagcgagtgg tggctcccg gtttagtgac tgcacatta 21540  
 accttggagc acgctggcc cttgactata tggacaacgt caacccattt aaccaccacc 21600  
 gcaatgctgg cctcgctac cgctcaatgt tgctggccaa tggtegctat gtggcccttcc 21660  
 acatccaggt gcctcagaag ttcttgccca ttaaacaccc ctttctccgt cccggctcat 21720  
 acacctacga gtggaaactt aggaaggatg tttacatggg tctgcagagc tccttaggaa 21780  
 atgacctaag gtttgacgga gccagcattt agtttatacg catttgcctt tacgcccaccc 21840  
 tctttccat gggccacaac accgcctcca cgcttgaggc catgctttag aacgacaccca 21900  
 acgaccagtc tttaacacgt tatctctccg cccgcaacat gctctaccc atacccgcca 21960  
 acgctaccaa cgtgcccata tccatcccc cccgcaactt ggcgggttcc cggggctggg 22020  
 ctttacacgc cottaagact aaggaaaccc catcaactgg ctggggctac gacccttattt 22080  
 acacctactt tggctctata ccctacttag atggaaacctt ttacctcaac cacacccctta 22140  
 agaagggtgc cattacctt gacttctgtc ttagctggcc tggcaatgac cgcctgctta 22200  
 ccccaacga gtttggaaattt aagcgcttag ttgacggggg ggggttacaac gttggccatg 22260  
 gtaacatgac caaagactgg ttcttggtac aatgtctagc taactacaaat attggcttacc 22320  
 agggcttcta tatcccagag agctacaagg accgcatgtt ctccttctt agaaacttcc 22380  
 agcccatgag ccgtcagggtt gtggatgata ctaaatacaa ggactaccaa caggtgggca 22440  
 tcctacacca acacaacaac tcttgattt tggtctactt tgccccccacc atgcgcgaag 22500  
 gacggccta ccctgtactt ttcccatttcc cgcttataagg caagaccgca gttgacagca 22560  
 ttacccagaa aaagtttctt tgcatcgca ccctttggcg catccatttc tccagtaact 22620  
 ttatgtccat gggcgactc acagacctgg gccaaaactt tctctacgccc aactccgccc 22680  
 acgcgtaga catgactttt gaggtggatc ccatggacga gcccaccctt ctttatgttt 22740  
 tgtttgaagt ttgtgacgtt gtccctgtgc accggccca cggcgccgtc atcgaaaccc 22800  
 tgcacccatc tccggggccaa acggccacaac ataaagaagc aagcaacatc 22860  
 aacaacatg gccgcattgg gtccttgcgtt gcaaggactt aaagccattt tcaaagatct 22920  
 tgggtgtggg ccatattttt tgggcaccta tgacaagcgc ttccctaggct ttgttttctcc 22980  
 acacaagctc gcctgcgcca tagtcaatac ggccggcgtc gagactgggg gctgtacactg 23040  
 gatggccctt gcctggaaacc cgcactaaa aacatgttac ctcttggatc cttttggctt 23100  
 ttctgaccag cgacttcaacg aggttaccaat gttttagatc gatgtactcc tgcggccgtag 23160  
 cgccattgtcttcc accgctgtat aacgctggaa aagttccaccc aaagcgtaca 23220  
 gggcccaac tggccggctt gtggactatt ctgctgcattt tttctccacg cttttggccaa 23280  
 ctggccccaat tcccttcatgg atcacaaccc caccatgaac ctttattaccg gggtaacccaa 23340  
 ctccatgctc aacagtcccc aggtacagcc caccctgcgtt cgcacccagg aacagctcta 23400  
 cagttccctg gagcgccactt cgccttactt ccgcacccatc agtgcgcaga ttaggagcgc 23460  
 cacttctttt tgcacttgc aaaacatgtt aaaaatgtt actagagaca ctttcaataa 23520  
 aggccaaatgc ttttattttt acactctcggtt gtgttattt acccccaccc ttggccgtctg 23580  
 cgccgtttaa aatcaaagg gtttgcggc cgcacgttgc tgcggccactg gcagggacac 23640  
 ttgcgatatac ttgtgttttag tgctccactt aaactcaggc acaaccatcc gccggcgtc 23700  
 ggttgaagttt tcactccaca ggctgcgcac catcaccacatc gctttagac ggtcggggc 23760  
 cgatatacttgg aagtgcgtt tggggccctt gcccctgcgtt cgcacgttgc gatcacacagg 23820  
 gttgcagcac tggaaacacta tcagcgccgg gtgggtcagc ctggccagca tcaactttgg 23880  
 ggagatcaga tcccgcttcca ggttccctccgc gttgtcagg gccaacggag accgttagtg 23940  
 tagtgcctt cccaaaaagg ggcgtgccc aggcttttagt ttgcactcgc accgttagtg 24000  
 catcaaaaagg tgaccgtgcc cggcttgggc gttaggatac aggcctgtca taaaaggctt 24060  
 gatctgttta aaagccaccc gggcccttgc gccttccagg aagaacatgc cgcaagactt 24120  
 gccggaaaaac tgattggccg gacaggccgc gtcgtgcacg cgcacccctt cgtcggtgtt 24180  
 ggagatctgc accacatttc ggcccccaccc gtttcttcaacg atcttggct tgcctagactg 24240  
 ctcccttccgc ggcgtgtcc cgttttgcgtt cgtcacatcc atttcaatca cgtgtctctt 24300  
 atttatatac atgctttccgt ttagacactt aagctcgctt tgcacatcg cgcacgggtt 24360  
 cagccacaac ggcgcaggcccg tgggtctgtt atgctttgttgc acgttgcacttgc 24420  
 caggtacgcc tgcaggaaatc gcccattcat cgtcacacaaat gtcgttgc tgggtgaaggt 24480  
 cagctgcaac cgcgggtgtt ctcgttgc caggttccgtt catacggccg ccagagcttc 24540  
 cacttggtca ggcgttagtt tgaaggatcg ctttagatcg ttatccacgt ggtacttgc 24600  
 catcaggccg cgcgcaggccctt ccatggccctt ctcccacgc gacacgatcg gcacactcag 24660  
 cgggttccatc accgttacattt cactttccgc ttcgttggc tcttcttccgtt 24720  
 ccgcatacca cgcgcactt ggtcgcttcc attcagccgc cgcactgtgc gtttaccccttcc 24780  
 tttggccatgc ttgatttagca cccgtgggtt gtcggaaaccc accatttgc ggcacccatc 24840  
 ttcttcttcttcc ttcgttgcgtt ccacgattac ctcttggatc ggcggccgtt cgggcttggg 24900  
 agaaggggcgc ttcttttttcc tcttggccgc aatggccaaa tccggccggc aggtcgatgg 24960  
 cccggggctg ggtgtgcgc gcaaccagcgc gtcttgcgtat gatgttccct cgttcctcgga 25020  
 ctcgatacgc cgcctcatcc gcttttttgg gggcgccccc gggaggccggc ggcacggggca 25080

cggggacgac acgtcctcca tggttgggg acgtcgccgc gcaccgcgtc cgcgctcg 25140  
 ggtgtttcg cgctgctct cttccgact ggcatttcc ttctctata ggcagaaaa 25200  
 gatcatggag tcagtcgaga agaaggacag ctaaccggc ccctctgagt tcgcccacc 25260  
 cgcctccacc gatgccgcca acgcgcctac cacccccc gtcgaggcac ccccgcttga 25320  
 ggaggaggaa gtgattatcg agcaggaccc aggtttgta agcgaagacg acgaggaccg 25380  
 ctcagtacca acagaggata aaaacaaga ccaggacaac gcagaggcaa acgaggaaca 25440  
 agtcggcgg ggggacgaaa ggcatggcga ctacctatgt gtgggagacg acgtgctgtt 25500  
 gaagcatctg cagcgcctgt ggcgcattat ctgcgacgcg ttgcaagagc gcagcgatgt 25560  
 gcccctcgcc atagccgatg tcagccttgc ctacgaacgc cacctattct caccgcgcgt 25620  
 accccccaaa cgccaagaaaa acggcacatg cgagcccaac cccgcctca acttctaccc 25680  
 cgtatggcc gtgcccagg tgctgcccac ctatcacatc tttttccaaa actgcaagat 25740  
 accccctatcc tgccgtgcca acccgagccg agcggacaag cagctggcct tgcggcagg 25800  
 cgctgtcata cctgatatacg cctcgctaa cgaagtgcga aaaaattttgggggtcttgg 25860  
 acgcgacgag aagcgcgcgg caaacgcgtct gcaacaggaa aacagcgaaa atgaaagtca 25920  
 ctctggagtg ttggtgaaac tcgagggtga caacgcgcgc ctatgggtac taaaacgcag 25980  
 catcgaggc accccacttg cctacccggc acttaaccta ccccccagg tcatgagcac 26040  
 agtcatgagt gagctgatcg tgccgcgtgc gcagccccgt gaggaggatg caaattttgc 26100  
 agaacaaca gaggaggggcc taccgcgt tggcgcacgg cagtagcgc gctggcttca 26160  
 aacgcgcgag cctgcgcact tggaggagcg acgcaaaacta atgatggccg cagtgctctg 26220  
 taccgtggag cttagtgcgca tgcacgcgtt ctttgcgtac cggagatgc agcgcaagct 26280  
 agaggaaaca ttgcactaca ccttcgaca gggctacgta cgccaggcct gcaagatctc 26340  
 caacgtggag ctctgcaacc tggtctccata ccttggaaatt ttgcacgaaa accgccttgg 26400  
 gcaaaacgtg cttcatttca cgctcaaggg cgaggcgcgc cgcactacg tccgcactg 26460  
 cgtttactta ttctatgtt acacccgtca gacggccatg ggcgttggc agcagtgttt 26520  
 ggaggagtg aacccatcaagg agtcgcagcg actgtaaaag caaaacttga aggacctatg 26580  
 gacggccttc aacgcgcgt ccgtggccgc gacacccatgg tccccgaacg 26640  
 cctgtttaaa accctgcac accgttctgcg agacttcacc agtcaaaagca ttttgcagaa 26700  
 ctttaggaac ttatccatgg agcgttcagg aatcttgcctt gccacccgtt gtcacttcc 26760  
 tagcgacttt gtgcccattt agtaccgcga ctagtgcacttccatggcata 26820  
 ccttctgcag ctggacttgc acgtcgctg atgcgttccatggcata 26880  
 tgacggctca ctggagtgatc acgtcgctg aatccatggcata 26940  
 ttgcaattcg cagtcgttta acgaaaagtca aattatcggt acctttggc tgcagggttcc 27000  
 ctcgcctgac gaaaagtccg cggtccggg gttgaaactc actccggggc ttttgcgttcc 27060  
 ggcttacattt cgcaaaattt tacctgagga ctaccacgcg cacgagatgc ggttctacga 27120  
 agaccaatcc cgcccgccaa atgcggagct taccgcgttccatggcata 27180  
 tcttggccaa ttgcaagcca tcaacaaaggc cccgccttccatggcata 27240  
 ggggtttac ttggacccccc agtccggcga ggagctcaac ccaatcccccc cgccgcgc 27300  
 gcccattatcg cagcgcgcgg gggcccttgc ttcccaggat ggcacccaaa aagaagctgc 27360  
 agctgcgcgc gccacccacg gacgaggagg aataactggc ttttgcgttccatggcata 27420  
 tggacgagga ggaggaggac atgatggaaatc actggggagag ctttagcgcg gaggaggat 27480  
 aggtcgaaga ggtgtcagac gaaacaccgt caccctcggt cgcattccccc tcgcggcgc 27540  
 cccagaaatc ggcacccgg tccacatgg ctacaaccc tcgttccctcg ggcgcgcgg 27600  
 cactgcccgt tcgcccggacc aaccgttagat gggacaccac ttggaaaccagg gccggtaagt 27660  
 ccaagcagcc gccgcgttta gccaagagc aacaacacgcg ccaaggctac cgctcatggc 27720  
 gggggcacaatc gaaacgcata gttcttgcgcatc caccctcggt cgcattccccc tcgcggcgc 27780  
 cccgcgcctt ttttctatcg catcacggcg ggacccatgg ttttgcgttccatggcata 27840  
 accgtcatct ctacagccca tactgcaccc gcccgcgcgg cagcggcgc aacagcgc 27900  
 gccacacaga agcaaaggcg accggatgc aagactctga caaacgcata gaaatccaca 27960  
 gggcggcggcag cagcaggagg aggagcgatc cgtctggcgc ccaacgcata cgtatcgacc 28020  
 cgcgagctt gaaacaggat ttttccact ctgtatgtca tatttcaaca gggcggcgc 28080  
 caagaacaag agctgaaaat aaaaaacagg tctctgcgtatccatggcata 28140  
 tatcacaatcg gcaagatca gtttgcgcgc acgctggaaatc acgcccggacc ttttgcgttccatggcata 28200  
 aaatactgcg cgctgactt taaggactatc ttttgcgttccatggcata 28260  
 aaaaatccatcg attttccacttccatggcata 28320

ttcacgcctc gtcaggcaat cctaactctg cagacacctg cctctgagcc ggcgtctgg 28860  
ggcattggaa ctctgcatt tattgaggag ttttgccat cggctactt taacccttc 28920  
tcgggaccc tcggccacta tccggatcaa ttattccct aacttgcacg ggtaaaggac 28980  
tcggcggacg gtcactgactg aatgttaagt ggagaggcag agcaactgcg cctgaaacac 29040  
ctggtcact gtcggccca gaattgcccc aggatcatat cgagggcccg ggcacggcg cggtgagtt ttgtacttt 29100  
gagttgccc gtagcctgat tcgggagtt acccagccg cctctgtat tgagcggac 29160  
aggggaccct gtgttctcac tggattgc aactgtccca accttgatt acatcaagat 29220  
ttaattaatt gccacatctt cttacaccc ttacatcatt gccaagaat aaagaatcgt 29280  
tttgtttag ttcacacgt tttatcccc aatttcagaa aatttcaagt cattttcat 29340  
tcagtagtat agccccacca ccacatagct tatacagatc accgtaccc aatcaaactc 29400  
acagaaccc agtattcaac ctgcacccctc cctcccaaca agcatcatat catggtaac cacagactt aatcaaactc 29460  
ctcccccgtt ggccttaaaa agcatcatat gtcacccatc cccatccaa cagagatcc acagactt 29520  
tattccacac ggttccctgt cgagccaaac gtcacccatc gatattataa aactccccc 29580  
gcagctact taagttcatg tcgtgtcca gtcgtgacg gatattataa aactccccc 29640  
gcccgttctt aacggggccgc gaaggagaag tccacgccta agacatgatt ctaggttta 29700  
cgtcatcg gataggccgg tggtgctgca gacgcgcgcg gatattataa aactccccc 29760  
gctccgtctt gcaaggaatac aacatggcag tggtctccctc cacaggctgc tgcacccatc 29820  
gcagcataag ggccttgc ctcggcac accacatccat ttttccatc aactccccc 29880  
cacagtaact gcaagcacagc accacaaat ttttccatc cccacagtgc aagcgtgt 30000  
atccaaactg catggggggg accacagaac ccacgtggcc atccatccatc aatcaaactc 30060  
agattaatg ggcacccctc ataaacacgc tggacataaa ctttccatc aactccccc 30120  
tgttaatccac caccccccgg taccatataa acctctgatt aaacatggcg ccatccacca 30180  
ccatctaaa ccagctggcc aaaacctgcc cgcggctatc gatcatatg ctcgtcatga 30240  
tggacaatg acagtggaga gcccagact cgtacccatc ctttccatc aactccccc 30300  
tatcaatgtt ggacacaacac aggacacacgt gacataactt ctcaggatt acaactctt 30360  
cccgcttagt aaccatatcc cagggaaacaa cccatccctg aatccatccac 30420  
tgcagggaaag acctgcacg taactacgt ttttccatc aactccccc 30480  
gcagccgtat atctccatg atggtagcgc gggtttctgt ctttccatc aactccccc 30540  
ccctactgta cgagtgccg cgagacaacc gagatctgt ttttccatc aactccccc 30600  
atggaaaccc ggacgtatgc atatttctg aagcaaaacc aggtggggc gtgacaaaca 30660  
gatctgcgtc tccggctctcg ccccttagat cgcctctgt ttttccatc aactccccc 30720  
tctctctaaa catccaggcg ccccttggc tggggctca ttttccatc aactccccc 30780  
gtgtccctgta taacatccac ccccgagaa taagccacac ccagccaaacc tacacattcg 30840  
ttctcgagtt cacacacggg aggagccgg agagctggaa gaaccatgtt ttttttttta 30900  
ttccaaaaga ttatccaaaa cctcaaaatg aagatctatt aagtgaacgc gctcccccctcc 30960  
gtggcgtgg tcaaactcta cagccaaaga acagataatg gcattttgtt gatgttgcac 31020  
aatgggttcc aaaaggcaaa cggccctc acgtttccac ttttccatc aactccccc 31080  
agggtgaatc tccttataaa acattccacg accttcaccc ttttccatc aactccccc 31140  
tcgcacccctt ctcataatata ctctacccaa atcccaaccc ttttccatc aactccccc 31200  
aatctgcctc agagccccc ccacccctc ctcacccaa atcccaaccc ttttccatc aactccccc 31260  
tcaggttctt cacagacctg tataagattc aaaagccggaa ctttccatc aactccccc 31320  
tccctgttgtt cccttcgcac ggccagctga acataatcgt gcaggctgc accggcaggc 31380  
ggggccactt ccccgccagg aaccttgaca aaagaacccca cactgatcc ttttccatc aactccccc 31440  
ctcgagacta tgctaccccg cgtagcccc atgtacgtt ttttccatc aactccccc 31500  
aaaatgcaag gtgtctctca aaaaatcagg ctttccatc aactccccc 31560  
gtgtatcgatc ttcgtccatg aaaggcaggta aagctcccg accaccacag aaaaagacac 31620  
cattttctc tcaaacatgt ctggggttt ctgtccatc aactccccc 31680  
aacattaaa cattagaagc ctgttccatc aacggaaaaaa caacccctt aagcataaga 31740  
cggaatcagg ccatggccggc gtgacccgtt aaaaatgggtt caccgtt aaaaagcacc 31800  
accgacagct ctcggctctc gtccggatcc ataatgttacg actcgatccaa cccatccatc aactccccc 31860  
tgattctcg ttcgtatcg aaaaaggccggaaatggccca accaccacag aaaaagacac 31920  
gcgttagagatc aaccatccatc cccctatagg aggtataaca aacggaaaaaa aatccaccc 31980  
cacataaaac ctcggccatc ctcctccctt aacggaaaaaa aatccaccc 32040  
aacatccatc gttccacccg ggcagccctaa ctttccatc aactccccc 32100  
tattaaaaaa acaccactcg acacggccacc agctccatc aactccccc 32160  
caagtgcaga gcgagatataat ataggactaa aaaaatgggtt aacggaaaaaa aatccaccc 32220  
aacaccccaaa aacccgcacg cgtacccatcg cccagaaaaac aacccacac 32280  
ttcctcaatg cgtcacttcc gttttccac gttacgttac ttttccatc aactccccc 32340  
caatcccaa ctcataacaaat ttactccgc cttttccatc aactccccc 32400  
cgcccccgcgca ctcgtcacaactccaccc ctttccatc aactccccc 32460  
aaggatattt attgtatgtt aatccaccc 32480

<210> 24  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 24  
ctcaacaatt gtggatccgt actcc

25

<210> 25  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 25  
gtgctcagca gatcttgcga ctgtg

25

<210> 26  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 26  
ggcgcgttcg gatccactct cttcc

25

<210> 27  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 27  
ctacatgcta ggcagatctc gttcggag

28

<210> 28  
<211> 1240  
<212> DNA  
<213> adenovirus

<400> 28  
ggatccactc tcttccgcatt cgctgtctgc gagggccagc tgttgggttg agtactccct 60  
ctgaaaagcg ggcattgactt ctgcgcataag attgtcagtt tccaaaaaagc aggaggattt 120  
gatattcacc tggcccgccg tgatgccttt gagggtggcc gcatccatct ggtcagaaaa 180  
gacaatcttt ttgttgtcaa gcttgggtggc aaacgacccg tagagggcgt tggacagcaa 240  
cttggcgatg gagcgcaggg tttggttttt gtcgcgatcg ggcgcgtcct tggccgcgt 300  
gttagctgc acgtattcgc ggcacacgca cgcattcg ggaaagacgg tggtgcgctc 360  
gtcgggcacc aggtgcacgc gccaaccgcg gttgtgcagg gtgacaaggt caacgctgg 420  
ggctacctct ccgcgttaggc gctcggtggt ccagcagagg cggccgcctt tgccgcgagca 480  
gaatggcggt agggggctca gtcgcgtctc gtccgggggg tctgcgtcca cggtaaaagac 540  
cccgccgacg cggcgcgcgt cgaagtagtc tatcttgcatt ctttgcattt ctagcgcctg 600

ctgccccatgcg cggggcgccaa ggcgcgcgctc gatatgggtt agtgggggac cccatggcat 660  
 ggggtgggtg agcgcggagg cgtacatgcc gcaaatgtcg taaacgtaga ggggctctct 720  
 gagtattcca agatatgtag ggtacatct tccaccgcgg atgctggcgc gcacgtaatc 780  
 gtatagttcg tgcgaggggag cgaggagggtc gggaccgagg ttgctacggg cgggctgctc 840  
 tgctcggaaag actatctgcc tgaagatggc atgtgagttt gatgatatgg ttggacgctg 900  
 gaagacgttg aagctgggtc ctgtgagacc taccgcgtca cgcacgaaagg aggcgttagga 960  
 gtcgcgcagg ttgtgacca gtcggcggt gacctgcacg tctaggcgcc agtagtccag 1020  
 ggttcccttg atgatgtcat acttatcttg tccctttttt ttccacagct cgcgggttag 1080  
 gacaaactct tcgcggctt tccagttactc ttggatcgga aaccgtcg cctccgaacg 1140  
 agatccgtac tccggcccg agggacctga gcgagtccgc atcgaccgga tcggaaaacc 1200  
 ttcgcagaaa ggcgtctaacc cagtcacagt cgcaagatct 1240

&lt;210&gt; 29

&lt;211&gt; 8383

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>  
<223> Description of Artificial Sequence: plasmid pDV60

&lt;400&gt; 29

gacggatcg gagatctccc gatcccstat ggtcgactct cagataatc tgctctgatg 60  
 cccgcatagtt aagccagtt ctgtccctg cttgtgttt ggaggtcgat gaggatgtcg 120  
 cgacaaaat ttaagctaca acaaggcaag gttgaccga caattgcatt aagaatctgc 180  
 ttagggtagt gcttttgcg ctgcattcgat atgtacgggc cagatataacg cgttgacatt 240  
 gattattgac tagttattaa tagtaatcaa ttacgggtc attagttcat agcccatata 300  
 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc 360  
 ccccccatt gacgtcaata atgacgtatg ttccatatagt aacgccaata gggactttcc 420  
 attagacgtca atgggtggac tattacggt aaactgcca cttggcgtat catcaagtgt 480  
 atcatatgcc aagtacggcc cttattgtacg tcaatgacgg taaatggccc gcctggcatt 540  
 atgcccagta catgaccta tgggactttc ctacttggca gtacatctac gtattagtca 600  
 tcgttattac catggtgatg cggtttggc agtacatcaa tgggctgtgg tagcggtttg 660  
 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggattttgg ttttggcacc 720  
 aaaatcaacg ggacatccca aaatgtcgta acaactccgc cccattgtacg caaatggccg 780  
 gttaggcgtgt acgggtggag gtctatataa cggagactct ctgttgcatt agagaaccca 840  
 ctgttactg gtttatcgaa attataacga ctcaactatag ggagacccaa gcttggtacc 900  
 gagctcggat ccactctttt ccgcacatcgat gtctgcgagg gcaagctgtt ggggtgagta 960  
 ctccctctga aaagcggcga tgacttctgc gctaagatgg tcagttccca aaaacgagga 1020  
 ggatttgata ttcaccttgc cccgggtgat gccttgggg gtggccgcat ccattctggc 1080  
 agaaaagaca atcttttgg tgcacgtt ggtggcaac gacccgtataa gggcgttggg 1140  
 cagaacttgc gcgatggcgc gcaagggttgg tttttgtcg cgatcgccgc gtccttggc 1200  
 cgcgatgtt agctgcacgt attcgccgcg aacgcacccgc cattcggaa agacgggtgt 1260  
 ggcgcgtcg ggcaccaagg gcacgcgcac acggcggttg tgcagggtga caaggtcaac 1320  
 gctgggtggct acctctccgc gttaggcgttc gttggccaaag cagagccgc cggcccttgcg 1380  
 cgacgagaat ggcggtaggg ggttagtgcg tgcgtcgcc ggggggtctg cgtccacgggt 1440  
 aaagaccccg ggcacggcgc ggcgtcgaa gtatgtatc ttgcattccctt gcaagtctag 1500  
 cgccctgtgc catgcgggg cggcaagcgcc ggcgtcgat ggggtgagtg ggggacccca 1560  
 tggcatgggg tgggtgacgc cggaggcgta catgcccggaa atgtcgtaaa ctagaggggg 1620  
 ctctctgagt attccaagat atgtaggta gcatcttccca cccggatgc tggcggcgcac 1680  
 gtaatcgat agttcggtcg aggaggcgg gagggtcgccgga cccggatgtc taccggccgg 1740  
 ctgctctgtc cggaaagacta tctgcgttca gatggcatgt gaggatgtt atatgggtgg 1800  
 acgctggaaag acgttgcggc tgggtctgtt gacatcttccca ggcgtacgc gcaaggaggc 1860  
 gtaggatgtc cgcacgttgc tgaccagtc ggcgggtgacc tgacgtctt gggcgcgtat 1920  
 gttcagggtt tccttgcgtt gtcataactt atccctgtccc tttttttcc acagctcgcc 1980  
 gttgaggaca aactcttcgc ggtctttcca gtactcttgg atcgaaaacc cgtcggccctc 2040  
 cgaacgagat ccgtacttgc cccggaggac accttgcggc gtcggcatcg accggatcg 2100  
 aaaacctctc gagaaggcg tctaaaccatg cacatcgca agatcgca tgaagcgcc 2160  
 aagaccgtct gaagatccct tcaacccctgt gatccatata gacacggaaa cccgtccccc 2220  
 aactgtgcct ttttttactc ctccctttgtt atcccccaat gggttcaag agatcccccc 2280  
 tggggtactc tctttgcgc tatccgaacc tctagttacc tccaaatggca tgcttgcgt 2340  
 caaaaatggcc aacggccctt ctctggacga ggccggcaac cttacctccc aaaatgtaac 2400  
 cactgtgagc ccacctctca aaaaaacca gtcacacata aacctggaaa tatctgcacc 2460

cctcacagtt acctcagaag ccctaactgt ggctgcggcc gcacactcaa tggtgcggg 2520  
caacacaccc accatgcaat cacaggcccc gctaaccgtg cactgactcca aacttagcat 2580  
tgccacccaa ggaccctca cagtgtcaga agggaaagcta gcccgtcaaa catcaggccc 2640  
cctcaccacc accgatagca gtacccttac tatcaactgcc tcacccctc taactactgc 2700  
cactggtagc ttggcattt acttggaaaga gcccattat acacaaaatg gaaaactagg 2760  
actaaagtagc gggctcctt tgcgtatcatac agagacacca aacacttgcg cctgtagcaac 2820  
tggtccaggt gtgacttataa ataaatactt cttgaaactt aaggttactg gggcttggg 2880  
ttttgattca caaggcataa tgcaacttac tgtagcagga ggactaagga ttgattctca 2940  
aaacagacgc ctatacttgc atgttagtta tccgtttgat gctcaaaacc aactaaatct 3000  
aagacttagga cagggccctc tttttataaa ctcagccac aacttggata ttaacactaaa 3060  
caaaggcctt tacttgtta cactgcaag ggggtatgt cagcttcaaa caattccaaa aagcttgggg ttaacactaa 3120  
tgaattttgt tccactatac cacaacacca aaatccctc ctttggggat aagatgggg 3180  
cctagaattt gattcaaaaca cggcattttttttt ctttggggat aacacttgcg attaatgcag ttggccatgg 3240  
cagcacagg tccattttttt ctttggggat aacacttgcg attataatgggg 3300  
accagcttca tcttcttactt ctttggggat aacacttgcg attataatgggg 3360  
cttaacaaaaa tttttttttt ctttggggat aacacttgcg attataatgggg 3420  
tttggcttca atatctggaa tttttttttt ctttggggat aacacttgcg attataatgggg 3480  
tggagtgtca cttttttttt ctttggggat aacacttgcg attataatgggg 3540  
tcttactgaa ggcacagctt ctttggggat aacacttgcg attataatgggg 3600  
tccaaaatct ctttggggat aacacttgcg attataatgggg 3660  
agacaaaaact aaacctgtaa ctttggggat aacacttgcg attataatgggg 3720  
cacaacttca agtgcataact tttttttttt ctttggggat aacacttgcg attataatgggg 3780  
taatgaaata tttttttttt ctttggggat aacacttgcg attataatgggg 3840  
ggggccgctc gggccatgtc tttttttttt ctttggggat aacacttgcg attataatgggg 3900  
ctcgctgatc agccatgtc tttttttttt ctttggggat aacacttgcg attataatgggg 3960  
ccgtgccttc ctttggggat aacacttgcg attataatgggg 4020  
aaattgcatac gttttttttt ctttggggat aacacttgcg attataatgggg 4080  
acagcaaggg ggaggattgg tttttttttt ctttggggat aacacttgcg attataatgggg 4140  
tggcttctga gggccggaaaaa tttttttttt ctttggggat aacacttgcg attataatgggg 4200  
ggggccgatt aagcgccggc tttttttttt ctttggggat aacacttgcg attataatgggg 4260  
gccccttagc gcccgtctt tttttttttt ctttggggat aacacttgcg attataatgggg 4320  
ttccccgtca agtcttaaat tttttttttt ctttggggat aacacttgcg attataatgggg 4380  
acctcgaccc caaaaaactt tttttttttt ctttggggat aacacttgcg attataatgggg 4440  
agacggtttt tcgcctttt tttttttttt ctttggggat aacacttgcg attataatgggg 4500  
aaactggaaac aacactcaat tttttttttt ctttggggat aacacttgcg attataatgggg 4560  
ggatttcggc ctatgggtt tttttttttt ctttggggat aacacttgcg attataatgggg 4620  
tctgtgaaat gtgtgtcgt tttttttttt ctttggggat aacacttgcg attataatgggg 4680  
gtatgcaaaag catgcatttc tttttttttt ctttggggat aacacttgcg attataatgggg 4740  
cagcaggcag aagtatgcaat tttttttttt ctttggggat aacacttgcg attataatgggg 4800  
taactccccc catcccgccc tttttttttt ctttggggat aacacttgcg attataatgggg 4860  
gactaattt tttttttttt ctttggggat aacacttgcg attataatgggg 4920  
agtagtgagg aggtttttt tttttttttt ctttggggat aacacttgcg attataatgggg 4980  
tatccatttt cgatctgtat tttttttttt ctttggggat aacacttgcg attataatgggg 5040  
atggatttgc cgcagggttct tttttttttt ctttggggat aacacttgcg attataatgggg 5100  
cacaacagac aatcggtctc tttttttttt ctttggggat aacacttgcg attataatgggg 5160  
cggttctttt tgtaagacc tttttttttt ctttggggat aacacttgcg attataatgggg 5220  
cgccgtatctt gttttttttt ctttggggat aacacttgcg attataatgggg 5280  
ctgaagcggg aaggacttgg tttttttttt ctttggggat aacacttgcg attataatgggg 5340  
ctcaccctgc tccctggccag tttttttttt ctttggggat aacacttgcg attataatgggg 5400  
cgcttgcattc ggctacctgc tttttttttt ctttggggat aacacttgcg attataatgggg 5460  
gtactcggat ggaagccggg tttttttttt ctttggggat aacacttgcg attataatgggg 5520  
tcgcggcagc cgaactgttc tttttttttt ctttggggat aacacttgcg attataatgggg 5580  
tcgtgaccca tggcgatgc tttttttttt ctttggggat aacacttgcg attataatgggg 5640  
gattcatgca ctgtggccgg tttttttttt ctttggggat aacacttgcg attataatgggg 5700  
cccggtatat tgcgtaaagag tttttttttt ctttggggat aacacttgcg attataatgggg 5760  
gtatcgccgc tcccgatttc tttttttttt ctttggggat aacacttgcg attataatgggg 5820  
gagcgggact ctggggttcg aatgtggccga tttttttttt ctttggggat aacacttgcg attataatgggg 5880  
tttcgattcc accggccgcctt tttttttttt ctttggggat aacacttgcg attataatgggg 5940  
cgcttggatg atcccttcagg tttttttttt ctttggggat aacacttgcg attataatgggg 6000  
gttatttgc gcttataatg tttttttttt ctttggggat aacacttgcg attataatgggg 6060  
aqtatttttt tcaactgcatt tttttttttt ctttggggat aacacttgcg attataatgggg 6120  
aqtatttttt tcaactgcatt tttttttttt ctttggggat aacacttgcg attataatgggg 6180

tgtctgtata ccgtcgaccc ctagctagag cttggcgtaa tcatggtcat agctgtttcc 6240  
 tgtgttaaat tggttatccgc tcacaattcc acacaacata cgagccggaa gcataaaagt 6300  
 taaagcctgg ggtgcctaatt gaggtagcta actcacatta attgcgttgc gtcactgccc 6360  
 cgcttccag tcgggaaacc tgctgtccca gctgcattaa tgaatcggcc aacgcgcggg 6420  
 gagaggcggt ttgcgtatgg ggcgcetttc cgcttcctcg ctcactgact cgctgcgc 6480  
 ggtcggttcgg ctgcggcgag cggatcgcg tcaactcaaaag gggtaataac gtttatccac 6540  
 agaatcaggg gataacgcg gaaagacat gtgagcaaaa ggccagcaaa aggcccaggaa 6600  
 ccgtaaaaag ggcgcgttgc tggcggtttt ccataggctc cgccccctg acgagcatca 6660  
 caaaaatcgaa cgctcaagtc agagggtggcg aaacccgaca ggactataaa gataccaggc 6720  
 gttttccctt ggaagctccc tcgtgcgtc tcctgttccg accctgcgc ttacccgata 6780  
 cctgtccgc tttctccctt cgggaagcgt ggcgccttct caatgtcact gctgttaggt 6840  
 tctcagttcg gtgttagtgc ttcgtccaa gctgggctgt gtgcacgaa ccccccgttca 6900  
 gcccacccgc tgccgccttcc cggtaacta tcgttgcgttgc tccaaacccgg taagacacga 6960  
 cttatcgccca ctggcagcag ccactgtttaa caggattagc agagcgaggat atgttaggcgg 7020  
 tgctacagag ttctttaaagg ggtggcttaa ctacggctac actagaagga cagtattttgg 7080  
 tatctgcgtc ctgctgaagc cagttaccc cggaaaaaaga gttggtagct cttgatccgg 7140  
 caaacaacc accgcgttgc gccgggggtt tttgtttgc aaggacgaga ttacgcgc 7200  
 aaaaaaaagga tctcaagaag atccctttgtat cttttctacg gggttgtacg ctcagtggaa 7260  
 cgaaaactca cgttaaggaa ttttggctatc gaggattataa aaaaaggatct tcaccttagat 7320  
 ccttttaaat taaaatggaa gtttttaatc aatctaaatg atatatgagt aaacttggc 7380  
 tgacagttac caatgtctaa tcagtggagc acctatctca gogatctgtc tatttcgttc 7440  
 atccatagtt gcctgactcc cggcgtgtt gataactacg atacggggagg gtttaccatc 7500  
 tggcccccagt gctgcaatga taccgcgaga cccacgcgtca cccggcgtccag atttatcagc 7560  
 aataaaccag ccagccggaa gggccggagcg cagaagtgtt cctgcaactt tattccgcctc 7620  
 catccagtct attaattttt ggcggaaagc tagagtaatg agttcgccag ttaatagtt 7680  
 ggcgaacggtt gttggccattt ctacaggcat cgtgggtgtca cgctcgtcgt ttgggtatggc 7740  
 ttcattcagc tccgggtttcc aacgatcaag gcgagttaca tgatccccca ttgggtgtgca 7800  
 aaaagcgggtt agtccttcg gtcctccgtat cgttgcaga agtaatgtgg ccgcagtgtt 7860  
 atcaactcatg gttatggcag cactgcataa ttcttcttact gtcatggccat cgttaagatg 7920  
 cttttctgtg actgggtgagt actcaaccaa gtcattctga gaatagtgtt tgccggcacc 7980  
 gaggtgtctt tgccggcggtt caatacgga taataccgcg ccacatagca gaactttaaa 8040  
 agtgcctatc atggaaaac gtttttcggg gcgaaaaactc tcaaggatct taccgctgtt 8100  
 gagatccagt tcgatgttaac ccactcgtgc acccaactga tcttcagcat cttttacttt 8160  
 caccagcgtt tctgggttag caaaaacagg aaggcaaat gccgaaaaaa aggaataag 8220  
 ggcgacacacgg aaatgttggaa tactcatact cttccctttt caatattttt gaagcattta 8280  
 tcagggttat tgcgtcatga gcgatatacat atttgaatgtt atttagaaaaa ataaacaaat 8340  
 aggggttccg cgcacatttc cccggaaatg gccacactgac gtc 8383

&lt;210&gt; 30

&lt;211&gt; 7960

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>  
<223> Description of Artificial Sequence: plasmid pDV67

<400> 30  
 gacggatcg gtagatccccc gatccccat ggtcgactct cagtagataatc tgctctgtat 60  
 ccgcataatg aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gtagtagtgc 120  
 cgagcaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180  
 tttagggtagt gctgtttcgat ctgcttcgcg atgtacgggc cagatataacg ctttgacatt 240  
 gattattgtac tagttatcaa tagtaatcaa ttacggggtc attgttcatc agcccatata 300  
 tggagttccg cgttacataa ctacggtaa atggccccc tggctgaccg cccaaacgacc 360  
 cccggccattt gacgtcaata atgacgtatg ttcccatatg aacgccaata gggactttcc 420  
 attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480  
 atcatatgc aagtacgccc cttattgacg tcaatgacgg taaatggccc gcctggcatt 540  
 atgccccatgtt catgacccat tggactttc ctacttggca gtagatctac gtatttagtca 600  
 tgcgtattac catgggtatg cgggtttggc agtacatcaa tggcggttga tagcggttt 660  
 actcacgggg atttccaaatg tttccacccca ttgacgtcaa tggagtttgc ttttggcacc 720  
 aaaaatcaacg ggacttccaa aatgtcgta acaactccgc cccattgacg caaatggcg 780  
 gtaggcggtt acgggtggag gtcataatcaa gcagagctct ctggctact agagaaccca 840  
 ctgcattactg gcttattcgaa attaatacga ctcactatag ggagacccaa gctggctacg 900

gtttaaactt aagcttggta ccgagctcg atccactctc ttccgatcg ctgtctgcga 960  
ggccagctg ttgggttag tactccctct gaaaagcggg catgacttgc ggcctaagat 1020  
tgtcaatttc caaaaacgag gaggatttg tattcacctg gcccgggtg atgcctttga 1080  
gggtggccgc atccatctgg tcagaaaaga caatctttt gttgtcaagc ttgttggca 1140  
acgacccgta gaggggcggt gacagaaact tggcgatgg ggcgagggtt tggttttgt 1200  
cgcgatcgcc ggcgtccctg gccgcgtatgt ttagctgcac gtattcgcgc gcaacgcacc 1260  
gccatccggg aaagacgggt gtgcgtcggt cgggcaccaag gtgcacgcgc caaccgcgg 1320  
tgtcagggt gacaagggtca acgctgggtt ctacctctcc gcttaggcgc tgcgttggc 1380  
agcagaggcg gccgcgcctg cgcgagcaga atggcggtat ggggtttagc tgcgttctcg 1440  
ccggggggtc tgcgtccacg gtaaaagaccc cgggcacca ggcgcgtcg aagttagtcta 1500  
tcttgcattt ttgcgttca acgctgtgtt gccatcgccg ggcggcaagc ggcgcgtcg 1560  
atgggtttag tggggggaccc catggcatgg ggtgggttag cgccggaggcg tacatgcgc 1620  
aaatgtcgta aacgttagagg ggctctctga tattccaag atatgttaggg tagcatcttc 1680  
caccgcggat gctggcgcc acgttaatctg atagttcggtt cgaggggagcg aggagggtcg 1740  
gaccgagggtt gtcacggcg ggtctgtcg ctccggaaatgcttgcgttatggcat 1800  
gtgagtttggta tgatatgtttt ggacgtcgaa acgctgttaga gtcgggtctt gtgagaccta 1860  
ccgcgtcaccg cacgaaggag gctgttaggtt cgcgcgttgcgtt gttgaccagc tcggcggtga 1920  
cctgcacgtc tagggcgccg tagttccagggtt tttcccttgcgtt gatgtcataat ttatcctgtc 1980  
cctttttttt ccacagctcg cgggttggat cttccggaaatgcttgcgttatggcat 2040  
ggatcgaaaa cccgtcgcc tccgaacggat atccgtactt cgcgcgttgcgtt ggcacccgtt 2100  
gagtcgcgttccat cgaccggatc gggaaacccctc tggagaaagg ctgttccatggat gtcacagtcg 2160  
caagatccaa gatgaaggcg gcaagaccgtt ctgttccatggat ttcctccctt gtttatccat 2220  
atgacacgcg aaccgggtctt ccaactgtgc ttccatggat ttcctccctt gtttatccat 2280  
atgggttca agagatgttttccctgggttgcgttccatggat ttcctccctt gtttatccat 2340  
cctccatggat catgttgcgttccatggat ttcctccatggat ttcctccatggat gaggccggca 2400  
accttacccctt cccaaatgttccatggat ttcctccatggat ttcctccatggat aagtccaaaca 2460  
taaacctggat aatatctgtccatggat ttcctccatggat ttcctccatggat agccctaactt gtcggcgcc 2520  
ccgcacccctt aatgggtcgcc ggcacacacat ttcctccatggat ttcctccatggat cccgttccatggat 2580  
tgcacgactt cccaaatgttccatggat ttcctccatggat ttcctccatggat ttcctccatggat 2640  
tagccctgtccatggat aacatcgatccatggat ttcctccatggat ttcctccatggat ttcctccatggat 2700  
cctcaatccccccatggat ttcctccatggat ttcctccatggat ttcctccatggat ttcctccatggat 2760  
atacacaatggat tggaaaactatggat ttcctccatggat ttcctccatggat ttcctccatggat 2820  
taaacacttttccatggat tggcgatgtccatggat ttcctccatggat ttcctccatggat ttcctccatggat 2880  
ctaaagtttccatggat tggcgatgtccatggat ttcctccatggat ttcctccatggat ttcctccatggat 2940  
gaggactaacttccatggat tggcgatgtccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3000  
atgtcaatggat cccaaatgttccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3060  
acaacttggat tattaaacttccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3120  
aaaagcttgcgttccatggat tggcgatgtccatggat ttcctccatggat ttcctccatggat 3180  
ccattaatgtccatggat tggcgatgtccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3240  
tcaaaaatggat aattggccat tggcgatgtccatggat ttcctccatggat ttcctccatggat 3300  
taggaacttggat ctttagtttccatggat tggcgatgtccatggat ttcctccatggat ttcctccatggat 3360  
ataagcttgcgttccatggat tttgtggacc ttcctccatggat ttcctccatggat ttcctccatggat 3420  
aagatgttccatggat ttcctccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3480  
cagttttggat tggcgatgtccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3540  
ttattataatggat atttgccat tggcgatgtccatggat ttcctccatggat ttcctccatggat 3600  
attggacttggat tagaaatggat ttcctccatggat ttcctccatggat ttcctccatggat 3660  
ttatgccttccatggat ctttagtttccatggat tggcgatgtccatggat ttcctccatggat 3720  
tcagtcaatggat ttactttaatggat ttcctccatggat ttcctccatggat ttcctccatggat 3780  
acggtacacaatggat gggaaacagga gacacaacttccatggat ttcctccatggat ttcctccatggat 3840  
actggcttccatggat ccacaacttccatggat ttcctccatggat ttcctccatggat ttcctccatggat 3900  
acattggccatggat agaataaaatggat aaggccggccg ttcctccatggat ttcctccatggat 3960  
gatcggccatggat gactgtggcc ttcctccatggat ttcctccatggat ttcctccatggat 4020  
cttccttgcgttccatggat cttccggat ttcctccatggat ttcctccatggat ttcctccatggat 4080  
catcgatccatggat ttcctccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4140  
agggggggatggat ttggcgatgtccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4200  
ctgaggccatggat aagaaccacgttccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4260  
cattaagccatggat ggggggttccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4320  
tagcgccccatggat tccctccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4380  
gtcaagcttccatggat aaatcgccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4440  
acccaaaaatggat acttgatttag ggtgtatggat ttcctccatggat ttcctccatggat ttcctccatggat 4500  
tttttcgccccatggat ttgtacgttccatggat gaggccacgttccatggat ttcctccatggat ttcctccatggat 4560  
gaacaacacttccatggat ttcctccatggat ttcctccatggat ttcctccatggat ttcctccatggat 4620

cggccttattt	gttaaaaaat	gagctgattt	aacaaaaatt	taacgcgaat	taattctgtg	4680
gaatgtgt	caggtaggt	gtggaaaatgc	cccaaggctcc	ccaggcaggc	agaagtatgc	4740
aaagcatgc	tctcaattag	tcaaaaaacca	gggtggaaa	gtccccaggc	tccccagcag	4800
cgcaagat	gcaaggcatg	catctcaatt	agtcaagcaac	catagtcgg	ccccctaactc	4860
cgccccatccc	gcccctaact	ccgcccagtt	ccgccccattc	tccggcccat	ggctgactaa	4920
ttttttttat	ttatgcagag	cccgaggccg	cctctgcctc	tgagctattc	cagaagtagt	4980
gaggaggott	tttggaggc	ctaggctt	gcaaaaaggt	cccccggagct	tgtatatcca	5040
ttttcggatc	tgatcagcac	gtgtgacaa	ttaatcatcg	gcatagtata	tcggcatagt	5100
ataatacgcac	aaggtaggaa	actaaaccat	ggccaagttt	accagtggcg	ttccggtgct	5160
caccgcgcgc	gacgtcgccg	gagcggcgtga	gttctggacc	gaccggctcg	ggttctcccg	5220
ggacttcgtg	gaggacgact	tcgcccgtgt	ggtccgggac	gacgtgaccc	tgttcatcag	5280
cgcggtccag	gaccagggtgg	tgccggacaa	caccctggcc	tgggggttggg	tgccggccgt	5340
ggacgagctg	tacgcccagt	ggtcggaggt	cgttccacg	aacttccggg	acgcctccgg	5400
gcccggccatg	accaggatcg	gcgacggcc	gtggggcccg	gagttcgccc	tgcgcgaccc	5460
ggccggcaac	tcggcgtact	tcgtggccga	ggagcaggac	tgacacgtgc	tacgagattt	5520
cgattccacc	ggcccttct	atgaaaaggtt	gggttcggga	atcgtttcc	gggacgcccgg	5580
ctggatgatc	ctccagcgcg	gggatctcat	gctggagttc	ttcgcacc	ccaacttgt	5640
tattgcagct	tataatggtt	acaaaaaataag	caatagcatc	acaatttca	caataaaagc	5700
attttttca	ctgcattcta	gttgggttt	gtccaaactc	atcaatgtat	tttatcatgt	5760
ctgtatcaccc	tcgacctcta	gctagagctt	ggcgtaatca	ttggcatagc	tggttctgt	5820
gtgaaaattgt	tatccgctca	caattccaca	caacatacga	gcccgaagca	taaagtgtaa	5880
agcctgggt	gcctaattgag	tgagctaaat	cacattaatt	gcgttgcgt	cactgcccgc	5940
tttccagtcg	ggaaacctgt	cgtgcccagt	gcattaatga	atcgcccaac	gcccggggag	6000
aggcggtttg	cgatttggc	gctcttccgc	ttctctgcgt	actgactcgc	tgccgtcggt	6060
cggtcgctg	cgccgagccg	tatcagctca	ctcaaaggcg	gtaatacgg	tatccacaga	6120
atcaggggat	aacccggaa	agaacatgtg	agaaaaaggc	cagaaaaagg	ccaggaacccg	6180
taaaaaaggcc	gctttgtctgg	cgttttcca	taggctccgc	ccccctgacg	agcatcacaa	6240
aaatcgacgc	tcaagtcaaa	ggtggcgaaa	cccgacaggaa	ctataaaagat	accaggcggt	6300
tcccccttgg	agetcctctcg	tgcgctctcc	tgttccgacc	ctggccgtt	ccggatatac	6360
gtccgcctt	ctcccttccgg	gaagcgtggc	gctttctcaa	tgctcacgt	ftaggtatct	6420
cagttccgtt	taggtcgttc	gctccaagct	gggtgtgtg	cacgaacccc	ccgttcagcc	6480
cgaccgcgtc	gctttatccg	gtaactatcg	tcttgcgttcc	aacccgttaa	gacacgactt	6540
atcgccactg	gcagcagccaa	ctggtaacag	gattagcaga	gcgaggatgt	tagccgggtc	6600
tacagagttc	ttgaagtgg	ggcctaacta	cggctactact	agaaggacag	tatttggat	6660
ctgcgtctg	ctgaagccag	ttaccccttgg	aaaaaggtt	ggtagctat	gatccggcaa	6720
acaaaacc	gctggtagcg	gtggttttt	tgttgcggaa	cagcagatta	cgccgcagaaa	6780
aaaaggatct	caagaagatc	cttgcatttt	tttacccgggg	tctgcacgtc	agtggAACGA	6840
aaatcactgt	taaggattt	tggtcatgag	attatcaaaa	aggatctca	cctagatct	6900
tttaaattaa	aaatgaagtt	ttaaattcaat	ctaaaggata	tatgagtaaa	cttgcgtctc	6960
cagttaccaa	tgcttaatca	gtgaggcacc	tatctcagcg	atctgtctat	ttcgttcatc	7020
catagttgc	tgactcccccg	tcgtgtatag	aactacgata	cgggggggt	taccatctgg	7080
ccccactgtct	gcaatgatac	cgcgagaccc	acgctcaccg	gctccagatt	tatcagcaat	7140
aaacggccaa	gccccggagg	ccgacggccag	aagtggctt	gcaactttat	ccgcctccat	7200
ccagttattt	aattttttgc	gggaagctag	agtaagtagt	tcgcccgtt	atagtttgcg	7260
caacgttgtt	gcccattgtca	caggcatcg	gggtgtcacgc	tcgtcggtt	gtatggcttc	7320
attcagctcc	ggttcccaac	gatcaaggcg	agttacatcg	tcccccattgt	tgtgcaaaaa	7380
agcgtttagc	tccttcgggt	ctcccgatgt	tgtcagaatgt	aagtggccg	cagtgttato	7440
actcatgtt	atggcagcac	tgcataattc	tcttactgtc	atgcctatcc	taagatgtct	7500
ttctgtact	gggtgagact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	7560
ttgcttgc	ccggcgctcaa	tacgggataa	taccggccca	catagcagaa	ctttaaaaatgt	7620
gctcatcatt	ggaaaacgtt	cttcggggcg	aaaactctca	aggatcttc	cgtgttgag	7680
atccagttcg	atgttaaccct	ctcggtcc	caactgtatc	tcagcatctt	ttatcttcac	7740
cagcgtttct	gggtgagcaa	aaacaggaag	ggaaaatgtcc	gcaaaaaagg	gaataaggc	7800
gacccggaaa	tgttgcataat	tcataacttt	cctttttca	tattattgaa	gcatttatca	7860
gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	7920
ggttcccgcc	acatttcccc	ggaaaatgtcc	acctgacgtc	gggttcccgcc	gggttcccgcc	7960

<210> 31

<211> 30

<212> DNA

<213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer  
 <400> 31  
 atgggatcca agatgaagcg cgcaagaccg 30  
 <210> 32  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer  
 <400> 32  
 cactatagcg gccgcattct cagtcattctt 30  
 <210> 33  
 <211> 7989  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: plasmid pDV69  
 <400> 33  
 gacggatcg ggatctccc gatcccattt ggtcgactct cagtcacaatc tgctctgtat 60  
 cccatagtt aagccagtt ctgcctccctg ctgtgtgtt ggaggatcgct gaggatgtcg 120  
 cgagcaaaat ttaactaca acaaggcag gttgaccga caattgcatt aagaatctgc 180  
 ttagggtagt gcttttgcg ctgttcgcg atgtacgggc cagatatacg cgttgacatt 240  
 gattattgac tagttatcaa tagtaatcaa ttacgggttc attagttcat agcccatata 300  
 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc 360  
 ccccccatt gacgtcaata atgacgtatg tttccatagt aacgccaata gggactttcc 420  
 attgacgtca atgggtggac tatttacggt aaatgccca cttggcagta catcaagtgt 480  
 atcatatgcc aagtacggcc cctattgcg tcaatgcagg taaatggccc gcctggcatt 540  
 atgcccaga catgaccctt tggactttc ctacttggca gtacatctac gtattagtca 600  
 tcgttattac catggatgtt cgggtttggc agtacatcaa tggcgtgga tagcggttg 660  
 actcacgggg atttccaatg ctccacccca ttgacgtcaa tgggagtttgc ttttggcacc 720  
 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgcg caaatggcgc 780  
 gtaggggtgt acgggtggag gtcttataaa gtagacttgcgcttgcgatggatggatgg 840  
 ctgttactt gcttatcgaa attaatacg atccacttgc ttccgcattcg ctgtctgcg 900  
 gtttaactt aagcttgcg ccgagctcg gaaaageggg catgacttgc ggcctaagat 960  
 gggccagctg ttggggtag tactccctct tattcacctg gcccggcgtg atgcctttga 1020  
 tgcgttcc caaaaacgag gaggatttga caatctttt gttgtcaagc ttgggtggcaa 1080  
 ggggtggccgc atccatctgg tcagaaaaga ttagcttgcgatggatggatggatgg 1140  
 acgaccgcgtg gggggcggtt gacgacact tggcgtatggatggatggatggatgg 1200  
 cggcgtccgc ggcgttccgt gccgcgtatgtt tagctgcac ttagtgcgcg gcaacgcacc 1260  
 gccattccggg aagacgggtt gtgcgtctgttggggccatggatggatggatggatgg 1320  
 tgcgttccgc gacaagggtca acgttgcgttgg ctacctctcc gcttgcgttgcg tgcgttccgc 1380  
 agcagaggcg gccgccttgc cgcgagcaga atggcggtatggatggatggatggatgg 1440  
 cgggggggtc tgcgttccacg gtaaagaccc cggggcggccgcgatggatggatggatgg 1500  
 tcttgcattcc ttgcgtatgtt acgcgttgc gccatgcgcg ggcggcaagc ggcgcgttgcg 1560  
 atgggtttagt tggggggaccatggatggatggatggatggatggatggatggatggatgg 1620  
 aatatgtcgta aacgttagagg ggctctctgtatggatggatggatggatggatggatgg 1680  
 caccgcggat gctggcgccgc acgttaatcgat atagttcgatggatggatggatggatgg 1740  
 gaccgagggtt gctacggcg ggcgttgcgttgcgatggatggatggatggatggatggatgg 1800  
 gtgaggttggat tggatgttgcgatggatggatggatggatggatggatggatggatggatgg 1860  
 cccgcgttccgc caccgttgcgatggatggatggatggatggatggatggatggatggatgg 1920  
 cctgcacgttgc tagggcgccatggatggatggatggatggatggatggatggatggatggatgg 1980  
 cttttttttt ccacagctcg cgggttggatggatggatggatggatggatggatggatggatgg 2040  
 ggtatggaaa cccgttccgc tccgaacggat atccgttactc cggccggccatggatggatggatgg 2100  
 gatccgcat cggccggatc ggaaaacctc tgcgatggatggatggatggatggatggatggatgg 2160

caagatccaa gatgaagcgc gcaagacgt ctgaagatac cttcaacccc gtgtatccat 2220  
 atgacacgga aaccggctt ccaactgtc ctttcttac tcctccctt gtatccccca 2280  
 atgggttca agagactcc cttgggtac tctcttgcg cctatccgaa cctctagtt 2340  
 cctccaatgg catgttgcg ctcaaaatgg gcaacggcct ctctctggac gaggccggca 2400  
 accttaccc ccaaaaatgta accactgtg gcccacctc caaaaaaaaacc aagtccaaaca 2460  
 taaacctgga aatatctgca cccctcacag ttacccatcga agccctaact gtggctccg 2520  
 cccgacccct aatggctcgcg ggcacacac tcacccatcga atcacaggcc cgcctaaccg 2580  
 tgcacgactc caaacttagc attggccccc aaggacccc cccctcacca ccaccgatag cagactgtca gaaggaaagc 2640  
 tagccctgca aacatcaggc gccactggta gcttggcat tgacttggaa gagccattt 2760  
 cctcaccccc tctactact atacacaaaaa tggaaaacta ggactaaagt acggggctcc tttgcatgtc acagacgacc 2820  
 taaacacttt gaccgttagc gcttggtagt gttgtactat taataactact tccttgcaaa 2880  
 ctaaagttac tggagccctt gggatggaa cacaaggcaa tatacaactt aatgttagcag 2940  
 gaggactaag gattgttct atgctcaaaa ccaactaaat acaacttgg aataacttac aactatcactg 2700  
 acaacttgg aataacttac aaaagcttga ggttaaccta ccattaaatgc aggagatggg tggatggtagt tatccgtttg 3000  
 tcaaaacaaa aattggccat taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 3060  
 ctcttaaaac agatcttggg ttatggcaag tactacacg attatatttt tggtcaatgc ttactgtt gtttttata aactcagccc 3120  
 ttatggccatc aaaaacccca agatagcaaa gatatgtaac tctccattaa tttactgtt gtcacccatc aacaatttcca 3180  
 ctcttaaaac agatcttggg tttttttata aactcagccc 3240  
 ttttttata aactcagccc 3300  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 3360  
 ctcttaaaac agatcttggg tttttttata aactcagccc 3420  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 3480  
 ctcttaaaac agatcttggg tttttttata aactcagccc 3540  
 ttttttata aactcagccc 3600  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 3660  
 ctcttaaaac agatcttggg tttttttata aactcagccc 3720  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 3780  
 ctcttaaaac agatcttggg tttttttata aactcagccc 3840  
 ttttttata aactcagccc 3900  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 3960  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4020  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4080  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4140  
 ttttttata aactcagccc 4200  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4260  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4320  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4380  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4440  
 ttttttata aactcagccc 4500  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4560  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4620  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4680  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4740  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4800  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4860  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 4920  
 ctcttaaaac agatcttggg tttttttata aactcagccc 4980  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5040  
 ctcttaaaac agatcttggg tttttttata aactcagccc 5100  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5160  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5220  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5280  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5340  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5400  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5460  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5520  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5580  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5640  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5700  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5760  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5820  
 taggaactgg ctttagttt ataagcttaac tttgtggacc aaaaacccca agatagcaaa gatatgtaac gctaattggaa 5880

aacatacgg	ccggaagcat	aaagtgtaaa	gcctggggtg	cctaatacgat	gagctaactc	5940
acattaattg	cgttgcgctc	actgcccgt	ttccagtcgg	gaaacctgtc	gtgcgcagctg	6000
cattaatgaa	tcggccaacg	cgcggggaga	ggcggttgc	gtattggcg	ctcttcgcgt	6060
tcctcgctca	ctgactcgct	gcgctcggtc	gttccgctgc	ggcgagcggt	atcaagctcac	6120
tcaaaaggcg	taatacgggt	atccacagaa	tcaggggata	acgcaggaaa	gaacatgtga	6180
gcaaaaaggcc	agcaaaaaggc	caggaacgt	aaaaaggccg	cgtgtctggc	gtttttccat	6240
aggctccgccc	ccctgacga	gcatcacaaa	aatcgcgct	caagttagag	gtggcgaaac	6300
ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	gtctccctgt	gogctctcct	6360
gttccgaccc	tgcgcgttac	cggatactcg	tccgccttgc	tcccttcggg	aagcgtggcg	6420
ctttctcaat	gctcacgtgc	taggtatctc	agttcggtgt	aggtcggtcg	ctccaagctg	6480
ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctcg	ccttataccgg	taatcatctgt	6540
cttagtgc	acccggtaag	acacgactta	tcgcccactgg	cagcagccac	tggtaacagg	6600
attagcagag	cgagggtatgt	aggcggtgtc	acagagtct	tgaagtgttg	gcctaaactac	6660
ggctacacta	gaaggacagt	atttggtatac	tgcgtctgc	tgaaggccagt	tacccctcgga	6720
aaaagagttg	gtagctcttg	atccggccaa	caaaccacccg	ctggtagccg	tggttttttt	6780
gttccaaaggc	agcagattac	gogcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	6840
tctacggggt	ctgacgctca	gtggaaacgaa	aactcacgtt	aagggtat	ggtcatgaga	6900
ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaaa	aatgaagt	taaatcaatc	6960
taaagtatata	atgagtaaac	ttggctcgac	agtaccaat	gcttaatcag	tggggcacct	7020
atctcagcga	tctgtctatt	tggttcatcc	atagttgcct	gactccccgt	cgtgtagata	7080
actacgatac	gggaggggctt	accatctggc	cccaatgtctg	caatgatacc	gcgagaccca	7140
cgctcacccg	ctccagattt	atcagaata	aaccaggccag	ccggaaaggcc	cgagcgcaga	7200
agtggctctg	caactttatc	cgccctccatc	cagtctatta	attgttgcgg	ggaagctaga	7260
gtaagttagt	cgccagttaa	tagtttgcgc	aacgttgg	ccattgttgcac	aggcatgtg	7320
gtgtcacgct	cgtcggttgg	tatggcttca	ttagctccg	gttcccaacg	atcaaggcga	7380
gttacatgtat	cccccatgtt	gtgcaaaaa	gcccgttagct	cottctggtcc	tccgatcggt	7440
gtcagaagta	agtggccgc	agtgttatac	ctcatggtta	tggcagact	gcataattct	7500
cttagtgc	tccatccgt	aagatgtttt	tctgtgactg	gtgagtaact	aaccaagtca	7560
ttctgagaat	agtgtatgcg	gchgaccgat	tgccttgc	cggcgtcaat	acgggataat	7620
accgcgccac	atagcagaac	ttttaaaagt	ctcatcattg	gaaaacgttc	tccggggcga	7680
aaactctcaa	ggatcttacc	gctgttgaga	tccagttcg	tgttaaccac	tgtgcaccc	7740
aactgatctt	cagcatctt	tactttcacc	acggtttctg	ggtgagcaaa	aacaggaagg	7800
caaaaatgcgc	caaaaaagg	aataaggcg	acacggaaat	gttgaatact	cataactcttc	7860
cttttcaat	attattgaag	catttatcg	ggttattgtc	tcatgagccg	atacatatattt	7920
gaatgtattt	agaaaaataaa	acaaataggg	gttccgcgc	catttccccg	aaaagtgc	7980
cctgacgtc						7989

<210> 34  
<211> 7607  
<212> RNA

<213> Artificial sequence

<220> Description of Artificial Sequence: plasmid GRE5-E1-SV40-Hygro  
<223>

<400> 34	tctagaagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	gtacaggatg	60
ttttagtac	ttttagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	120	
gtacaggatg	ttttagtac	ttttagat	ccgtgtacag	gatgttctag	ctactttatt	180	
agatcgatct	cctggccgtt	cggggtcaaa	aaccaggttt	ggctataaaa	gggggtgggg	240	
gcgcgttcgt	cctcaacttc	ttccgcatcg	ctgtctgcga	gggcaggat	cgatcctgag	300	
aacttcaggg	tgagtttggg	gacccttgcgt	tgttttttct	tttcgcgtat	tgtaaaattc	360	
atgttataatg	gagggggcaa	agtttccagg	gttttgcgttta	aatggggaaag	atgtcccttg	420	
tatcaccatg	gaccctcatg	ataattttgt	ttttttcaact	ttctactctg	ttgacaaccca	480	
ttgtcttcctc	ttattttctt	ttcattttct	gtaacttttt	cgtttaaactt	tagttgcatt	540	
ttgttaacgaa	tttttaaattt	cacttttgcgt	tattgtcag	attgttaactt	ctttctctaa	600	
tcactttttt	ttcaaggcaa	tcagggtata	ttatattgtt	cttcagcaca	gttttagaga	660	
acaattgtta	taattaaatg	ataaggtaga	atattttctgc	atataaattt	tggctggcgt	720	
ggaaatattt	ttatgttgcgt	aaacaactac	atccctggtca	tcatcctgcc	tttctcttta	780	
tggttacat	gatataactac	gtttgagatg	aggataaaaat	actctgagtc	caaaccgggc	840	
ccctctgcta	accatgttca	tgcccttctc	tttttcttac	agctccttggg	caacgtgtcg	900	
gttattgtgc	tgtctcatca	ttttggcaaa	gaatttagatc	taagcttctg	cagctcgagg	960	

actcggtcga ctgaaaatga gacatattat ctgccacgga ggtgttatta ccgaagaaat 1020  
 ggccgcagt ctttggacc agctgatcga agaggtactg gctgataatc ttccacctcc 1080  
 tagccattt gaaccaccta cccttcacga actgtatgat ttagacgtga cgccccccga 1140  
 agatccaaac gaggaggccg tttcgcagat tttcccgac tctgtaatgt tgccgggtgca 1200  
 ggaagggatt gacttactca cttttccgcc ggcggccggg tctccggagc cgcctcacct 1260  
 ttcccgccag cccgagcagc cggagcagag agccttgggt cgggttcta tgccaaacct 1320  
 tgtacccggag gtatcgatc ttacctgcca cgaggctggc tttccaccca gtgacgacga 1380  
 ggatgaagag ggtgaggagt ttgtgttaga ttatgtggag caccggcgc acggttgcag 1440  
 gtctgtcat tattcaccgga ggaatacggg ggacccagat attatgtgtt cgctttgcta 1500  
 tatgaggacc tttggatgtt ttgttacag taatgtaaaa ttatggcag tggtgtatag 1560  
 agtgggttgggt ttgggtgtt aattttttt taaattttta cagttttgtg gtttaaagaa 1620  
 ttttggatgg tttttttttaaaggctt gtgtctgaac ctgagccctga gcccggacca 1680  
 gaaccggcgt ctgcaagacc taccggccgt cctaaaatgg cgcctgtat cctgagacgc 1740  
 ccgcacatcac ctgtgtctag agaatgcaat agtagtacgg atagctgtga ctccggctt 1800  
 tctaaacacac ctccctgagat acacccgggt gtccggctgt gccccattaa accagttgcc 1860  
 gtgagagttt gtggggctcg ccaggctgtg gaatgtatcg aggactgtct taacgagcc 1920  
 gggcaacccctt tggacttggat ctgtttaacccctt gtttgcgtt gtagttgatg taatgtttaat aaagggttag 2040  
 cgtgtgttgg ttaacccctt gtttgcgtt gtagttgatg taatgtttaat aaagggttag 2100  
 ataatgttta acttgcattt cgtttaaaat gggggggggc taaaaggta tataatgcgc 2160  
 cgtggggctaa tcttggttac atctgacctc atggaggctt gggagtgtt ggaagagattt 2220  
 tctgtgtgc gtaacttgc ggaacagacg tctaaacagta cctctgggtt ttggagggtt 2280  
 ctgtggggctt catcccgaggc aaagttgtc tgcagaattha aggaggatttta caagtggaa 2340  
 ttttggatgg ttttggatgg ttttggatgg ttttggatgg ccacaccggg ggcgcgtcg 2400  
 ggcgttttcc aagagaaggt catcaagact ttggatggt ccacaccggg ggcgcgtcg 2460  
 gctgtgttg ctttttggatgg ttttataaaag gataaaatgga gcaagaaac ccatctgagc 2520  
 ggggggttacc tgctggatgg tctggccatg ctttttggatgg ttttggatgg ttttggatgg 2580  
 aatccctgc ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 2640  
 cagcagcagg aggaaggccag gcccggccgg ctttttggatgg ttttggatgg ttttggatgg 2700  
 ggcttggacc ctcgggatgtt aatggatgtt gtttggatgg ttttggatgg ttttggatgg 2760  
 gcatttttgc aattacagag gatggggcagg gctaaagggtt gtttggatgg ttttggatgg 2820  
 ctttggatggc tacagaggag gcttggatgg ttttggatgg ttttggatgg ttttggatgg 2880  
 ctgagtgtat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 2940  
 cgcagaagta ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3000  
 aggaggctat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3060  
 gcaacttgcg aatatttcagg aattttggatgg ttttggatgg ttttggatgg ttttggatgg 3120  
 tagatcggaa ggttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3180  
 ttggcatggaa cgggggttgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3240  
 cgggttttcc ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3300  
 atacctgtgtt ggaaggctgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3360  
 ggaagggggtt ggttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3420  
 ggttacccctt ggttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3480  
 actgtgttgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3540  
 gcaactgcga ggacaggccc ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3600  
 tgaagaccat tcacgtggc agccacttcc ttttggatgg ttttggatgg ttttggatgg 3660  
 tactgaccat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3720  
 gcaattttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3780  
 acgggggttgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3840  
 ccagggtcgat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3900  
 atgtgaccat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 3960  
 gctctagcga ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4020  
 gaaagaatata ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4080  
 ccggccatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4140  
 ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4200  
 tccttggccgc ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4260  
 ctgcagccctc ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4320  
 ttgttccctt ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4380  
 agttgacggc ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4440  
 agcagctgtt ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4500  
 cggtttaaaa ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4560  
 gctgttccat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4620  
 ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg 4680  
 aattttccat ttttggatgg ttttggatgg ttttggatgg ttttggatgg ttttggatgg

aatgtatctt	atcatgtctg	gtcgactcta	gactttccg	tttcctcgct	cactgactcg	4740
ctgcgctcg	tcgttccggct	ggcgcgagcg	gtatcagctc	actcaaaggc	ggtataacgg	4800
ttatccacag	aatcagggaa	taacgcgaga	aagaacatgt	gagcaaaagg	ccagcaaaag	4860
gccaggaaacc	gtaaaaaggc	cgcggttgcg	gcgttttcc	ataggctccg	ccccctgac	4920
gagcatcaca	aaaatcgacg	ctcaagtctg	aggtggcgaa	acccgacagg	actataaaga	4980
taccaggcgt	ttccccctgg	aagctccctc	gtgcgctctc	ctgttccgac	cctggcgct	5040
acggatacc	tgtccgcctt	tctcccttcg	ggaacgctgg	cgctttctca	tagctcacgc	5100
tgttaggtatc	tcagttcggt	gtaggtcggt	cgctccaagc	tgggctgtgt	gcaccaaccc	5160
cccggtcagc	ccgacccgtg	cgccttatcc	gttaactatc	gtcttgagtc	caacccggt	5220
agacacgact	tatccgcact	ggcagcagcc	actggtaaca	ggatttagcag	agcggaggtat	5280
gtaggcgtg	ctacagagtt	cttgaagtgg	tggcttaact	acggctacac	tagaaggaca	5340
gtatgggtt	tctcgctct	gctgaaggca	gttacccctc	aaaaaagagt	tggtagctct	5400
tgatccggca	aacaaaccac	cgctggtagc	gggtggttt	ttgttgcgaa	gcacggaggat	5460
acgcgcagaa	aaaaaaggatc	tcaagaagat	ctttgatct	tttctacgggg	gtctgacgct	5520
cagtggaaacg	aaaactcactg	ttaagggatt	ttggtcatga	gattatcaaa	aaggatcttc	5580
acctagatcc	ttttaaaatcc	aaaatgaagt	ttaaaatcaa	tctaaaatgt	atatggatcaa	5640
acttggctcg	acagttacca	atgcttaatc	agtggggcac	ctatctcagc	gatctgtcta	5700
tttgcgtcat	ccatagttgc	ctgactcccc	gtcggtgaga	taactacat	acggggagggc	5760
ttaccatctg	gccccagtgc	tgcaatgata	ccggcgagacc	cacgtcacc	ggctccagat	5820
ttatcagcaa	taaaccagcc	agccggaaagg	ggccggcgca	gaagtggtcc	tgcaacttta	5880
tccgcctcca	tccagttctat	taatttgc	cgggaaagct	gagtaagttag	ttcgcgcgtt	5940
aatagtttgc	gcaacgtgt	tgccattgtct	acaggcatcg	tggtgtcaag	ctcgctcgtt	6000
ggtagtgcgtt	cattcagtc	cggttcccaa	cgatcaaggc	gagttacatg	atccccatg	6060
ttgtgcggaaa	aaagcgggttag	ctccttcgg	cctccgatcg	ttgtcggaaag	taatggggcc	6120
gcagtgttat	cactcatggt	tatggcagca	ctgcataatt	ctcttactgt	catggccatcc	6180
gtaagatgt	tttctgtgac	tggtgagtc	tcaaccaagt	cattttgtgaa	atagtgtatg	6240
cggcgcaccga	gttgccttgc	ccccggctca	atacgggata	ataccgcgccc	acatagcaga	6300
actttaaaag	tgtctcatcat	tggaaaacgt	tttcggggc	aaaaactctc	aaggatctta	6360
ccgctgttgc	gatccagttc	gatgttaaccc	actcggtcac	ccaaactgatc	ttcagcatct	6420
tttacttca	ccagcgtttc	tgggtgagca	aaaacaggaa	ggcaaaaatgc	cgcaaaaaag	6480
ggaataaggg	cgacacggaa	atgttgaata	ctcatactct	tccttttca	attattatgt	6540
agcatttatac	agggttattgc	tctcatgagc	ggatacatat	ttgaatgtat	ttagaaaaat	6600
aaacaaatag	gggttccgcg	cacattttcc	cggaaaagtgc	cacctgtacgt	ctaaagaaacc	6660
attattatca	tgacattaaac	ctataaaaaat	aggcgatata	cgaggccct	ttcgcttcgc	6720
gcgttccgtt	gatgcgggt	aaaacctctg	acacatgcag	ctcccgagg	cggtcacagc	6780
ttgtctgtaa	gcccgtgcgg	ggagcagaca	agcccgatcg	ggcgcgtcag	cgggtgttgg	6840
cgggtgtcgg	ggctggctta	actatcgcc	atcagagcag	attgtactga	gagtgcacca	6900
tatgcggtgt	gaaataccgc	acagatgcgt	aaaggagaaaa	tacccatca	gaaaattgt	6960
agcgtaataa	ttttgtttaaa	attcgcgtt	aattttgtt	aatcagctc	atttttttaac	7020
caataggccg	aatatcgccaa	aatcccttat	aatcaaaaag	aatagaccga	gatagggttgc	7080
agtgttgttc	cagtttggaa	caagagtcca	ctattaaaga	acgtggactc	caacgtcaaa	7140
gggcggaaaaaa	ccgtctatca	gggcgtatgc	coactactgt	aaccatcacc	ctaaatcaatg	7200
tttttgggggt	cgagggtgcgg	taaaagacta	aatcgaaac	ctaaaggagg	cccccgattt	7260
agagcttgac	ggggaaaaggc	ggcgaacgtg	gcgagaaaagg	aaaggaaagaa	agcggaaagg	7320
gcgggcgtca	ggggcgctgc	aagtgtacgg	gtcacgctgc	gctaaaccac	cacacccggc	7380
gcgcctaattg	cgccgtatca	gggcgtgtcc	cattcgccat	tcaggctgcg	caactgttgg	7440
gaaggccgtat	cggtcgccggc	ctcttcgcta	ttacgcgcagc	tgccgaaaagg	gggatgtgt	7500
gcaaggcgat	taagtgggt	aacgcggagg	ttttcccaat	cacgcgttgc	taaaacgacg	7560
gccagtgaat	tgtatatacg	ctcactatag	ggcgaattaa	ttcggggg		7607

<210> 35

<211> 11600

<212> DNA

<213> Artificial Sequence

<220> Description of Artificial Sequence: plasmid MMTV-E2a-SV40-Neo  
<223>

<400> 35 gaattccgca ttgcagagat attgtattta agtgcctagc tcgataacaat aaacgccatt 60  
tgaccattca ccacattggt gtgcacctcc aagcttggc agaaaatggtt gaactccgca 120

gagtgttccta caccctagggg agaaggcagcc aaggggttgt ttcccaccaa ggacgacccg 180  
 tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcaaactt 240  
 ggcatagtc tgctttgcct ggggtattt ggggaaagttt cggttcgtgc tcgcaggct 300  
 ctcaccctt actttttaa tagctctct gtcaagatt acaatctaaa caattcggag 360  
 aactcgacct tcctccttag gcaaggacca cagccaactt cctcttacaa gccgcacatcg 420  
 ttttgcctt cagaataga aataagaatg cttgtataaa attatattt taccataaaag 480  
 accaatccaa tagtagatt attagtact atgtaagaa atgtaagat aaaaatagaaa gagacgctca 600  
 actatttta ctcaccaatc gaagttaaa atggaatag aaaaatagaaa gagacgctca 600  
 acctcaatc aagaacaggc gcaaggacta ttgaccacag gccttagaagt aaaaaaggaa 660  
 aaaaagatg ttttgcctaa aataggagac aggtggtggc aaccaggac ttatagggaa 720  
 ctttacatct acagaccaac agatgcccc ttaccatata caggaagata tgacttaaat 780  
 tgggataggt gggttacagt caatggctat aaatgtttt atagatccct cccttttcgt 840  
 gaaagactcg ccagagctag acctccctgg tgtatgttgg ctcagaaga aaaaagacgac 900  
 atgaaacaac aggtacatga ttatattttt taggaaacag gaatgactt ttggggaaag 960  
 attttcata ccaaggaggc gacagtggc ggactaatag aacattatttc tgcaaaaact 1020  
 catggcatga gtttattatg atagcctta ttggcccaac cttgcgggttc ccagggtctta 1080  
 agtaagttt tggttacaaa ctgttcttaa aacgaggatg tgagacaagt ggttctctga 1140  
 cttgggttgg tatcaaaggt tctgatctga gctctgatgtt ctatgttctt 1200  
 ttggaattt tccaaatctt atgtaatgc ttatgttaaaac caagatataa aagagtgtct 1260  
 attttttag taaacttgc acagtctaa cattcacctc ttgtgtgtt gtgtctgttc 1320  
 gccatcccg tccgcgtcg acttatactt tcactttcca gagggtcccc ccgcagaccc 1380  
 cggcaccct caggtcgccg gactgcccga gctggcgccc gaacaggac ctcggataa 1440  
 gtgacccttgc tctctatttt tactatttttgg tggttgcctt gtatgttctt 1500  
 ggctatcatc acaagagcgg aacggactca ccatagggac caagtagcgtt ctetctgtcg 1560  
 cgtccaagac ctcaccaatg ttttggact tcgttgcgtcg aggcatatc aggtatgaca 1620  
 ggcacatcgcc gcaaggccag ctgcgttcc gctcggtctgc ggttggcactc gcaggatagg 1680  
 ggtatcttc agttttggaa aaagatgtga taggtggcaa gcacctctgg cacggcaat 1740  
 acgggttaga agttgaggcg cgggttggc tcgatgtgc cgtttcttg ggttgggggg 1800  
 ggtacgcccgt gtgagaatag gtggcgttgc taggcaaggc tgacatccgc tatggcggg 1860  
 ggcacatcgcc tgcgtcttttgc caacgcgtc cagataatgg cgcactggcg ctgcagatgc 1920  
 ttcacacagca cgtcgctccctt cacaatctgg tagtgcggcat gccttcgttc cccccggcc 1980  
 acttgcctt cgttgcctt gctgttgc tggcttgcctt tttatcttc ttttggtaact 2040  
 gagcgggttgc cgtcgcttgc gcttacaaa cctgggttgc gctcgataat cacttcctcc 2100  
 tcctcaagcg ggggtgcctc gacgggaaag gtggtaggcg ctttgcgtccatc tgatgttctc 2160  
 gcggtgttgg cgaactcaga gggggccggt aggctgtctt cgttgcgtccatc atcggtggag 2220  
 atctttttct gcttatagga gaaggaaatg gccagtcggg tcttgcgtccatc aagaggagca ggcgcaaaacc 2280  
 acccccggc gggcagcggg tggccgcga cgtcccccaa ccatggagga cgttcgtcc 2340  
 cctcccccgt cggccggcc tccccggcg cccccaaaaaa agcggatgtag gcggcgtatc 2400  
 gagtcggagg acgaccaaga ctcatacaca gacgcgttgc tgccgcgtac acccagcccg 2460  
 cggccatcgaa cttcggccggc ggattttggcc attgcgcaca aagaaaaaaaa gaagccccc 2520  
 tctcccaagc ccgagcggcc gccatcacca gagtaatcg tggacagcga ggaagaaaga 2580  
 gaagatgtgg cgttacaaaat gttgggtttc agcaacccac cgtgtctaat caagcatggc 2640  
 aaaggaggtt acgcacacat gggggctg aatgaagacg acccagtggc gcgtggatag 2700  
 cggacgcaag aggaagagga agagcccgac gaagcggaaa gtgaaattac ggtgatgaac 2760  
 cgcgtgatgt tgccgatcg tctgcgtgg gagaaggcga tggaggtctgc ggcgcgtcg 2820  
 atggacaagt accacgttgc taacgatcta aaggcgaact tcaactatgc gcgtaccataa 2880  
 gtggaaagctc tggccggccct atgcaagacc tggctgaacg aggacaccgc cgggttgcag 2940  
 ctgcacccatc ccagcaacaa gacccgttgc acgtatgtt ggcatttcct gcaggcgtac 3000  
 ctgcagtctg ttgcagggat gacccataag catcacgagc ccacggctg cgcgttgcgg 3060  
 ctgcacccgt ggcgtgatgt cgaaggcag cttaaatgtc tacacgaaag cttatgtata 3120  
 aataaggagc acgtgattga aatggatgtt acgagcggaaac cggccacgcg cgcgtctaaag 3180  
 gagcagtctt gcaaggccaa gatcgtaag aaccgggtgg gccgaatgt ggtgcagatc 3240  
 tccaaacaccc acgcacagggt ctgcgtgcac gacccggccct gtcggccaa tcagtttcc 3300  
 ggcaagtctt gggcatgtt ctctctgtt ggcgcaaaagg ctcaggtggc ttttaagcag 3360  
 atcaaggctt ttatgcaggc gctgtatctt aacgcccaga cggggcacgg tcacccctttt 3420  
 atgcacactac ggtgcgtatgtt caactcaaag cctggccacg cggccctttt gggaggcag 3480  
 ctacccaaatgt tgactccgtt cggccctgacg aacggccgggg acctggacgc ggtatgtatc 3540  
 tccgacaaga gctgtgtggc cagcgtgcac caccggccgc tgatagttt ccagtgtctc 3600  
 aaccctgtgt atcgcaactc ggcgcgcgc gggggaggcc ccaactgcga ctcaagata 3660  
 tcggcccccgg acctgttaaa cgcgttgcgtt atggcgcga gctgtggag tggaaaacttc 3720  
 accgacgtgc cgcggatgtt tggcgttgc tttaaatgtt gcaactaaaca ccagtatcgc 3780  
 aacgtgtccc tgccagtggc gcatagcgt ggcggccaga acccctttga tttttaaacg 3840

ggcgcagacgg caagggtggg ggtaaataat caccgcagag tgtacaaata aaagcatttg 3900  
 ccttattgt aagtgtctc agtacattat ttttacatgt ttttcaagtg acaaaaagaa 3960  
 gtggcgtcc taatctgcgc actgtggctg cggaaatgtt gcgagtgccg ctccaggaag 4020  
 ctgttagct gttctgggt gcgacgcagg gtggctgtt cctggggact gttagcatg 4080  
 gagttggta ccccgtaat aaggttcatg gtggggttgt gatccatggg agtttgggc 4140  
 cagttggca aaggctgggaa aacatgcag cagaatagtg cacaggccgc cgagttggg 4200  
 ccctgtacgc tttgggtgg cttttccagc gttatcagc gtcggggaa agaagcaatg 4260  
 ggcgtacggc gcaggagt gtcgtacta aactgtt aactgtt gttttgagt ggggttcca ggcaaggcc 4320  
 gaaaagccaa aaggcttcaa gaggttcatg gttttgagt ggggttcca ggcaaggcc 4380  
 atccagtgtt cggcccaact ctcgcgaccg gccgtattgtt cttatggcga ggcgagctt 4440  
 tggagaaaa caaaggctgg aaagcgttg tcataggtgc ccaaaaata tgcccacaa 4500  
 ccaagatctt tgacaatggc tttcaatggc tgctcaatggc agccatggc ggcagctgtt 4560  
 gttgtatgg tttgttctt tatgtgtgg ctgtggccg cgagaaggcc gtgcgcagg 4620  
 acacggtttccatgacgcgcg cggtggccg gttgcacacg gaccacgtca aagacttcaa 4680  
 acaaaacata aagaagggtt ggctgttcca tggatccat atataggcc cgggttataa 4740  
 ttacccaggc tgcacccgtt gggatctt tgaaggaaacc ttacttctgt ggtgtgacat 4800  
 aattggacaa actacactaca gagattttaa gctctaagggtt aaataaaaaa ttttaatgtt 4860  
 tataatgtgt taaactactg attctaattt tttgtgtt ttagatccca acctatggaa 4920  
 ctgtatgttggagcgttgg tggatgcctt ttaatggatggaa aacctgttt tgctcagaag 4980  
 aaatggccatc tagttagttagt gaggacttgc ttacttctca acatttact cctccaaaaa 5040  
 agaaagaaaa ggttagaagac cccaaaggact ttccttcaga attgctaagt tttttagtgc 5100  
 atgtgtttttagtataaga acttgcgtt gctttgttat ttacaccaca aaggaaaaaa 5160  
 ctgcactgtt atacaagaaaa attatggaaa aatattctgt aacccatttata agtaggcata 5220  
 acagttataa tcataacata ctgttttttccat tttactccaca caggcataga gtgtctgtca 5280  
 ttaataacta tgctcaaaaa ttgtgttactt tagctttttagtataa aatgggttataa 5340  
 aggaatattttagt gatgtatgtt gcttgcactt gatgtatca tcagccatac cacattgtt 5400  
 gaggtttttac ttgtttttaa aaacctccca cacccccc tgaacctgaa acataaaatg 5460  
 aatgcatttgc ttgtttttttaa cttgttttattt gcaatgttata atggtttacaa ataaagcaat 5520  
 agcatcacaa atttcacaaaaa taaagcattt ttttacttgc attctatgtt tgggttgc 5580  
 aaactcatca atgtatctt tcatgttgcg atccggctt ggttgcgtt ggttgcgtt 5640  
 tggggaaatgtt ccccaaggctt cccaggccgc agaagtatgc aagcatgca tctcaatttgc 5700  
 tcaccaacca ggtgtggaaa gtcggccagg tccccagcag gcagaagtat gcaagcatg 5760  
 catctcaatttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 5820  
 ccccccatttgc tccggcccat ggttgcgttgc ttttgcgttgc ttttgcgttgc 5880  
 gcccaggccg cccaggctt ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 5940  
 cttaggttttgc gcaaaaaatgtt ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6000  
 ggaagccgaa cacgtggaaa gccatccgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6060  
 gctactggcc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6120  
 gtgggttttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6180  
 tgccagcttgc ggcgccttgc ggttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6240  
 tcttgcgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6300  
 gatcggttttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6360  
 agaggcttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6420  
 tccggctgtc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6480  
 tgaatgtacttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6540  
 ggcgcagcttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6600  
 ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6660  
 atccggcttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6720  
 ggttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6780  
 cggccgaaacttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6840  
 cccatggcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6900  
 ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 6960  
 atattgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7020  
 cccgttttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7080  
 gactctgggg ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7140  
 gacggccaaacttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7200  
 cttcgaaatc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7260  
 ggagtttttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7320  
 gctggacgac ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7380  
 cagggcttatc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7440  
 ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7500  
 tacctacaga gatttaaacttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc ttttgcgttgc 7560

aactactgat tctaattgtt tggatatttt agattccaaac ctatggaaact gatgaatggg 7620  
 agcgatggg gaatgccttt aatgaggaaa acgttgggg ctcagaagaa atgcccattca 7680  
 gtgatgatga ggctactgt gactctcaac attctactcc tccaaaaaag aagagaaaagg 7740  
 tagaagaccc caaggacttt cttcagaat tgctaaat tttgagtcat gctgtgttta 7800  
 gtaatagaac tttgttgc tttgttattt acaccacaaa ggaaaaaagct gcaactgctat 7860  
 acaagaaaat tatggaaaaa tattctgtaa ccttataaag taggcataac agttataatc 7920  
 ataacatact gtttttctt actccacaca ggcataagat gtctgttattt aataactatg 7980  
 ctcaaaaattt gtttgcattt agcttttaa tttgatggg ggttaataag gaatatttga 8040  
 tttatgtc tttgtactaga gatcataatc agccataccca cattttaga gtttttactt 8100  
 gttttaaaaa acctcccaca cttcccccgt aacctgaaac ataaaatgaa tgcattgtt 8160  
 gttttaact tttttatttgc agcttataat ggttacaaat aaagcataatg catcacaat 8220  
 ttcacaaaata aagcattttt ttcactgtc ttttttttttgc gtttgcattt aactcatcaat 8280  
 gtatcttattt atgtctggat ccccaaggg cttcttgc ttttttttttgc ccttaacccctc 8340  
 ctctacttgc gggacatcc caatcatagg ctgcccattcc accctctgtt ttttttttttgc 8400  
 aatttagtca ttttacaaaaggaaatttgg gtaggggtttt ttcacagacc gttttctaaag 8460  
 ggtttaatttta aatatactgg gaagttccctt ccactgtgtt gtttgcattt aactcatcaat 8520  
 cagccccacaa atgtcaacag cagaacataca aagctgtca gtttgcattt aactcatcaat 8580  
 accctgtca tcaagaagca ctgtgggttgc ttttttttttgc ttttttttttgc ccccaaccc 8640  
 atttcccccata cttgtgttagg ttttttttttgc ttttttttttgc ttttttttttgc 8700  
 aaccctggac aaccctggat aaccatttttcc ttttttttttgc ttttttttttgc 8760  
 catctgtca ctgtcaactt tagcattttt ttttttttttgc ttttttttttgc gtttgcattt 8820  
 cttgttagttt gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 8880  
 aaaatttgac ctttgcattt gtttttttttgc ttttttttttgc ttttttttttgc 8940  
 atgcacatgtt aacatagcag ttaccccaat aaccctgtt ttttttttttgc ttttttttttgc 9000  
 catcaaaaata tttccacagg ttttttttttgc ttttttttttgc ttttttttttgc 9060  
 cggaaaggccc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9120  
 tagacgttagt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9180  
 taaatacattt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9240  
 tatttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9300  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9360  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9420  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9480  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9540  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9600  
 atgacttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9660  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9720  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9780  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9840  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9900  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9960  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10020  
 gtttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10080  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10140  
 atgacttgcattt ttttttttttgc ttttttttttgc ttttttttttgc 10200  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10260  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10320  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10380  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10440  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10500  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10560  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10620  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10680  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10740  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10800  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10860  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10920  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10980  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 11040  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 11100  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 11160  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 11220  
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 11280

tttgcgtgc ttgcgtatgt acggggcaga tatacggtta tctgagggga ctaggggtgtg 11340  
tttaggcgaa aagcggggct tcgggtgtac gcggttagga gtcggcttag gatatagttag 11400  
tttcgtttt gcatagggag gggaaatgt agtcttatgc aatacaactt tagtcttgca 11460  
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcgtgcc 11520  
gattgggttga agtaagggttgg tacgatcgta ctttattttt aaggcaacag acgggtctga 11580  
catggattgg acgaaccact 11600

<210> 36  
<211> 53  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 36  
gtcactcgag gactcggtcg actgaaaatg agacatatta tctgccacgg acc 53

<210> 37  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 37  
cgagatcgat cacctccggc acaagggttg gcatag 36

<210> 38  
<211> 37  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 38  
catgaagatc tggaaagggtgc tgaggtacga tgagacc 37

<210> 39  
<211> 51  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 39  
gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c 51

<210> 40  
<211> 38  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 40  
cacgaatttc tcagcgcttc tcgtcggttc caagaccc 38

<210> 41  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 41  
 caccgggggg aggccggcggc gacggggacg gg

32

<210> 42  
 <211> 7231  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: plasmid pDV80

<400> 42  
 ctgtccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60  
 acaaggcaag gcttgaccga caattgcatt aagaatctgc ttagggttag gcgttttgcg 120  
 ctgttcgcg atgtacgggc cagatatacg cttgtacatt gattattgac tagttattaa 180  
 tagtaatcaa ttacggggtc attagttcat agcccatata tggaggcccg cgttacataa 240  
 cttacggtaa atggcccgcc tggctgaccg cccaaacgacc cccggccatt gacgtcaata 300  
 atgacgtatg ttcccatagt aacccaaata gggactttcc attgacgtca atgggtggac 360  
 tatttacggt aaactgccc cttggcagta catcaagtgt atcatatgcc aagtacgccc 420  
 cctattacgg tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacccta 480  
 tgggactttc tcaatggca gtacatctac gtattagtcg tcgctattac catggtgatg 540  
 cgggtttggc agtacatcaa tggggctgga tagcggttg actcacgggg atttccaagt 600  
 ctcaccccca ttgacgtcaa tgggagttt tttggccacc aaaatcaacg ggactttcca 660  
 aaatgtcgta acaactccgc cccattgacg caaatggggc gtaggcgtgt acgggtggag 720  
 gtctatataa gcagagctct ctggctact agagaaccca ctgcttactg gcttatacgaa 780  
 attaatacga ctcaatctatgg gggacccaa gctggcttagc gtttaaactt aagcttggta 840  
 ccgagctcg atccactctc ttccgcattcg gttgtcgca gggcagctg ttgggttgag 900  
 tactccctct gaaaagccgg catgacttct ggcgctaagat tgcgttcc caaaaacgag 960  
 gaggatttga tattcacctg gcccgggtt atgccttgcg ggttggccgc atccatctgg 1020  
 tcagaaaaga caatctttt gttgtcaagc ttgttggccaa acgacccgta gagggcgttg 1080  
 gacagcaact tggcgatgg ggcggagggtt ttgtttttgt cgcgatccgc ggcgtccctg 1140  
 gccgcgtatgt ttagtgcac gtattgcgc gcaacgcacc gccattcgaa aagacgggtg 1200  
 gtgcgtcggt cgggcaccag gtgcacgcgc caaccgcgggt tgcgttgcg gacaagggtca 1260  
 acgctgggtt ctacctctcc gcttggcgc tcgttggcc acgacggggc gccgccttg 1320  
 cgcgagcaga atggcggtt ggggtcttgcg tgcgtctcg cgggggggtc tgcgtccacg 1380  
 gtaaagaccc cgggcagcag ggcggcgtcg aagtatgtca tcttgcattcc ttgcaagtct 1440  
 agccgcgtct gccatgcgc ggcggcaagg tacatgcgc aatgtcgta aacgttagagg 1500  
 catggcattgg ggtgggttag cgcggaggcg tagcatcttcc caccgcggat gctggcgcgc 1560  
 ggctctctga gtattccaag atatgttaggg aggaggctgg gaccgggtt gctacggggcg 1620  
 acgtaatcgt atagttcggtt cgagggagcg aagatggcat gtgatgttggaa tgatatgggtt 1680  
 ggctgtctgt ctcggaaagat tattgtcggtt gtcggcgttgcg ggcgtctcg atgggttgag 1740  
 ggacgctggaa agacgtttaga gctggcgctt gtgagacta cccgcgtcaccg cacgaaggag 1800  
 gcttggaggat cgcgcgtt gttgaccagc tcggcggttgcg cctgcacgtc tagggcgcag 1860  
 tagtccagggt tttccttgcgat gatgtcatac ttatcctgtc cctttttt ccacagctcg 1920  
 cggttggatca caaactcttc gcggttccgc cagtactt ggtatcgaaa cccgttggcc 1980  
 tccgaacggat atccgtactc cgcggcggag ggacgttgcg gatgttggaa gacccggatc 2040  
 gggaaacccctc tcgagaaaagg cgtctaaaccat gtcacagtgc caagatccaa gatgaagcgc 2100  
 gcccggccccc gcaagatgtat cttcaacccc gtctaccctt atggtacgc gcgaaatcag 2160  
 aatatccctt tcctcactcc cccctttgtc ttctccgtt gattcaaaaaa cttccccccct 2220  
 ggggtactgt cactcaaact ggttgcattca atcaccatca ccaatggggat tgcgttcc 2280  
 aagggtggag gtggtctcac tttgcattca ggaaggctaa cttgtaaaccc taaggctcca 2340  
 ctgcgaatgttataactgataa aaaactttagat gttgcattatcataatccatt tgaaagttagt 2400  
 gtaataaaac ttatgtttaaa agtaggacat ggattaaaaag tattagatga aaaaagtgt 2460

gcggggttaa aagatataat tggcaaactt gtggtttaa cagaaaaagg aataggcact 2520  
 gaaaatttag aaaatacaga tggtagcagc agaggaattt gtataaatgt aagagcaaga 2580  
 gaagggttga catttgacaa ttagtgatc ttggtagcat ggaacccaaa gtatgacacg 2640  
 cgcacactt ggacaacacc agacacatct cccaaactgca caattgtc aagataaggac 2700  
 tctaaactca ctttggtaact tacaatgtt ggaagtcaaa tattagctaa tgggtcttt 2760  
 atttggtcg cagggaaagta ccacatata aataataaga caaatccaaa aataaaaaagt 2820  
 tttactatta aactgctatt taataagaac ggagtctt tagacaactc aaatcttgg 2880  
 aaagcttatt ggaactttag aagtggaaat tccaatgtt cgacagctt tggaaaaagca 2940  
 attggttta tgcctaattt ggttagctt cccaaacccca gtaattctaa aaaatatgca 3000  
 agagacatag ttatggac tatataatc ggtggaaaac ctgatcagcc agcagtcatt 3060  
 aaaactacat ttaaccaaga aactgttggtaa gtaactcttca tcacatattaa ctttagttgg 3120  
 tccaaacccat atgaaaatgt tgaatttggaa accacccctt ttaccccttc ctatattgccc 3180  
 caagaatgaa agagcggccg ctgcagtcg gaggcccgt ttaaaccgc tgatcagcc 3240  
 cgactgtgcc ttctatgttgc cagccatctg ttgggttgc ccccccgtg cttcccttga 3300  
 cccttggagg tgccactccc actgtcttt cctaataaaa tgaggaaattt gcatcgccatt 3360  
 gtctgagtag gtgtcattt atttgggggg gtgggggtggg gggaggccggc aaggggggagg 3420  
 atttgggaga caatagcagg catgtgggg atgcgggtggg ctctatggct tctgaggcgg 3480  
 aaagaaaccat ctggggctt cgggggttccat cccacgcgcg ctgtagccgc gcatcaagcg 3540  
 cggcgggtgt ggtggtaa cgcagcgtga cgcctacact tgccagccgc ctacgcggcc 3600  
 ctcccttcgc ttcttccct tccttctcg ccacgttccgc cggcttccc cgtcaagctc 3660  
 taaatcgggg catccctta ggggtccgtat ttagtcttgc acggccctc gaccccaaaa 3720  
 aacttggatta ggggtatgtt tcaatgttgc gggccatcgcc ctgatagacg gtttttcgc 3780  
 ctttgacgtt ggatccacg ttctttaataa gtggactctt gttccaaact ggaacaacac 3840  
 tcaaccctat ctggctctat tcttttattataaaggat tttgggatt tcggccttatt 3900  
 ggttaaaaaaa tgagcttattataaaaaat ttaacgcgaa ttaatctgtt ggaatgttgc 3960  
 tcagtttaggg tggggaaatg ccccgaggctc cccaggcagg cagaatgttgcg 4020  
 atctcaattt gtcagcaacc aggttggaa agtcccccagg ctcccccagg ggcagaagta 4080  
 tgcaaagcat gcatctcaat tagtcagccaa ctatgtccc gcccctaact ccgccccatcc 4140  
 cgccccttaac tccggccat tccggccattt ctccggccca tggctgacta attttttttt 4200  
 ttatgcaga gggcgaggcc gcctctgcct ctgagctatt ccagaatgttgcg 4260  
 ttttggagg cctaggctt tgcaaaaaggc tcccgaggcc ttgtatatacc attttccggat 4320  
 ctgatcagca cgtgttgcata attaatcattt ggcatagat atccggcatag tataatacga 4380  
 caaggtgagg aactaaacca tggccaaatggcgtt gggatcccg gacccggccat 4440  
 cgacgtgcgc ggagcggctg agtttggac ctgcacccggc gggttctccc gggacttcgt 4500  
 ggaggacgac ttgcgggtgt tggtccggga cgacgtgacc ctgttcatca ggcgggtccca 4560  
 ggaccagggtg gtgcgggaca acaccctggc ctgggtgtgg gtgcggccgc tggacgagct 4620  
 gtacgcccgg tggtcggagg tcgttccac gaaatcccg gacccggccat 4680  
 gaccgagatc ggcgagcgc cgtggggggcg ggagttccgc ctgcgcgacc cggccggccaa 4740  
 ctgggtgcac ttctgtggcc aggacggaga ctgacacgtt ctacggatatttccac 4800  
 cgcggccattt tataaaaaatggcgtt tggtcttccgc aatcgatccatc gctggatgt 4860  
 cctccagcgc gggatctca tgctggagtt ctgcggccac cccaaacttgc ttattgcaggc 4920  
 ttataatggt tacaataaa gcaatagcat cacaatatttca acaaataaaatggcgtt 4980  
 actgcattct agtttgcgtt tggtccaaact catcaatgtt tcttgcatttgc tctgtatacc 5040  
 gtcgacccctc agcttagagct tggcttgcata atggctatgc ctgttccgt tggaaatgg 5100  
 ttatccgcctc acaatccac aacaatatacg agccggaaatc ataaatgttgc aagcctgggg 5160  
 tgcttaatga gtgagcttac tcacattat tgcgttgcgc tcactgcccgc tttccagtc 5220  
 gggaaacctg tcgtggccagc tgcattatgt aatcgcccaaa cgcgcggggg gaggcgggtt 5280  
 gcttatttggc cgcttcccg ctccctcgct cactgactcg ctgcgtccgg tcgttccgtt 5340  
 gcccggcggcg gtatcagtc actcaaaggc ggtatcaggc ttatccacag aatcagggg 5400  
 taacgcggaa aagaacatgtt gggatcccg ccacggaaatggcgtt ccacggccat 5460  
 cgcgttgcgt gcttttcc ataggctccg ccccccgtac gggatccaca aaaatcgacg 5520  
 ctcaagttagt aggtggcggaa acccgacagg actataaaga taccaggcgt tttccctgg 5580  
 aagctccctc gtgcgtctc ctgttccgc cctccggccctt accggatacc tgcgtccgtt 5640  
 tctcccttcg ggaagcgtgg cgccttctca atgcgtccgc tgtaggtatc tcaatgcgtt 5700  
 gttagtgcgtt cgcttccaaatc tggctgtgt gcaacccggta agacacgact ttcgcact 5820  
 cgccttattcc ggttaactatc gtcttgcgtt cactggatccatc gggatccgtt ccacggccat 5880  
 ggcggcggcc actggtaaca ggatggcgtt agcggatacc tgcgtccgtt tgcgtccgtt 5940  
 cttaatgttgc tggcttccgtt acggctacac tagaaggaca gttatccgtt tgcgtccgtt 6000  
 gcttaatgttgc gttacccctc gaaaatggat tggttagctt tgcgtccgtt tgcgtccgtt 6060  
 cgttgcgttgc ggtgggtttt ttgtttgcac gcaatggatccatc acggcggccat 6120  
 tcaagaatgttgc ctttgcattt tttctacggg gtcgtccgtt cgttgcgtt gcaatggatccatc 6180  
 ttaatggattt tggctatcaaa aaggatcttcc acctagatcc tttttaaatataa

aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggctcg acagttacca 6240  
 atgcttaatc agtgaggcac ctatctcagc gatctgtcta ttctgtcat ccatagttgc 6300  
 ctgactcccc gtcgtgtaga taactacat acgggagggc ttaccatctg gccccagtgc 6360  
 tgcaatgata cccgagacc cacgctcacc ggctccagat ttatcagaa taaaccagcc 6420  
 agccggaagg gcccagcga gaagtggtcc tgcacttta tccgcctcca tccagtttat 6480  
 taattgttc cgggaagct gagtaatg ttccggcgtt aatagttgc gcaacgttgc 6540  
 tgccattgtc acaggcatcg tgggtcacg ctcgtcggtt ggtatggctt cattcagctc 6600  
 cggttcccaa cgatcaaggc gagttacatg atccccatg ttgtcaaaa aagcggttag 6660  
 ctccctcggt cttccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatgg 6720  
 tatggcagca ctgcataatt ctcttactgt catgcctatcc gtaagatgt tttctgtgac 6780  
 tggtagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgtcttg 6840  
 cccggcgtca atacgggata atacggcgc acatagcaga actttaaaag tgctcatcat 6900  
 tggaaaacgt tcttcggggc gaaaacttc aaggatctt ccgcgttga gatccagttc 6960  
 gatgttaacc actctgtcac ccaactgatc ttccagcatct ttactttca ccagcggttc 7020  
 tgggtgagca aaaacaggaa ggcaaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7080  
 atgttgaata ctctactct tccttttca atattattga agcattatc agggttattt 7140  
 tctcatgacg gatacatat ttgaatgtat tttagaaaaat aaacaaatag gggttcccg 7200  
 cacatttccc cggaaagtgc cacctgacgt c 7231

&lt;210&gt; 43

&lt;211&gt; 48

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt; Description of Artificial Sequence: primer

<400> 43  
tgtcttggat ccaagatgaa gcgcgcgc cccagcgaag atgacttc

48

&lt;210&gt; 44

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt; Description of Artificial Sequence: primer

<400> 44  
aaacacggcg gccgctttt cattcttg

28

&lt;210&gt; 45

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Ad 37 N-terminus

<400> 45  
Met Ser Lys Arg Leu Arb Val Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr  
1 5 10 15

&lt;210&gt; 46

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; artificial sequence

&lt;400&gt; 46

Lys Arg Ala Arg Pro Ser  
1 5

&lt;210&gt; 47

&lt;211&gt; 17

<212> PRT  
<213> Ad5 modified N-terminus

<400> 47  
Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr  
1 5 10 15

<210> 48  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 48  
ggatccatgg gatacttggt agca

24

<210> 49  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 49  
gcaactcgag tcattcttgg gcaatatagg

30

<210> 50  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 50  
cgcgctgact cttaggact agtttc

26

<210> 51  
<211> 37  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer

<400> 51  
gcgcattt aacatcatca ataataacc ttat

37